id	sid	tid	token	lemma	pos
cuesj-385	1	1	tx_1	tx_1	PROPN
cuesj-385	1	2	~	~	X
cuesj-385	1	3	abs	ab	NOUN
cuesj-385	1	4	:	:	PUNCT
cuesj-385	1	5	at	at	ADP
cuesj-385	1	6	/	/	SYM
cuesj-385	1	7	add	add	VERB
cuesj-385	1	8	:	:	PUNCT
cuesj-385	1	9	tx_2	tx_2	PROPN
cuesj-385	1	10	~	~	NOUN
cuesj-385	1	11	abs	ab	NOUN
cuesj-385	1	12	:	:	PUNCT
cuesj-385	1	13	at	at	ADP
cuesj-385	1	14	28	28	NUM
cuesj-385	1	15	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	1	16	cuesj	cuesj	ADJ
cuesj-385	1	17	2021	2021	NUM
cuesj-385	1	18	,	,	PUNCT
cuesj-385	1	19	5	5	NUM
cuesj-385	1	20	(	(	PUNCT
cuesj-385	1	21	1	1	NUM
cuesj-385	1	22	):	):	PUNCT
cuesj-385	1	23	28	28	NUM
cuesj-385	1	24	-	-	SYM
cuesj-385	1	25	33	33	NUM
cuesj-385	1	26	research	research	NOUN
cuesj-385	1	27	article	article	NOUN
cuesj-385	1	28	immunohistochemical	immunohistochemical	ADJ
cuesj-385	1	29	and	and	CCONJ
cuesj-385	1	30	molecular	molecular	ADJ
cuesj-385	1	31	studies	study	NOUN
cuesj-385	1	32	of	of	ADP
cuesj-385	1	33	p53	p53	NOUN
cuesj-385	1	34	and	and	CCONJ
cuesj-385	1	35	kras	kras	PROPN
cuesj-385	1	36	protein	protein	NOUN
cuesj-385	1	37	and	and	CCONJ
cuesj-385	1	38	their	their	PRON
cuesj-385	1	39	relations	relation	NOUN
cuesj-385	1	40	to	to	ADP
cuesj-385	1	41	colorectal	colorectal	ADJ
cuesj-385	1	42	carcinoma	carcinoma	NOUN
cuesj-385	1	43	merza	merza	PROPN
cuesj-385	1	44	h.	h.	PROPN
cuesj-385	1	45	homady1	homady1	PROPN
cuesj-385	1	46	*	*	PROPN
cuesj-385	1	47	,	,	PUNCT
cuesj-385	1	48	tanya	tanya	PROPN
cuesj-385	1	49	s.	s.	PROPN
cuesj-385	1	50	salih2	salih2	PROPN
cuesj-385	1	51	,	,	PUNCT
cuesj-385	1	52	mariamm	mariamm	PROPN
cuesj-385	1	53	m.	m.	PROPN
cuesj-385	1	54	al	al	PROPN
cuesj-385	1	55	-	-	PUNCT
cuesj-385	1	56	jubori3	jubori3	PROPN
cuesj-385	1	57	,	,	PUNCT
cuesj-385	1	58	mustafa	mustafa	PROPN
cuesj-385	1	59	d.	d.	PROPN
cuesj-385	1	60	younus2	younus2	PROPN
cuesj-385	2	1	1department	1department	NUM
cuesj-385	2	2	of	of	ADP
cuesj-385	2	3	biomedical	biomedical	ADJ
cuesj-385	2	4	sciences	science	NOUN
cuesj-385	2	5	,	,	PUNCT
cuesj-385	2	6	cihan	cihan	VERB
cuesj-385	2	7	university	university	NOUN
cuesj-385	2	8	-	-	PUNCT
cuesj-385	2	9	erbil	erbil	PROPN
cuesj-385	2	10	,	,	PUNCT
cuesj-385	2	11	kurdistan	kurdistan	PROPN
cuesj-385	2	12	region	region	NOUN
cuesj-385	2	13	,	,	PUNCT
cuesj-385	2	14	iraq	iraq	PROPN
cuesj-385	2	15	,	,	PUNCT
cuesj-385	2	16	2department	2department	NUM
cuesj-385	2	17	of	of	ADP
cuesj-385	2	18	general	general	ADJ
cuesj-385	2	19	biology	biology	NOUN
cuesj-385	2	20	,	,	PUNCT
cuesj-385	2	21	cihan	cihan	VERB
cuesj-385	2	22	university	university	NOUN
cuesj-385	2	23	-	-	PUNCT
cuesj-385	2	24	erbil	erbil	PROPN
cuesj-385	2	25	,	,	PUNCT
cuesj-385	2	26	kurdistan	kurdistan	PROPN
cuesj-385	2	27	region	region	NOUN
cuesj-385	2	28	,	,	PUNCT
cuesj-385	2	29	iraq	iraq	PROPN
cuesj-385	2	30	,	,	PUNCT
cuesj-385	2	31	3college	3college	PROPN
cuesj-385	2	32	of	of	ADP
cuesj-385	2	33	medicine	medicine	NOUN
cuesj-385	2	34	,	,	PUNCT
cuesj-385	2	35	babylon	babylon	PROPN
cuesj-385	2	36	university	university	PROPN
cuesj-385	2	37	,	,	PUNCT
cuesj-385	2	38	iraq	iraq	PROPN
cuesj-385	2	39	abstract	abstract	NOUN
cuesj-385	2	40	the	the	DET
cuesj-385	2	41	study	study	NOUN
cuesj-385	2	42	included	include	VERB
cuesj-385	2	43	50	50	NUM
cuesj-385	2	44	tissue	tissue	NOUN
cuesj-385	2	45	blocks	block	NOUN
cuesj-385	2	46	embedded	embed	VERB
cuesj-385	2	47	in	in	ADP
cuesj-385	2	48	paraffin	paraffin	NOUN
cuesj-385	2	49	wax	wax	NOUN
cuesj-385	2	50	(	(	PUNCT
cuesj-385	2	51	16	16	NUM
cuesj-385	2	52	 	 	SPACE
cuesj-385	2	53	females	female	NOUN
cuesj-385	2	54	and	and	CCONJ
cuesj-385	2	55	34	34	NUM
cuesj-385	2	56	 	 	SPACE
cuesj-385	2	57	males	male	NOUN
cuesj-385	2	58	)	)	PUNCT
cuesj-385	2	59	,	,	PUNCT
cuesj-385	2	60	obtained	obtain	VERB
cuesj-385	2	61	from	from	ADP
cuesj-385	2	62	a	a	DET
cuesj-385	2	63	patients	patient	NOUN
cuesj-385	2	64	group	group	NOUN
cuesj-385	2	65	with	with	ADP
cuesj-385	2	66	colorectal	colorectal	ADJ
cuesj-385	2	67	cancer	cancer	NOUN
cuesj-385	2	68	(	(	PUNCT
cuesj-385	2	69	crc	crc	NOUN
cuesj-385	2	70	)	)	PUNCT
cuesj-385	2	71	,	,	PUNCT
cuesj-385	2	72	as	as	ADV
cuesj-385	2	73	well	well	ADV
cuesj-385	2	74	as	as	ADP
cuesj-385	2	75	35	35	NUM
cuesj-385	2	76	tissue	tissue	NOUN
cuesj-385	2	77	blocks	block	NOUN
cuesj-385	2	78	that	that	PRON
cuesj-385	2	79	were	be	AUX
cuesj-385	2	80	embedded	embed	VERB
cuesj-385	2	81	in	in	ADP
cuesj-385	2	82	paraffin	paraffin	NOUN
cuesj-385	2	83	wax	wax	NOUN
cuesj-385	2	84	from	from	ADP
cuesj-385	2	85	normal	normal	ADJ
cuesj-385	2	86	colon	colon	NOUN
cuesj-385	2	87	(	(	PUNCT
cuesj-385	2	88	ulcerative	ulcerative	ADJ
cuesj-385	2	89	colitis	colitis	NOUN
cuesj-385	2	90	)	)	PUNCT
cuesj-385	2	91	as	as	ADP
cuesj-385	2	92	controls	control	NOUN
cuesj-385	2	93	.	.	PUNCT
cuesj-385	3	1	a	a	DET
cuesj-385	3	2	 	 	SPACE
cuesj-385	3	3	relatively	relatively	ADV
cuesj-385	3	4	few	few	ADJ
cuesj-385	3	5	oncogenes	oncogene	NOUN
cuesj-385	3	6	and	and	CCONJ
cuesj-385	3	7	most	most	ADV
cuesj-385	3	8	prominently	prominently	ADV
cuesj-385	3	9	tumor	tumor	NOUN
cuesj-385	3	10	-	-	PUNCT
cuesj-385	3	11	suppressing	suppress	VERB
cuesj-385	3	12	genes	gene	NOUN
cuesj-385	3	13	,	,	PUNCT
cuesj-385	3	14	kirsten	kirsten	ADJ
cuesj-385	3	15	rat	rat	NOUN
cuesj-385	3	16	sarcoma	sarcoma	PROPN
cuesj-385	3	17	virus	virus	PROPN
cuesj-385	3	18	(	(	PUNCT
cuesj-385	3	19	kras	kras	PROPN
cuesj-385	3	20	)	)	PUNCT
cuesj-385	3	21	,	,	PUNCT
cuesj-385	3	22	and	and	CCONJ
cuesj-385	3	23	p53	p53	NOUN
cuesj-385	3	24	genes	gene	NOUN
cuesj-385	3	25	have	have	AUX
cuesj-385	3	26	been	be	AUX
cuesj-385	3	27	mutated	mutate	VERB
cuesj-385	3	28	into	into	ADP
cuesj-385	3	29	a	a	DET
cuesj-385	3	30	significant	significant	ADJ
cuesj-385	3	31	part	part	NOUN
cuesj-385	3	32	of	of	ADP
cuesj-385	3	33	crcs	crcs	NOUN
cuesj-385	3	34	,	,	PUNCT
cuesj-385	3	35	and	and	CCONJ
cuesj-385	3	36	a	a	DET
cuesj-385	3	37	broad	broad	ADJ
cuesj-385	3	38	collection	collection	NOUN
cuesj-385	3	39	of	of	ADP
cuesj-385	3	40	mutated	mutate	VERB
cuesj-385	3	41	genes	gene	NOUN
cuesj-385	3	42	has	have	AUX
cuesj-385	3	43	been	be	AUX
cuesj-385	3	44	defined	define	VERB
cuesj-385	3	45	in	in	ADP
cuesj-385	3	46	crc	crc	NOUN
cuesj-385	3	47	subsets	subset	NOUN
cuesj-385	3	48	.	.	PUNCT
cuesj-385	4	1	current	current	ADJ
cuesj-385	4	2	findings	finding	NOUN
cuesj-385	4	3	showed	show	VERB
cuesj-385	4	4	very	very	ADV
cuesj-385	4	5	significant	significant	ADJ
cuesj-385	4	6	differences	difference	NOUN
cuesj-385	4	7	between	between	ADP
cuesj-385	4	8	patients	patient	NOUN
cuesj-385	4	9	and	and	CCONJ
cuesj-385	4	10	control	control	NOUN
cuesj-385	4	11	subjects	subject	NOUN
cuesj-385	4	12	in	in	ADP
cuesj-385	4	13	the	the	DET
cuesj-385	4	14	p53	p53	NOUN
cuesj-385	4	15	-	-	PUNCT
cuesj-385	4	16	positive	positive	ADJ
cuesj-385	4	17	rate	rate	NOUN
cuesj-385	4	18	(	(	PUNCT
cuesj-385	4	19	p	p	X
cuesj-385	4	20	<	<	X
cuesj-385	4	21	0.001	0.001	NUM
cuesj-385	4	22	)	)	PUNCT
cuesj-385	4	23	.	.	PUNCT
cuesj-385	5	1	tp53	tp53	PROPN
cuesj-385	5	2	pro	pro	ADJ
cuesj-385	5	3	/	/	SYM
cuesj-385	5	4	pro	pro	ADJ
cuesj-385	5	5	genotype	genotype	NOUN
cuesj-385	5	6	positivity	positivity	NOUN
cuesj-385	5	7	was	be	AUX
cuesj-385	5	8	higher	high	ADJ
cuesj-385	5	9	in	in	ADP
cuesj-385	5	10	the	the	DET
cuesj-385	5	11	control	control	NOUN
cuesj-385	5	12	group	group	NOUN
cuesj-385	5	13	than	than	ADP
cuesj-385	5	14	in	in	ADP
cuesj-385	5	15	the	the	DET
cuesj-385	5	16	patient	patient	NOUN
cuesj-385	5	17	group	group	NOUN
cuesj-385	5	18	and	and	CCONJ
cuesj-385	5	19	this	this	PRON
cuesj-385	5	20	was	be	AUX
cuesj-385	5	21	a	a	DET
cuesj-385	5	22	significant	significant	ADJ
cuesj-385	5	23	difference	difference	NOUN
cuesj-385	5	24	(	(	PUNCT
cuesj-385	5	25	p	p	X
cuesj-385	5	26	<	<	X
cuesj-385	5	27	0.001	0.001	NUM
cuesj-385	5	28	)	)	PUNCT
cuesj-385	5	29	with	with	ADP
cuesj-385	5	30	an	an	DET
cuesj-385	5	31	odds	odd	NOUN
cuesj-385	5	32	ratio	ratio	NOUN
cuesj-385	5	33	of	of	ADP
cuesj-385	5	34	<	<	X
cuesj-385	5	35	1	1	NUM
cuesj-385	5	36	.	.	PUNCT
cuesj-385	6	1	the	the	DET
cuesj-385	6	2	genotype	genotype	NOUN
cuesj-385	6	3	 	 	SPACE
cuesj-385	6	4	pro	pro	ADJ
cuesj-385	6	5	/	/	ADJ
cuesj-385	6	6	pro	pro	ADJ
cuesj-385	6	7	was	be	AUX
cuesj-385	6	8	considered	consider	VERB
cuesj-385	6	9	to	to	PART
cuesj-385	6	10	be	be	AUX
cuesj-385	6	11	protective	protective	ADJ
cuesj-385	6	12	against	against	ADP
cuesj-385	6	13	colorectal	colorectal	ADJ
cuesj-385	6	14	carcinoma	carcinoma	NOUN
cuesj-385	6	15	preventively	preventively	ADV
cuesj-385	6	16	fractured	fracture	VERB
cuesj-385	6	17	0.767	0.767	NUM
cuesj-385	6	18	.	.	PUNCT
cuesj-385	7	1	the	the	DET
cuesj-385	7	2	positive	positive	ADJ
cuesj-385	7	3	rate	rate	NOUN
cuesj-385	7	4	of	of	ADP
cuesj-385	7	5	p53	p53	NOUN
cuesj-385	7	6	 	 	SPACE
cuesj-385	7	7	arg	arg	PROPN
cuesj-385	7	8	/	/	SYM
cuesj-385	7	9	arg	arg	NOUN
cuesj-385	7	10	genotype	genotype	NOUN
cuesj-385	7	11	in	in	ADP
cuesj-385	7	12	patients	patient	NOUN
cuesj-385	7	13	was	be	AUX
cuesj-385	7	14	more	more	ADV
cuesj-385	7	15	frequent	frequent	ADJ
cuesj-385	7	16	and	and	CCONJ
cuesj-385	7	17	statistically	statistically	ADV
cuesj-385	7	18	significant	significant	ADJ
cuesj-385	7	19	(	(	PUNCT
cuesj-385	7	20	p	p	X
cuesj-385	7	21	<	<	X
cuesj-385	7	22	0.01	0.01	NUM
cuesj-385	7	23	)	)	PUNCT
cuesj-385	7	24	,	,	PUNCT
cuesj-385	7	25	because	because	SCONJ
cuesj-385	7	26	the	the	DET
cuesj-385	7	27	odd	odd	ADJ
cuesj-385	7	28	ratio	ratio	NOUN
cuesj-385	7	29	was	be	AUX
cuesj-385	7	30	more	more	ADJ
cuesj-385	7	31	than	than	ADP
cuesj-385	7	32	one	one	NUM
cuesj-385	7	33	.	.	PUNCT
cuesj-385	8	1	the	the	DET
cuesj-385	8	2	genotype	genotype	NOUN
cuesj-385	8	3	 	 	SPACE
cuesj-385	8	4	arg	arg	NOUN
cuesj-385	8	5	/	/	SYM
cuesj-385	8	6	arg	arg	NOUN
cuesj-385	8	7	would	would	AUX
cuesj-385	8	8	be	be	AUX
cuesj-385	8	9	considered	consider	VERB
cuesj-385	8	10	a	a	DET
cuesj-385	8	11	colorectal	colorectal	ADJ
cuesj-385	8	12	carcinoma	carcinoma	NOUN
cuesj-385	8	13	risk	risk	NOUN
cuesj-385	8	14	factor	factor	NOUN
cuesj-385	8	15	.	.	PUNCT
cuesj-385	9	1	we	we	PRON
cuesj-385	9	2	conclude	conclude	VERB
cuesj-385	9	3	that	that	SCONJ
cuesj-385	9	4	p53	p53	NOUN
cuesj-385	9	5	overexpression	overexpression	NOUN
cuesj-385	9	6	is	be	AUX
cuesj-385	9	7	used	use	VERB
cuesj-385	9	8	as	as	ADP
cuesj-385	9	9	an	an	DET
cuesj-385	9	10	indicator	indicator	NOUN
cuesj-385	9	11	of	of	ADP
cuesj-385	9	12	p53	p53	NOUN
cuesj-385	9	13	mutation	mutation	NOUN
cuesj-385	9	14	(	(	PUNCT
cuesj-385	9	15	as	as	SCONJ
cuesj-385	9	16	identified	identify	VERB
cuesj-385	9	17	by	by	ADP
cuesj-385	9	18	immunohistoric	immunohistoric	ADJ
cuesj-385	9	19	chemistry	chemistry	NOUN
cuesj-385	9	20	)	)	PUNCT
cuesj-385	9	21	and	and	CCONJ
cuesj-385	9	22	kras	kra	NOUN
cuesj-385	9	23	protein	protein	NOUN
cuesj-385	9	24	expression	expression	NOUN
cuesj-385	9	25	was	be	AUX
cuesj-385	9	26	negatively	negatively	ADV
cuesj-385	9	27	impaired	impaired	ADJ
cuesj-385	9	28	for	for	ADP
cuesj-385	9	29	all	all	DET
cuesj-385	9	30	the	the	DET
cuesj-385	9	31	patients	patient	NOUN
cuesj-385	9	32	in	in	ADP
cuesj-385	9	33	the	the	DET
cuesj-385	9	34	current	current	ADJ
cuesj-385	9	35	study	study	NOUN
cuesj-385	9	36	.	.	PUNCT
cuesj-385	10	1	keywords	keyword	NOUN
cuesj-385	10	2	:	:	PUNCT
cuesj-385	10	3	kirsten	kirsten	ADJ
cuesj-385	10	4	rat	rat	PROPN
cuesj-385	10	5	sarcoma	sarcoma	PROPN
cuesj-385	10	6	virus	virus	NOUN
cuesj-385	10	7	,	,	PUNCT
cuesj-385	10	8	carcinoma	carcinoma	NOUN
cuesj-385	10	9	,	,	PUNCT
cuesj-385	10	10	stage	stage	NOUN
cuesj-385	10	11	,	,	PUNCT
cuesj-385	10	12	colorectal	colorectal	NOUN
cuesj-385	10	13	,	,	PUNCT
cuesj-385	10	14	histology	histology	NOUN
cuesj-385	10	15	introduction	introduction	NOUN
cuesj-385	10	16	carcinogenesis	carcinogenesis	NOUN
cuesj-385	10	17	and	and	CCONJ
cuesj-385	10	18	colorectal	colorectal	ADJ
cuesj-385	10	19	cancer	cancer	NOUN
cuesj-385	10	20	(	(	PUNCT
cuesj-385	10	21	crc	crc	NOUN
cuesj-385	10	22	)	)	PUNCT
cuesj-385	10	23	development	development	NOUN
cuesj-385	10	24	are	be	AUX
cuesj-385	10	25	a	a	DET
cuesj-385	10	26	multistage	multistage	NOUN
cuesj-385	10	27	process	process	NOUN
cuesj-385	10	28	where	where	SCONJ
cuesj-385	10	29	colorectal	colorectal	ADJ
cuesj-385	10	30	epithelial	epithelial	ADJ
cuesj-385	10	31	cells	cell	NOUN
cuesj-385	10	32	are	be	AUX
cuesj-385	10	33	transported	transport	VERB
cuesj-385	10	34	through	through	ADP
cuesj-385	10	35	small	small	ADJ
cuesj-385	10	36	adenoma	adenoma	ADJ
cuesj-385	10	37	,	,	PUNCT
cuesj-385	10	38	large	large	ADJ
cuesj-385	10	39	adenoma	adenoma	ADJ
cuesj-385	10	40	,	,	PUNCT
cuesj-385	10	41	and	and	CCONJ
cuesj-385	10	42	subsequently	subsequently	ADV
cuesj-385	10	43	into	into	ADP
cuesj-385	10	44	adenocarcinoma.[1	adenocarcinoma.[1	ADV
cuesj-385	10	45	]	]	PUNCT
cuesj-385	10	46	the	the	DET
cuesj-385	10	47	development	development	NOUN
cuesj-385	10	48	of	of	ADP
cuesj-385	10	49	crc	crc	NOUN
cuesj-385	10	50	involves	involve	VERB
cuesj-385	10	51	several	several	ADJ
cuesj-385	10	52	steps	step	NOUN
cuesj-385	10	53	,	,	PUNCT
cuesj-385	10	54	which	which	PRON
cuesj-385	10	55	occur	occur	VERB
cuesj-385	10	56	through	through	ADP
cuesj-385	10	57	the	the	DET
cuesj-385	10	58	development	development	NOUN
cuesj-385	10	59	of	of	ADP
cuesj-385	10	60	several	several	ADJ
cuesj-385	10	61	genetic	genetic	ADJ
cuesj-385	10	62	changes	change	NOUN
cuesj-385	10	63	,	,	PUNCT
cuesj-385	10	64	including	include	VERB
cuesj-385	10	65	chromosome	chromosome	NOUN
cuesj-385	10	66	defects	defect	NOUN
cuesj-385	10	67	,	,	PUNCT
cuesj-385	10	68	gene	gene	NOUN
cuesj-385	10	69	mutations	mutation	NOUN
cuesj-385	10	70	,	,	PUNCT
cuesj-385	10	71	and	and	CCONJ
cuesj-385	10	72	the	the	DET
cuesj-385	10	73	epigenetics	epigenetic	NOUN
cuesj-385	10	74	of	of	ADP
cuesj-385	10	75	various	various	ADJ
cuesj-385	10	76	genes	gene	NOUN
cuesj-385	10	77	which	which	PRON
cuesj-385	10	78	control	control	VERB
cuesj-385	10	79	and	and	CCONJ
cuesj-385	10	80	differentiate	differentiate	VERB
cuesj-385	10	81	cell	cell	NOUN
cuesj-385	10	82	growth	growth	NOUN
cuesj-385	10	83	,	,	PUNCT
cuesj-385	10	84	apoptosis	apoptosis	NOUN
cuesj-385	10	85	,	,	PUNCT
cuesj-385	10	86	and	and	CCONJ
cuesj-385	10	87	angiogenesis	angiogenesis	NOUN
cuesj-385	10	88	.	.	PUNCT
cuesj-385	11	1	crc	crc	NOUN
cuesj-385	11	2	generally	generally	ADV
cuesj-385	11	3	develops	develop	VERB
cuesj-385	11	4	from	from	ADP
cuesj-385	11	5	a	a	DET
cuesj-385	11	6	benign	benign	ADJ
cuesj-385	11	7	polyp	polyp	NOUN
cuesj-385	11	8	called	call	VERB
cuesj-385	11	9	an	an	DET
cuesj-385	11	10	adenoma	adenoma	NOUN
cuesj-385	11	11	and	and	CCONJ
cuesj-385	11	12	the	the	DET
cuesj-385	11	13	subsequent	subsequent	ADJ
cuesj-385	11	14	abnormal	abnormal	ADJ
cuesj-385	11	15	cell	cell	NOUN
cuesj-385	11	16	growth	growth	NOUN
cuesj-385	11	17	,	,	PUNCT
cuesj-385	11	18	leading	lead	VERB
cuesj-385	11	19	to	to	ADP
cuesj-385	11	20	carcinoma	carcinoma	NOUN
cuesj-385	11	21	,	,	PUNCT
cuesj-385	11	22	which	which	PRON
cuesj-385	11	23	can	can	AUX
cuesj-385	11	24	spread	spread	VERB
cuesj-385	11	25	to	to	ADP
cuesj-385	11	26	other	other	ADJ
cuesj-385	11	27	areas	area	NOUN
cuesj-385	11	28	of	of	ADP
cuesj-385	11	29	the	the	DET
cuesj-385	11	30	body.[2,3	body.[2,3	NOUN
cuesj-385	11	31	]	]	X
cuesj-385	11	32	tumor	tumor	NOUN
cuesj-385	11	33	suppressing	suppress	VERB
cuesj-385	11	34	genes	gene	NOUN
cuesj-385	11	35	and	and	CCONJ
cuesj-385	11	36	oncogenes	oncogene	NOUN
cuesj-385	11	37	mutations	mutation	NOUN
cuesj-385	11	38	and	and	CCONJ
cuesj-385	11	39	probably	probably	ADV
cuesj-385	11	40	several	several	ADJ
cuesj-385	11	41	pathways	pathway	NOUN
cuesj-385	11	42	lead	lead	VERB
cuesj-385	11	43	to	to	ADP
cuesj-385	11	44	lesion	lesion	NOUN
cuesj-385	11	45	pathology	pathology	NOUN
cuesj-385	11	46	transitions	transition	NOUN
cuesj-385	11	47	and	and	CCONJ
cuesj-385	11	48	tumor	tumor	NOUN
cuesj-385	11	49	drive	drive	VERB
cuesj-385	11	50	toward	toward	ADP
cuesj-385	11	51	malignancy	malignancy	NOUN
cuesj-385	11	52	and	and	CCONJ
cuesj-385	11	53	metastasis.[3	metastasis.[3	NOUN
cuesj-385	11	54	]	]	X
cuesj-385	11	55	crc	crc	NOUN
cuesj-385	11	56	is	be	AUX
cuesj-385	11	57	not	not	PART
cuesj-385	11	58	one	one	NUM
cuesj-385	11	59	disease	disease	NOUN
cuesj-385	11	60	;	;	PUNCT
cuesj-385	11	61	it	it	PRON
cuesj-385	11	62	involves	involve	VERB
cuesj-385	11	63	a	a	DET
cuesj-385	11	64	heterogeneous	heterogeneous	ADJ
cuesj-385	11	65	complex	complex	NOUN
cuesj-385	11	66	of	of	ADP
cuesj-385	11	67	diseases	disease	NOUN
cuesj-385	11	68	with	with	ADP
cuesj-385	11	69	various	various	ADJ
cuesj-385	11	70	genetic	genetic	ADJ
cuesj-385	11	71	and	and	CCONJ
cuesj-385	11	72	epigenetic	epigenetic	ADJ
cuesj-385	11	73	changes.[4	changes.[4	NOUN
cuesj-385	11	74	]	]	PUNCT
cuesj-385	11	75	modifications	modification	NOUN
cuesj-385	11	76	of	of	ADP
cuesj-385	11	77	various	various	ADJ
cuesj-385	11	78	genes	gene	NOUN
cuesj-385	11	79	include	include	VERB
cuesj-385	11	80	activating	activate	VERB
cuesj-385	11	81	k	k	PROPN
cuesj-385	11	82	-	-	PUNCT
cuesj-385	11	83	ras	ras	ADJ
cuesj-385	11	84	oncogene	oncogene	NOUN
cuesj-385	11	85	,	,	PUNCT
cuesj-385	11	86	mutating	mutating	NOUN
cuesj-385	11	87	,	,	PUNCT
cuesj-385	11	88	and	and	CCONJ
cuesj-385	11	89	removing	remove	VERB
cuesj-385	11	90	p53	p53	NOUN
cuesj-385	11	91	antioncogene.[5	antioncogene.[5	NOUN
cuesj-385	11	92	]	]	PUNCT
cuesj-385	11	93	in	in	ADP
cuesj-385	11	94	particular	particular	ADJ
cuesj-385	11	95	,	,	PUNCT
cuesj-385	11	96	mutations	mutation	NOUN
cuesj-385	11	97	of	of	ADP
cuesj-385	11	98	the	the	DET
cuesj-385	11	99	tp53	tp53	PROPN
cuesj-385	11	100	tumor	tumor	NOUN
cuesj-385	11	101	suppressor	suppressor	NOUN
cuesj-385	11	102	gene	gene	NOUN
cuesj-385	11	103	and	and	CCONJ
cuesj-385	11	104	kras	kras	PROPN
cuesj-385	11	105	oncogene	oncogene	PROPN
cuesj-385	11	106	contribute	contribute	VERB
cuesj-385	11	107	to	to	ADP
cuesj-385	11	108	more	more	ADJ
cuesj-385	11	109	than	than	ADP
cuesj-385	11	110	80	80	NUM
cuesj-385	11	111	%	%	NOUN
cuesj-385	11	112	of	of	ADP
cuesj-385	11	113	cases	case	NOUN
cuesj-385	11	114	of	of	ADP
cuesj-385	11	115	crc.[6	crc.[6	PROPN
cuesj-385	11	116	]	]	X
cuesj-385	11	117	tp53	tp53	PROPN
cuesj-385	11	118	encodes	encode	VERB
cuesj-385	11	119	the	the	DET
cuesj-385	11	120	tumor	tumor	NOUN
cuesj-385	11	121	suppressor	suppressor	NOUN
cuesj-385	11	122	protein	protein	NOUN
cuesj-385	11	123	p53	p53	NOUN
cuesj-385	11	124	,	,	PUNCT
cuesj-385	11	125	which	which	PRON
cuesj-385	11	126	is	be	AUX
cuesj-385	11	127	a	a	DET
cuesj-385	11	128	cell	cell	NOUN
cuesj-385	11	129	cycle	cycle	NOUN
cuesj-385	11	130	regulator	regulator	NOUN
cuesj-385	11	131	;	;	PUNCT
cuesj-385	11	132	mutations	mutation	NOUN
cuesj-385	11	133	in	in	ADP
cuesj-385	11	134	tp53	tp53	PROPN
cuesj-385	11	135	leading	lead	VERB
cuesj-385	11	136	to	to	ADP
cuesj-385	11	137	crc	crc	NOUN
cuesj-385	11	138	commonly	commonly	ADV
cuesj-385	11	139	occur	occur	VERB
cuesj-385	11	140	in	in	ADP
cuesj-385	11	141	exons	exon	NOUN
cuesj-385	11	142	5	5	NUM
cuesj-385	11	143	-	-	SYM
cuesj-385	11	144	8	8	NUM
cuesj-385	11	145	.[7	.[7	NOUN
cuesj-385	11	146	]	]	PUNCT
cuesj-385	11	147	in	in	ADP
cuesj-385	11	148	mitogen	mitogen	PROPN
cuesj-385	11	149	active	active	ADJ
cuesj-385	11	150	protein	protein	NOUN
cuesj-385	11	151	kinase	kinase	PROPN
cuesj-385	11	152	signals	signal	NOUN
cuesj-385	11	153	,	,	PUNCT
cuesj-385	11	154	kras	kras	PROPN
cuesj-385	11	155	encodes	encode	VERB
cuesj-385	11	156	a	a	DET
cuesj-385	11	157	gtpase	gtpase	NOUN
cuesj-385	11	158	;	;	PUNCT
cuesj-385	11	159	crcrelated	crcrelate	VERB
cuesj-385	11	160	kras	kras	PROPN
cuesj-385	11	161	mutations	mutation	NOUN
cuesj-385	11	162	are	be	AUX
cuesj-385	11	163	common	common	ADJ
cuesj-385	11	164	in	in	ADP
cuesj-385	11	165	codons	codon	NOUN
cuesj-385	11	166	12	12	NUM
cuesj-385	11	167	and	and	CCONJ
cuesj-385	11	168	13	13	NUM
cuesj-385	11	169	,	,	PUNCT
cuesj-385	11	170	both	both	CCONJ
cuesj-385	11	171	within	within	ADP
cuesj-385	11	172	exon.[8	exon.[8	NOUN
cuesj-385	11	173	]	]	PUNCT
cuesj-385	11	174	then	then	ADV
cuesj-385	11	175	,	,	PUNCT
cuesj-385	11	176	the	the	DET
cuesj-385	11	177	aim	aim	NOUN
cuesj-385	11	178	of	of	ADP
cuesj-385	11	179	this	this	DET
cuesj-385	11	180	study	study	NOUN
cuesj-385	11	181	is	be	AUX
cuesj-385	11	182	,	,	PUNCT
cuesj-385	11	183	therefore	therefore	ADV
cuesj-385	11	184	,	,	PUNCT
cuesj-385	11	185	to	to	PART
cuesj-385	11	186	clarify	clarify	VERB
cuesj-385	11	187	the	the	DET
cuesj-385	11	188	proposed	propose	VERB
cuesj-385	11	189	role	role	NOUN
cuesj-385	11	190	for	for	ADP
cuesj-385	11	191	mutations	mutation	NOUN
cuesj-385	11	192	in	in	ADP
cuesj-385	11	193	crc	crc	NOUN
cuesj-385	11	194	of	of	ADP
cuesj-385	11	195	the	the	DET
cuesj-385	11	196	p53	p53	NOUN
cuesj-385	11	197	and	and	CCONJ
cuesj-385	11	198	the	the	DET
cuesj-385	11	199	kras	kras	PROPN
cuesj-385	11	200	genes	gene	NOUN
cuesj-385	11	201	through	through	ADP
cuesj-385	11	202	the	the	DET
cuesj-385	11	203	determination	determination	NOUN
cuesj-385	11	204	of	of	ADP
cuesj-385	11	205	frequent	frequent	ADJ
cuesj-385	11	206	crc	crc	NOUN
cuesj-385	11	207	mutation	mutation	NOUN
cuesj-385	11	208	of	of	ADP
cuesj-385	11	209	kras	kras	PROPN
cuesj-385	11	210	and	and	CCONJ
cuesj-385	11	211	p53	p53	NOUN
cuesj-385	11	212	by	by	ADP
cuesj-385	11	213	estimating	estimate	VERB
cuesj-385	11	214	the	the	DET
cuesj-385	11	215	rate	rate	NOUN
cuesj-385	11	216	of	of	ADP
cuesj-385	11	217	protein	protein	NOUN
cuesj-385	11	218	over	over	ADP
cuesj-385	11	219	-	-	PUNCT
cuesj-385	11	220	expression	expression	NOUN
cuesj-385	11	221	employing	employ	VERB
cuesj-385	11	222	immunohistochemical	immunohistochemical	ADJ
cuesj-385	11	223	(	(	PUNCT
cuesj-385	11	224	ihc	ihc	PROPN
cuesj-385	11	225	)	)	PUNCT
cuesj-385	11	226	staining	stain	VERB
cuesj-385	11	227	and	and	CCONJ
cuesj-385	11	228	anti	anti	ADJ
cuesj-385	11	229	-	-	ADJ
cuesj-385	11	230	kras	kras	ADJ
cuesj-385	11	231	antibodies	antibody	NOUN
cuesj-385	11	232	and	and	CCONJ
cuesj-385	11	233	anit	anit	NOUN
cuesj-385	11	234	-	-	NOUN
cuesj-385	11	235	p53	p53	NOUN
cuesj-385	11	236	,	,	PUNCT
cuesj-385	11	237	respectively	respectively	ADV
cuesj-385	11	238	.	.	PUNCT
cuesj-385	12	1	corresponding	correspond	VERB
cuesj-385	12	2	author	author	NOUN
cuesj-385	12	3	:	:	PUNCT
cuesj-385	12	4	merza	merza	PROPN
cuesj-385	12	5	h.	h.	PROPN
cuesj-385	12	6	homady	homady	PROPN
cuesj-385	12	7	,	,	PUNCT
cuesj-385	12	8	department	department	NOUN
cuesj-385	12	9	of	of	ADP
cuesj-385	12	10	biomedical	biomedical	ADJ
cuesj-385	12	11	sciences	science	NOUN
cuesj-385	12	12	,	,	PUNCT
cuesj-385	12	13	cihan	cihan	VERB
cuesj-385	12	14	university	university	NOUN
cuesj-385	12	15	-	-	PUNCT
cuesj-385	12	16	erbil	erbil	PROPN
cuesj-385	12	17	,	,	PUNCT
cuesj-385	12	18	kurdistan	kurdistan	PROPN
cuesj-385	12	19	region	region	NOUN
cuesj-385	12	20	,	,	PUNCT
cuesj-385	12	21	iraq	iraq	PROPN
cuesj-385	12	22	.	.	PUNCT
cuesj-385	13	1	e	e	X
cuesj-385	13	2	-	-	NOUN
cuesj-385	13	3	mail	mail	NOUN
cuesj-385	13	4	:	:	PUNCT
cuesj-385	13	5	merza.homady@	merza.homady@	NOUN
cuesj-385	13	6	cihanuniversity.edu.iq	cihanuniversity.edu.iq	NOUN
cuesj-385	13	7	received	receive	VERB
cuesj-385	13	8	:	:	PUNCT
cuesj-385	13	9	may	may	AUX
cuesj-385	13	10	16	16	NUM
cuesj-385	13	11	,	,	PUNCT
cuesj-385	13	12	2021	2021	NUM
cuesj-385	13	13	accepted	accept	VERB
cuesj-385	13	14	:	:	PUNCT
cuesj-385	13	15	june	june	PROPN
cuesj-385	13	16	13	13	NUM
cuesj-385	13	17	,	,	PUNCT
cuesj-385	13	18	2021	2021	NUM
cuesj-385	13	19	published	publish	VERB
cuesj-385	13	20	:	:	PUNCT
cuesj-385	13	21	may	may	AUX
cuesj-385	13	22	20	20	NUM
cuesj-385	13	23	,	,	PUNCT
cuesj-385	13	24	2021	2021	NUM
cuesj-385	13	25	doi	doi	NOUN
cuesj-385	13	26	:	:	PUNCT
cuesj-385	13	27	10.24086	10.24086	NUM
cuesj-385	13	28	/	/	SYM
cuesj-385	13	29	cuesj.v5n1y2021.28	cuesj.v5n1y2021.28	X
cuesj-385	13	30	-	-	SYM
cuesj-385	13	31	33	33	NUM
cuesj-385	13	32	copyright	copyright	NOUN
cuesj-385	13	33	©	©	PROPN
cuesj-385	13	34	2021	2021	NUM
cuesj-385	13	35	merza	merza	PROPN
cuesj-385	13	36	h.	h.	PROPN
cuesj-385	13	37	homady	homady	PROPN
cuesj-385	13	38	,	,	PUNCT
cuesj-385	13	39	tanya	tanya	PROPN
cuesj-385	13	40	s.	s.	PROPN
cuesj-385	13	41	salih	salih	PROPN
cuesj-385	13	42	,	,	PUNCT
cuesj-385	13	43	mariamm	mariamm	PROPN
cuesj-385	13	44	m.	m.	PROPN
cuesj-385	13	45	al	al	PROPN
cuesj-385	13	46	-	-	PUNCT
cuesj-385	13	47	jubori	jubori	PROPN
cuesj-385	13	48	,	,	PUNCT
cuesj-385	13	49	mustafa	mustafa	PROPN
cuesj-385	13	50	d.	d.	PROPN
cuesj-385	13	51	younus	younus	PROPN
cuesj-385	13	52	.	.	PUNCT
cuesj-385	14	1	this	this	PRON
cuesj-385	14	2	is	be	AUX
cuesj-385	14	3	an	an	DET
cuesj-385	14	4	open	open	ADJ
cuesj-385	14	5	-	-	PUNCT
cuesj-385	14	6	access	access	NOUN
cuesj-385	14	7	article	article	NOUN
cuesj-385	14	8	distributed	distribute	VERB
cuesj-385	14	9	under	under	ADP
cuesj-385	14	10	the	the	DET
cuesj-385	14	11	creative	creative	ADJ
cuesj-385	14	12	commons	common	NOUN
cuesj-385	14	13	attribution	attribution	NOUN
cuesj-385	14	14	license	license	NOUN
cuesj-385	14	15	(	(	PUNCT
cuesj-385	14	16	cc	cc	NOUN
cuesj-385	14	17	by	by	ADP
cuesj-385	14	18	-	-	PUNCT
cuesj-385	14	19	nc	nc	VERB
cuesj-385	14	20	-	-	PROPN
cuesj-385	14	21	nd	nd	PRON
cuesj-385	14	22	4.0	4.0	NUM
cuesj-385	14	23	)	)	PUNCT
cuesj-385	14	24	.	.	PUNCT
cuesj-385	15	1	cihan	cihan	VERB
cuesj-385	15	2	university	university	NOUN
cuesj-385	15	3	-	-	PUNCT
cuesj-385	15	4	erbil	erbil	PROPN
cuesj-385	15	5	scientific	scientific	ADJ
cuesj-385	15	6	journal	journal	NOUN
cuesj-385	15	7	(	(	PUNCT
cuesj-385	15	8	cuesj	cuesj	PROPN
cuesj-385	15	9	)	)	PUNCT
cuesj-385	15	10	homady	homady	NOUN
cuesj-385	15	11	,	,	PUNCT
cuesj-385	15	12	et	et	PROPN
cuesj-385	15	13	al	al	PROPN
cuesj-385	15	14	.	.	PROPN
cuesj-385	15	15	:	:	PUNCT
cuesj-385	16	1	immunohistochemical	immunohistochemical	ADJ
cuesj-385	16	2	and	and	CCONJ
cuesj-385	16	3	molecular	molecular	ADJ
cuesj-385	16	4	studies	study	NOUN
cuesj-385	16	5	of	of	ADP
cuesj-385	16	6	p53	p53	NOUN
cuesj-385	16	7	and	and	CCONJ
cuesj-385	16	8	kras	kras	PROPN
cuesj-385	16	9	protein	protein	NOUN
cuesj-385	16	10	29	29	NUM
cuesj-385	16	11	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	16	12	cuesj	cuesj	ADJ
cuesj-385	16	13	2021	2021	NUM
cuesj-385	16	14	,	,	PUNCT
cuesj-385	16	15	5	5	NUM
cuesj-385	16	16	(	(	PUNCT
cuesj-385	16	17	1	1	NUM
cuesj-385	16	18	):	):	PUNCT
cuesj-385	16	19	28	28	NUM
cuesj-385	16	20	-	-	SYM
cuesj-385	16	21	33	33	NUM
cuesj-385	16	22	materials	material	NOUN
cuesj-385	16	23	and	and	CCONJ
cuesj-385	16	24	methods	method	NOUN
cuesj-385	16	25	this	this	DET
cuesj-385	16	26	study	study	NOUN
cuesj-385	16	27	was	be	AUX
cuesj-385	16	28	conducted	conduct	VERB
cuesj-385	16	29	in	in	ADP
cuesj-385	16	30	the	the	DET
cuesj-385	16	31	faculty	faculty	NOUN
cuesj-385	16	32	of	of	ADP
cuesj-385	16	33	science	science	NOUN
cuesj-385	16	34	,	,	PUNCT
cuesj-385	16	35	university	university	PROPN
cuesj-385	16	36	of	of	ADP
cuesj-385	16	37	kufa	kufa	PROPN
cuesj-385	16	38	,	,	PUNCT
cuesj-385	16	39	molecular	molecular	ADJ
cuesj-385	16	40	laboratories	laboratory	NOUN
cuesj-385	16	41	and	and	CCONJ
cuesj-385	16	42	al	al	PROPN
cuesj-385	16	43	-	-	PUNCT
cuesj-385	16	44	sadar	sadar	PROPN
cuesj-385	16	45	teaching	teaching	NOUN
cuesj-385	16	46	hospital	hospital	NOUN
cuesj-385	16	47	in	in	ADP
cuesj-385	16	48	al	al	PROPN
cuesj-385	16	49	-	-	PUNCT
cuesj-385	16	50	najaf	najaf	PROPN
cuesj-385	16	51	province	province	NOUN
cuesj-385	16	52	.	.	PUNCT
cuesj-385	17	1	each	each	DET
cuesj-385	17	2	paraffin	paraffin	NOUN
cuesj-385	17	3	block	block	NOUN
cuesj-385	17	4	was	be	AUX
cuesj-385	17	5	processed	process	VERB
cuesj-385	17	6	using	use	VERB
cuesj-385	17	7	hematoxylin	hematoxylin	NOUN
cuesj-385	17	8	and	and	CCONJ
cuesj-385	17	9	eosin	eosin	NOUN
cuesj-385	17	10	stain	stain	NOUN
cuesj-385	17	11	for	for	ADP
cuesj-385	17	12	histopathological	histopathological	ADJ
cuesj-385	17	13	assessment	assessment	NOUN
cuesj-385	17	14	,	,	PUNCT
cuesj-385	17	15	mutations	mutation	NOUN
cuesj-385	17	16	in	in	ADP
cuesj-385	17	17	p53	p53	NOUN
cuesj-385	17	18	(	(	PUNCT
cuesj-385	17	19	exon	exon	NOUN
cuesj-385	17	20	4	4	NUM
cuesj-385	17	21	codons	codon	NOUN
cuesj-385	17	22	72	72	NUM
cuesj-385	17	23	)	)	PUNCT
cuesj-385	17	24	were	be	AUX
cuesj-385	17	25	detected	detect	VERB
cuesj-385	17	26	by	by	ADP
cuesj-385	17	27	polymerase	polymerase	NOUN
cuesj-385	17	28	chain	chain	NOUN
cuesj-385	17	29	reaction	reaction	NOUN
cuesj-385	17	30	(	(	PUNCT
cuesj-385	17	31	pcr	pcr	PROPN
cuesj-385	17	32	)	)	PUNCT
cuesj-385	17	33	,	,	PUNCT
cuesj-385	17	34	mutations	mutation	NOUN
cuesj-385	17	35	detected	detect	VERB
cuesj-385	17	36	throughout	throughout	ADP
cuesj-385	17	37	restriction	restriction	NOUN
cuesj-385	17	38	fragment	fragment	NOUN
cuesj-385	17	39	length	length	NOUN
cuesj-385	17	40	polymorphism	polymorphism	NOUN
cuesj-385	17	41	-	-	PUNCT
cuesj-385	17	42	pcr	pcr	NOUN
cuesj-385	17	43	(	(	PUNCT
cuesj-385	17	44	rflp	rflp	NOUN
cuesj-385	17	45	-	-	PUNCT
cuesj-385	17	46	pcr	pcr	NOUN
cuesj-385	17	47	)	)	PUNCT
cuesj-385	17	48	in	in	ADP
cuesj-385	17	49	krason	krason	PROPN
cuesj-385	17	50	(	(	PUNCT
cuesj-385	17	51	exon	exon	NOUN
cuesj-385	17	52	2	2	NUM
cuesj-385	17	53	codon	codon	NOUN
cuesj-385	17	54	12	12	NUM
cuesj-385	17	55	)	)	PUNCT
cuesj-385	17	56	,	,	PUNCT
cuesj-385	17	57	protein	protein	NOUN
cuesj-385	17	58	expression	expression	NOUN
cuesj-385	17	59	had	have	AUX
cuesj-385	17	60	been	be	AUX
cuesj-385	17	61	detected	detect	VERB
cuesj-385	17	62	in	in	ADP
cuesj-385	17	63	p53	p53	NOUN
cuesj-385	17	64	and	and	CCONJ
cuesj-385	17	65	the	the	DET
cuesj-385	17	66	immunohistochemical	immunohistochemical	ADJ
cuesj-385	17	67	method	method	NOUN
cuesj-385	17	68	of	of	ADP
cuesj-385	17	69	kras	kras	PROPN
cuesj-385	17	70	.	.	PUNCT
cuesj-385	18	1	mouse	mouse	PROPN
cuesj-385	18	2	monoclonal	monoclonal	NOUN
cuesj-385	18	3	anti	anti	ADJ
cuesj-385	18	4	-	-	ADJ
cuesj-385	18	5	human	human	ADJ
cuesj-385	18	6	kras	kras	PROPN
cuesj-385	18	7	,	,	PUNCT
cuesj-385	18	8	p53	p53	NOUN
cuesj-385	18	9	,	,	PUNCT
cuesj-385	18	10	and	and	CCONJ
cuesj-385	18	11	p53	p53	NOUN
cuesj-385	18	12	were	be	AUX
cuesj-385	18	13	used	use	VERB
cuesj-385	18	14	to	to	PART
cuesj-385	18	15	detect	detect	VERB
cuesj-385	18	16	kras	kra	NOUN
cuesj-385	18	17	as	as	ADP
cuesj-385	18	18	primary	primary	ADJ
cuesj-385	18	19	antibodies	antibody	NOUN
cuesj-385	18	20	,	,	PUNCT
cuesj-385	18	21	and	and	CCONJ
cuesj-385	18	22	p53	p53	NOUN
cuesj-385	18	23	proteins	protein	NOUN
cuesj-385	18	24	were	be	AUX
cuesj-385	18	25	described	describe	VERB
cuesj-385	18	26	by	by	ADP
cuesj-385	18	27	al	al	PROPN
cuesj-385	18	28	-	-	PUNCT
cuesj-385	18	29	juborii(20l5).[9	juborii(20l5).[9	PROPN
cuesj-385	18	30	]	]	PUNCT
cuesj-385	18	31	staining	stain	VERB
cuesj-385	18	32	results	result	NOUN
cuesj-385	18	33	:	:	PUNCT
cuesj-385	18	34	a	a	DET
cuesj-385	18	35	visual	visual	ADJ
cuesj-385	18	36	scoring	scoring	NOUN
cuesj-385	18	37	system	system	NOUN
cuesj-385	18	38	was	be	AUX
cuesj-385	18	39	used	use	VERB
cuesj-385	18	40	by	by	ADP
cuesj-385	18	41	a	a	DET
cuesj-385	18	42	light	light	ADJ
cuesj-385	18	43	microscope	microscope	NOUN
cuesj-385	18	44	based	base	VERB
cuesj-385	18	45	on	on	ADP
cuesj-385	18	46	the	the	DET
cuesj-385	18	47	number	number	NOUN
cuesj-385	18	48	of	of	ADP
cuesj-385	18	49	positively	positively	ADV
cuesj-385	18	50	stained	stain	VERB
cuesj-385	18	51	neoplastic	neoplastic	ADJ
cuesj-385	18	52	cells	cell	NOUN
cuesj-385	18	53	in	in	ADP
cuesj-385	18	54	each	each	DET
cuesj-385	18	55	sample	sample	NOUN
cuesj-385	18	56	of	of	ADP
cuesj-385	18	57	tissue	tissue	NOUN
cuesj-385	18	58	.	.	PUNCT
cuesj-385	19	1	the	the	DET
cuesj-385	19	2	intensity	intensity	NOUN
cuesj-385	19	3	and	and	CCONJ
cuesj-385	19	4	staining	stain	VERB
cuesj-385	19	5	pattern	pattern	NOUN
cuesj-385	19	6	was	be	AUX
cuesj-385	19	7	assigned	assign	VERB
cuesj-385	19	8	to	to	ADP
cuesj-385	19	9	each	each	DET
cuesj-385	19	10	slide	slide	NOUN
cuesj-385	19	11	.	.	PUNCT
cuesj-385	20	1	total	total	ADJ
cuesj-385	20	2	intensity	intensity	NOUN
cuesj-385	20	3	ratings	rating	NOUN
cuesj-385	20	4	were	be	AUX
cuesj-385	20	5	evaluated	evaluate	VERB
cuesj-385	20	6	by	by	ADP
cuesj-385	20	7	counting	count	VERB
cuesj-385	20	8	the	the	DET
cuesj-385	20	9	percentage	percentage	NOUN
cuesj-385	20	10	of	of	ADP
cuesj-385	20	11	positive	positive	ADJ
cuesj-385	20	12	cells	cell	NOUN
cuesj-385	20	13	in	in	ADP
cuesj-385	20	14	100	100	NUM
cuesj-385	20	15	malignant	malignant	ADJ
cuesj-385	20	16	cells	cell	NOUN
cuesj-385	20	17	at	at	ADP
cuesj-385	20	18	40×	40×	NUM
cuesj-385	20	19	total	total	ADJ
cuesj-385	20	20	objective	objective	ADJ
cuesj-385	20	21	magnification	magnification	NOUN
cuesj-385	20	22	.	.	PUNCT
cuesj-385	21	1	the	the	DET
cuesj-385	21	2	immunostaining	immunostaining	NOUN
cuesj-385	21	3	was	be	AUX
cuesj-385	21	4	calculated	calculate	VERB
cuesj-385	21	5	as	as	ADP
cuesj-385	21	6	a	a	DET
cuesj-385	21	7	percent	percent	NOUN
cuesj-385	21	8	by	by	ADP
cuesj-385	21	9	the	the	DET
cuesj-385	21	10	number	number	NOUN
cuesj-385	21	11	of	of	ADP
cuesj-385	21	12	malignant	malignant	ADJ
cuesj-385	21	13	cells	cell	NOUN
cuesj-385	21	14	immunostaining	immunostaine	VERB
cuesj-385	21	15	(	(	PUNCT
cuesj-385	21	16	semi	semi	ADJ
cuesj-385	21	17	-	-	ADJ
cuesj-385	21	18	quantitative	quantitative	ADJ
cuesj-385	21	19	scoring	scoring	NOUN
cuesj-385	21	20	)	)	PUNCT
cuesj-385	21	21	.	.	PUNCT
cuesj-385	22	1	the	the	DET
cuesj-385	22	2	intensity	intensity	NOUN
cuesj-385	22	3	of	of	ADP
cuesj-385	22	4	stain	stain	NOUN
cuesj-385	22	5	was	be	AUX
cuesj-385	22	6	measured	measure	VERB
cuesj-385	22	7	by	by	ADP
cuesj-385	22	8	counting	count	VERB
cuesj-385	22	9	the	the	DET
cuesj-385	22	10	positive	positive	ADJ
cuesj-385	22	11	cell	cell	NOUN
cuesj-385	22	12	percentage	percentage	NOUN
cuesj-385	22	13	in	in	ADP
cuesj-385	22	14	100	100	NUM
cuesj-385	22	15	malignant	malignant	ADJ
cuesj-385	22	16	cells	cell	NOUN
cuesj-385	22	17	in	in	ADP
cuesj-385	22	18	25	25	NUM
cuesj-385	22	19	fields	field	NOUN
cuesj-385	22	20	representing	represent	VERB
cuesj-385	22	21	the	the	DET
cuesj-385	22	22	most	most	ADV
cuesj-385	22	23	positive	positive	ADJ
cuesj-385	22	24	area	area	NOUN
cuesj-385	22	25	with	with	ADP
cuesj-385	22	26	an	an	DET
cuesj-385	22	27	objective	objective	ADJ
cuesj-385	22	28	magnification	magnification	NOUN
cuesj-385	22	29	of	of	ADP
cuesj-385	22	30	40×.	40×.	NOUN
cuesj-385	22	31	the	the	DET
cuesj-385	22	32	staining	stain	VERB
cuesj-385	22	33	pattern	pattern	NOUN
cuesj-385	22	34	(	(	PUNCT
cuesj-385	22	35	qualitative	qualitative	ADJ
cuesj-385	22	36	assessment	assessment	NOUN
cuesj-385	22	37	)	)	PUNCT
cuesj-385	22	38	was	be	AUX
cuesj-385	22	39	either	either	CCONJ
cuesj-385	22	40	faint	faint	ADJ
cuesj-385	22	41	(	(	PUNCT
cuesj-385	22	42	staining	stain	VERB
cuesj-385	22	43	pattern	pattern	NOUN
cuesj-385	22	44	that	that	PRON
cuesj-385	22	45	could	could	AUX
cuesj-385	22	46	only	only	ADV
cuesj-385	22	47	be	be	AUX
cuesj-385	22	48	detected	detect	VERB
cuesj-385	22	49	using	use	VERB
cuesj-385	22	50	higher	high	ADJ
cuesj-385	22	51	magnification	magnification	NOUN
cuesj-385	22	52	,	,	PUNCT
cuesj-385	22	53	×40	×40	PROPN
cuesj-385	22	54	objective	objective	NOUN
cuesj-385	22	55	)	)	PUNCT
cuesj-385	22	56	or	or	CCONJ
cuesj-385	22	57	dense	dense	ADJ
cuesj-385	22	58	(	(	PUNCT
cuesj-385	22	59	a	a	DET
cuesj-385	22	60	diffuse	diffuse	ADJ
cuesj-385	22	61	cytoplasmic	cytoplasmic	ADJ
cuesj-385	22	62	staining	stain	VERB
cuesj-385	22	63	pattern	pattern	NOUN
cuesj-385	22	64	and	and	CCONJ
cuesj-385	22	65	easily	easily	ADV
cuesj-385	22	66	be	be	AUX
cuesj-385	22	67	seen	see	VERB
cuesj-385	22	68	by	by	ADP
cuesj-385	22	69	lower	low	ADJ
cuesj-385	22	70	power	power	NOUN
cuesj-385	22	71	objective	objective	ADJ
cuesj-385	22	72	×4	×4	NOUN
cuesj-385	22	73	)	)	PUNCT
cuesj-385	22	74	.	.	PUNCT
cuesj-385	23	1	kras	kras	PROPN
cuesj-385	23	2	tissue	tissue	NOUN
cuesj-385	23	3	evaluation	evaluation	NOUN
cuesj-385	23	4	:	:	PUNCT
cuesj-385	23	5	three	three	NUM
cuesj-385	23	6	scoring	scoring	NOUN
cuesj-385	23	7	scales	scale	NOUN
cuesj-385	23	8	were	be	AUX
cuesj-385	23	9	applied	apply	VERB
cuesj-385	23	10	at	at	ADP
cuesj-385	23	11	×40	×40	PROPN
cuesj-385	23	12	objective,[10,11	objective,[10,11	NOUN
cuesj-385	23	13	]	]	PUNCT
cuesj-385	23	14	as	as	SCONJ
cuesj-385	23	15	follows	follow	VERB
cuesj-385	23	16	:	:	PUNCT
cuesj-385	23	17	score	score	NOUN
cuesj-385	23	18	0	0	NUM
cuesj-385	23	19	:	:	PUNCT
cuesj-385	23	20	none	none	NOUN
cuesj-385	23	21	of	of	ADP
cuesj-385	23	22	the	the	DET
cuesj-385	23	23	cells	cell	NOUN
cuesj-385	23	24	revealed	reveal	VERB
cuesj-385	23	25	positively	positively	ADV
cuesj-385	23	26	for	for	ADP
cuesj-385	23	27	tumor	tumor	NOUN
cuesj-385	23	28	marker	marker	NOUN
cuesj-385	23	29	stains	stain	NOUN
cuesj-385	23	30	1score	1score	NUM
cuesj-385	23	31	l	l	NOUN
cuesj-385	23	32	:	:	PUNCT
cuesj-385	23	33	10	10	NUM
cuesj-385	23	34	%	%	NOUN
cuesj-385	23	35	of	of	ADP
cuesj-385	23	36	positive	positive	ADJ
cuesj-385	23	37	tumor	tumor	NOUN
cuesj-385	23	38	cells	cell	NOUN
cuesj-385	23	39	(	(	PUNCT
cuesj-385	23	40	weak	weak	ADJ
cuesj-385	23	41	)	)	PUNCT
cuesj-385	23	42	.	.	PUNCT
cuesj-385	24	1	2score	2score	NUM
cuesj-385	24	2	2	2	NUM
cuesj-385	24	3	:	:	PUNCT
cuesj-385	24	4	<	<	X
cuesj-385	24	5	50	50	NUM
cuesj-385	24	6	%	%	NOUN
cuesj-385	24	7	of	of	ADP
cuesj-385	24	8	positive	positive	ADJ
cuesj-385	24	9	cells	cell	NOUN
cuesj-385	24	10	(	(	PUNCT
cuesj-385	24	11	moderate	moderate	ADJ
cuesj-385	24	12	)	)	PUNCT
cuesj-385	24	13	.	.	PUNCT
cuesj-385	25	1	3	3	NUM
cuesj-385	25	2	score	score	NOUN
cuesj-385	25	3	i3	i3	NOUN
cuesj-385	25	4	:	:	PUNCT
cuesj-385	25	5	≥50	≥50	X
cuesj-385	25	6	%	%	NOUN
cuesj-385	25	7	of	of	ADP
cuesj-385	25	8	positive	positive	ADJ
cuesj-385	25	9	cells	cell	NOUN
cuesj-385	25	10	(	(	PUNCT
cuesj-385	25	11	strong	strong	ADJ
cuesj-385	25	12	)	)	PUNCT
cuesj-385	25	13	.	.	PUNCT
cuesj-385	26	1	p53	p53	NOUN
cuesj-385	26	2	tissue	tissue	NOUN
cuesj-385	26	3	evaluation	evaluation	NOUN
cuesj-385	26	4	:	:	PUNCT
cuesj-385	26	5	p53	p53	NOUN
cuesj-385	26	6	nuclear	nuclear	ADJ
cuesj-385	26	7	protein	protein	NOUN
cuesj-385	26	8	expression	expression	NOUN
cuesj-385	26	9	scored	score	VERB
cuesj-385	26	10	according	accord	VERB
cuesj-385	26	11	to	to	ADP
cuesj-385	26	12	:	:	PUNCT
cuesj-385	26	13	[	[	X
cuesj-385	26	14	12	12	NUM
cuesj-385	26	15	]	]	PUNCT
cuesj-385	26	16	score	score	NOUN
cuesj-385	26	17	0	0	NUM
cuesj-385	26	18	:	:	PUNCT
cuesj-385	26	19	0	0	NUM
cuesj-385	26	20	–	–	PUNCT
cuesj-385	26	21	l0	l0	NOUN
cuesj-385	26	22	%	%	NOUN
cuesj-385	26	23	positive	positive	ADJ
cuesj-385	26	24	staining	staining	NOUN
cuesj-385	26	25	of	of	ADP
cuesj-385	26	26	tumor	tumor	NOUN
cuesj-385	26	27	cells	cell	NOUN
cuesj-385	26	28	considered	consider	VERB
cuesj-385	26	29	negative	negative	ADJ
cuesj-385	26	30	staining	staining	ADJ
cuesj-385	26	31	;	;	PUNCT
cuesj-385	26	32	score	score	NOUN
cuesj-385	26	33	l+	l+	NOUN
cuesj-385	26	34	:	:	PUNCT
cuesj-385	26	35	11–25	11–25	NUM
cuesj-385	26	36	%	%	NOUN
cuesj-385	26	37	i	i	PRON
cuesj-385	26	38	positive	positive	ADJ
cuesj-385	26	39	staining	staining	NOUN
cuesj-385	26	40	of	of	ADP
cuesj-385	26	41	tumor	tumor	NOUN
cuesj-385	26	42	cells	cell	NOUN
cuesj-385	26	43	,	,	PUNCT
cuesj-385	26	44	mild	mild	ADJ
cuesj-385	26	45	or	or	CCONJ
cuesj-385	26	46	weak	weak	ADJ
cuesj-385	26	47	staining	staining	NOUN
cuesj-385	26	48	;	;	PUNCT
cuesj-385	26	49	score	score	NOUN
cuesj-385	26	50	2	2	NUM
cuesj-385	26	51	+	+	NOUN
cuesj-385	26	52	:	:	PUNCT
cuesj-385	26	53	26–50	26–50	NUM
cuesj-385	26	54	%	%	NOUN
cuesj-385	26	55	positive	positive	ADJ
cuesj-385	26	56	staining	staining	NOUN
cuesj-385	26	57	of	of	ADP
cuesj-385	26	58	tumor	tumor	NOUN
cuesj-385	26	59	cells	cell	NOUN
cuesj-385	26	60	,	,	PUNCT
cuesj-385	26	61	moderate	moderate	ADJ
cuesj-385	26	62	staining	staining	NOUN
cuesj-385	26	63	;	;	PUNCT
cuesj-385	26	64	and	and	CCONJ
cuesj-385	26	65	score	score	VERB
cuesj-385	26	66	+3i	+3i	PRON
cuesj-385	26	67	:	:	PUNCT
cuesj-385	26	68	>	>	PUNCT
cuesj-385	26	69	50	50	NUM
cuesj-385	26	70	positive	positive	ADJ
cuesj-385	26	71	staining	staining	NOUN
cuesj-385	26	72	of	of	ADP
cuesj-385	26	73	tumor	tumor	NOUN
cuesj-385	26	74	cells	cell	NOUN
cuesj-385	26	75	,	,	PUNCT
cuesj-385	26	76	strong	strong	ADJ
cuesj-385	26	77	staining	stain	VERB
cuesj-385	26	78	.	.	PUNCT
cuesj-385	27	1	results	result	VERB
cuesj-385	27	2	immunohistochemical	immunohistochemical	ADJ
cuesj-385	27	3	expression	expression	NOUN
cuesj-385	27	4	of	of	ADP
cuesj-385	27	5	p53	p53	NOUN
cuesj-385	27	6	and	and	CCONJ
cuesj-385	27	7	kras	kra	NOUN
cuesj-385	27	8	the	the	DET
cuesj-385	27	9	present	present	ADJ
cuesj-385	27	10	findings	finding	NOUN
cuesj-385	27	11	showed	show	VERB
cuesj-385	27	12	a	a	DET
cuesj-385	27	13	highly	highly	ADV
cuesj-385	27	14	significant	significant	ADJ
cuesj-385	27	15	difference	difference	NOUN
cuesj-385	27	16	in	in	ADP
cuesj-385	27	17	p53	p53	NOUN
cuesj-385	27	18	-	-	PUNCT
cuesj-385	27	19	positive	positive	ADJ
cuesj-385	27	20	rate	rate	NOUN
cuesj-385	27	21	between	between	ADP
cuesj-385	27	22	patients	patient	NOUN
cuesj-385	27	23	and	and	CCONJ
cuesj-385	27	24	control	control	NOUN
cuesj-385	27	25	subjects	subject	NOUN
cuesj-385	27	26	(	(	PUNCT
cuesj-385	27	27	p	p	X
cuesj-385	27	28	<	<	X
cuesj-385	27	29	0.001	0.001	NUM
cuesj-385	27	30	)	)	PUNCT
cuesj-385	27	31	,	,	PUNCT
cuesj-385	27	32	table	table	NOUN
cuesj-385	27	33	l.	l.	PROPN
cuesj-385	27	34	however	however	ADV
cuesj-385	27	35	,	,	PUNCT
cuesj-385	27	36	the	the	DET
cuesj-385	27	37	result	result	NOUN
cuesj-385	27	38	was	be	AUX
cuesj-385	27	39	limited	limit	VERB
cuesj-385	27	40	to	to	ADP
cuesj-385	27	41	patients	patient	NOUN
cuesj-385	27	42	with	with	ADP
cuesj-385	27	43	colonic	colonic	ADJ
cuesj-385	27	44	carcinoma	carcinoma	NOUN
cuesj-385	27	45	(	(	PUNCT
cuesj-385	27	46	46	46	NUM
cuesj-385	27	47	%	%	NOUN
cuesj-385	27	48	)	)	PUNCT
cuesj-385	27	49	whereas	whereas	SCONJ
cuesj-385	27	50	none	none	NOUN
cuesj-385	27	51	of	of	ADP
cuesj-385	27	52	the	the	DET
cuesj-385	27	53	control	control	NOUN
cuesj-385	27	54	subjects	subject	NOUN
cuesj-385	27	55	exhibited	exhibit	VERB
cuesj-385	27	56	a	a	DET
cuesj-385	27	57	positive	positive	ADJ
cuesj-385	27	58	p53	p53	NOUN
cuesj-385	27	59	expression	expression	NOUN
cuesj-385	27	60	(	(	PUNCT
cuesj-385	27	61	0	0	NUM
cuesj-385	27	62	%	%	NOUN
cuesj-385	27	63	)	)	PUNCT
cuesj-385	27	64	.	.	PUNCT
cuesj-385	28	1	the	the	DET
cuesj-385	28	2	p53	p53	NOUN
cuesj-385	28	3	ihc	ihc	PROPN
cuesj-385	28	4	expression	expression	NOUN
cuesj-385	28	5	was	be	AUX
cuesj-385	28	6	detected	detect	VERB
cuesj-385	28	7	as	as	ADP
cuesj-385	28	8	brown	brown	ADJ
cuesj-385	28	9	nuclear	nuclear	ADJ
cuesj-385	28	10	dots	dot	NOUN
cuesj-385	28	11	,	,	PUNCT
cuesj-385	28	12	as	as	SCONJ
cuesj-385	28	13	shown	show	VERB
cuesj-385	28	14	in	in	ADP
cuesj-385	28	15	figures	figure	NOUN
cuesj-385	28	16	l-3	l-3	PROPN
cuesj-385	28	17	.	.	PUNCT
cuesj-385	29	1	the	the	DET
cuesj-385	29	2	score	score	NOUN
cuesj-385	29	3	of	of	ADP
cuesj-385	29	4	p53	p53	NOUN
cuesj-385	29	5	was	be	AUX
cuesj-385	29	6	as	as	SCONJ
cuesj-385	29	7	follows	follow	VERB
cuesj-385	29	8	:	:	PUNCT
cuesj-385	29	9	score	score	NOUN
cuesj-385	29	10	l	l	PROPN
cuesj-385	29	11	accounted	account	VERB
cuesj-385	29	12	for	for	ADP
cuesj-385	29	13	2	2	NUM
cuesj-385	29	14	(	(	PUNCT
cuesj-385	29	15	9	9	NUM
cuesj-385	29	16	%	%	NOUN
cuesj-385	29	17	)	)	PUNCT
cuesj-385	29	18	of	of	ADP
cuesj-385	29	19	total	total	ADJ
cuesj-385	29	20	positive	positive	ADJ
cuesj-385	29	21	cases	case	NOUN
cuesj-385	29	22	;	;	PUNCT
cuesj-385	29	23	score	score	NOUN
cuesj-385	29	24	2	2	NUM
cuesj-385	29	25	was	be	AUX
cuesj-385	29	26	seen	see	VERB
cuesj-385	29	27	in	in	ADP
cuesj-385	29	28	18	18	NUM
cuesj-385	29	29	(	(	PUNCT
cuesj-385	29	30	78	78	NUM
cuesj-385	29	31	%	%	NOUN
cuesj-385	29	32	)	)	PUNCT
cuesj-385	29	33	of	of	ADP
cuesj-385	29	34	figure	figure	NOUN
cuesj-385	29	35	l	l	NOUN
cuesj-385	29	36	:	:	PUNCT
cuesj-385	29	37	immunohistochemical	immunohistochemical	ADJ
cuesj-385	29	38	section	section	NOUN
cuesj-385	29	39	p53	p53	NOUN
cuesj-385	29	40	expression	expression	NOUN
cuesj-385	29	41	in	in	ADP
cuesj-385	29	42	the	the	DET
cuesj-385	29	43	form	form	NOUN
cuesj-385	29	44	of	of	ADP
cuesj-385	29	45	brown	brown	ADJ
cuesj-385	29	46	nuclear	nuclear	ADJ
cuesj-385	29	47	stain	stain	NOUN
cuesj-385	29	48	score	score	NOUN
cuesj-385	29	49	1	1	NUM
cuesj-385	29	50	(	(	PUNCT
cuesj-385	29	51	arrow	arrow	NOUN
cuesj-385	29	52	)	)	PUNCT
cuesj-385	29	53	.	.	PUNCT
cuesj-385	30	1	notice	notice	VERB
cuesj-385	30	2	that	that	SCONJ
cuesj-385	30	3	<	<	NOUN
cuesj-385	30	4	10	10	NUM
cuesj-385	30	5	%	%	NOUN
cuesj-385	30	6	of	of	ADP
cuesj-385	30	7	the	the	DET
cuesj-385	30	8	cells	cell	NOUN
cuesj-385	30	9	are	be	AUX
cuesj-385	30	10	stained	stain	VERB
cuesj-385	30	11	(	(	PUNCT
cuesj-385	30	12	10×	10×	NUM
cuesj-385	30	13	)	)	PUNCT
cuesj-385	30	14	figure	figure	NOUN
cuesj-385	30	15	2	2	NUM
cuesj-385	30	16	:	:	PUNCT
cuesj-385	30	17	immunohistochemical	immunohistochemical	ADJ
cuesj-385	30	18	section	section	NOUN
cuesj-385	30	19	p53	p53	NOUN
cuesj-385	30	20	expression	expression	NOUN
cuesj-385	30	21	in	in	ADP
cuesj-385	30	22	the	the	DET
cuesj-385	30	23	form	form	NOUN
cuesj-385	30	24	of	of	ADP
cuesj-385	30	25	brown	brown	ADJ
cuesj-385	30	26	nuclear	nuclear	ADJ
cuesj-385	30	27	stain	stain	NOUN
cuesj-385	30	28	score	score	NOUN
cuesj-385	30	29	2	2	NUM
cuesj-385	30	30	(	(	PUNCT
cuesj-385	30	31	arrow	arrow	NOUN
cuesj-385	30	32	)	)	PUNCT
cuesj-385	30	33	.	.	PUNCT
cuesj-385	31	1	notice	notice	VERB
cuesj-385	31	2	that	that	SCONJ
cuesj-385	31	3	around	around	ADP
cuesj-385	31	4	10–50	10–50	NUM
cuesj-385	31	5	%	%	NOUN
cuesj-385	31	6	of	of	ADP
cuesj-385	31	7	the	the	DET
cuesj-385	31	8	cells	cell	NOUN
cuesj-385	31	9	are	be	AUX
cuesj-385	31	10	stained	stain	VERB
cuesj-385	31	11	(	(	PUNCT
cuesj-385	31	12	10×	10×	NUM
cuesj-385	31	13	)	)	PUNCT
cuesj-385	31	14	figure	figure	NOUN
cuesj-385	31	15	3	3	NUM
cuesj-385	31	16	:	:	PUNCT
cuesj-385	31	17	immunohistochemical	immunohistochemical	ADJ
cuesj-385	31	18	section	section	NOUN
cuesj-385	31	19	p53	p53	NOUN
cuesj-385	31	20	expression	expression	NOUN
cuesj-385	31	21	in	in	ADP
cuesj-385	31	22	the	the	DET
cuesj-385	31	23	form	form	NOUN
cuesj-385	31	24	of	of	ADP
cuesj-385	31	25	brown	brown	ADJ
cuesj-385	31	26	nuclear	nuclear	ADJ
cuesj-385	31	27	stain	stain	NOUN
cuesj-385	31	28	score	score	NOUN
cuesj-385	31	29	3	3	NUM
cuesj-385	31	30	(	(	PUNCT
cuesj-385	31	31	arrow	arrow	NOUN
cuesj-385	31	32	)	)	PUNCT
cuesj-385	31	33	.	.	PUNCT
cuesj-385	32	1	notice	notice	VERB
cuesj-385	32	2	that	that	SCONJ
cuesj-385	32	3	>	>	PUNCT
cuesj-385	32	4	50	50	NUM
cuesj-385	32	5	%	%	NOUN
cuesj-385	32	6	of	of	ADP
cuesj-385	32	7	the	the	DET
cuesj-385	32	8	cells	cell	NOUN
cuesj-385	32	9	are	be	AUX
cuesj-385	32	10	stained	stain	VERB
cuesj-385	32	11	(	(	PUNCT
cuesj-385	32	12	10×	10×	NUM
cuesj-385	32	13	)	)	PUNCT
cuesj-385	32	14	homady	homady	NOUN
cuesj-385	32	15	,	,	PUNCT
cuesj-385	32	16	et	et	PROPN
cuesj-385	32	17	al	al	PROPN
cuesj-385	32	18	.	.	PROPN
cuesj-385	32	19	:	:	PUNCT
cuesj-385	32	20	immunohistochemical	immunohistochemical	ADJ
cuesj-385	32	21	and	and	CCONJ
cuesj-385	32	22	molecular	molecular	ADJ
cuesj-385	32	23	studies	study	NOUN
cuesj-385	32	24	of	of	ADP
cuesj-385	32	25	p53	p53	NOUN
cuesj-385	32	26	and	and	CCONJ
cuesj-385	32	27	kras	kra	NOUN
cuesj-385	32	28	protein	protein	NOUN
cuesj-385	32	29	30	30	NUM
cuesj-385	32	30	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	32	31	cuesj	cuesj	ADJ
cuesj-385	32	32	2021	2021	NUM
cuesj-385	32	33	,	,	PUNCT
cuesj-385	32	34	5	5	NUM
cuesj-385	32	35	(	(	PUNCT
cuesj-385	32	36	1	1	NUM
cuesj-385	32	37	):	):	PUNCT
cuesj-385	32	38	28	28	NUM
cuesj-385	32	39	-	-	SYM
cuesj-385	32	40	33	33	NUM
cuesj-385	32	41	total	total	ADJ
cuesj-385	32	42	positive	positive	ADJ
cuesj-385	32	43	cases	case	NOUN
cuesj-385	32	44	;	;	PUNCT
cuesj-385	32	45	and	and	CCONJ
cuesj-385	32	46	score	score	NOUN
cuesj-385	32	47	3	3	NUM
cuesj-385	32	48	was	be	AUX
cuesj-385	32	49	present	present	ADJ
cuesj-385	32	50	in	in	ADP
cuesj-385	32	51	3	3	NUM
cuesj-385	32	52	(	(	PUNCT
cuesj-385	32	53	l3	l3	NOUN
cuesj-385	32	54	%	%	NOUN
cuesj-385	32	55	)	)	PUNCT
cuesj-385	32	56	of	of	ADP
cuesj-385	32	57	total	total	ADJ
cuesj-385	32	58	positive	positive	ADJ
cuesj-385	32	59	cases	case	NOUN
cuesj-385	33	1	[	[	X
cuesj-385	33	2	figure	figure	NOUN
cuesj-385	33	3	4	4	NUM
cuesj-385	33	4	]	]	PUNCT
cuesj-385	33	5	.	.	PUNCT
cuesj-385	34	1	the	the	DET
cuesj-385	34	2	present	present	ADJ
cuesj-385	34	3	results	result	NOUN
cuesj-385	34	4	did	do	AUX
cuesj-385	34	5	not	not	PART
cuesj-385	34	6	show	show	VERB
cuesj-385	34	7	any	any	DET
cuesj-385	34	8	significant	significant	ADJ
cuesj-385	34	9	difference	difference	NOUN
cuesj-385	34	10	in	in	ADP
cuesj-385	34	11	the	the	DET
cuesj-385	34	12	mean	mean	ADJ
cuesj-385	34	13	age	age	NOUN
cuesj-385	34	14	of	of	ADP
cuesj-385	34	15	patients	patient	NOUN
cuesj-385	34	16	with	with	ADP
cuesj-385	34	17	positive	positive	ADJ
cuesj-385	34	18	p53	p53	NOUN
cuesj-385	34	19	expression	expression	NOUN
cuesj-385	34	20	in	in	ADP
cuesj-385	34	21	comparison	comparison	NOUN
cuesj-385	34	22	to	to	ADP
cuesj-385	34	23	patients	patient	NOUN
cuesj-385	34	24	with	with	ADP
cuesj-385	34	25	negative	negative	ADJ
cuesj-385	34	26	p53	p53	NOUN
cuesj-385	34	27	expression	expression	NOUN
cuesj-385	34	28	.	.	PUNCT
cuesj-385	35	1	moreover	moreover	ADV
cuesj-385	35	2	,	,	PUNCT
cuesj-385	35	3	patients	patient	NOUN
cuesj-385	35	4	with	with	ADP
cuesj-385	35	5	rectosigmoid	rectosigmoid	NOUN
cuesj-385	35	6	location	location	NOUN
cuesj-385	35	7	showed	show	VERB
cuesj-385	35	8	the	the	DET
cuesj-385	35	9	highest	high	ADJ
cuesj-385	35	10	rate	rate	NOUN
cuesj-385	35	11	of	of	ADP
cuesj-385	35	12	p53	p53	NOUN
cuesj-385	35	13	expression	expression	NOUN
cuesj-385	35	14	(	(	PUNCT
cuesj-385	35	15	53.33	53.33	NUM
cuesj-385	35	16	%	%	NOUN
cuesj-385	35	17	)	)	PUNCT
cuesj-385	35	18	.	.	PUNCT
cuesj-385	36	1	in	in	ADP
cuesj-385	36	2	addition	addition	NOUN
cuesj-385	36	3	,	,	PUNCT
cuesj-385	36	4	there	there	PRON
cuesj-385	36	5	was	be	VERB
cuesj-385	36	6	no	no	DET
cuesj-385	36	7	significant	significant	ADJ
cuesj-385	36	8	association	association	NOUN
cuesj-385	36	9	between	between	ADP
cuesj-385	36	10	the	the	DET
cuesj-385	36	11	site	site	NOUN
cuesj-385	36	12	of	of	ADP
cuesj-385	36	13	colonic	colonic	ADJ
cuesj-385	36	14	tumor	tumor	NOUN
cuesj-385	36	15	,	,	PUNCT
cuesj-385	36	16	stage	stage	NOUN
cuesj-385	36	17	or	or	CCONJ
cuesj-385	36	18	grade	grade	NOUN
cuesj-385	36	19	,	,	PUNCT
cuesj-385	36	20	and	and	CCONJ
cuesj-385	36	21	p53	p53	NOUN
cuesj-385	36	22	expression	expression	NOUN
cuesj-385	36	23	.	.	PUNCT
cuesj-385	37	1	kras	kra	NOUN
cuesj-385	37	2	expression	expression	NOUN
cuesj-385	37	3	the	the	DET
cuesj-385	37	4	immunohistochemical	immunohistochemical	ADJ
cuesj-385	37	5	results	result	NOUN
cuesj-385	37	6	were	be	AUX
cuesj-385	37	7	negative	negative	ADJ
cuesj-385	37	8	in	in	ADP
cuesj-385	37	9	all	all	DET
cuesj-385	37	10	cases	case	NOUN
cuesj-385	37	11	of	of	ADP
cuesj-385	37	12	colonic	colonic	ADJ
cuesj-385	37	13	adenocarcinoma	adenocarcinoma	NOUN
cuesj-385	37	14	and	and	CCONJ
cuesj-385	37	15	there	there	PRON
cuesj-385	37	16	was	be	VERB
cuesj-385	37	17	not	not	PART
cuesj-385	37	18	significant	significant	ADJ
cuesj-385	37	19	correlation	correlation	NOUN
cuesj-385	37	20	between	between	ADP
cuesj-385	37	21	greyscale	greyscale	NOUN
cuesj-385	37	22	and	and	CCONJ
cuesj-385	37	23	stage	stage	NOUN
cuesj-385	37	24	of	of	ADP
cuesj-385	37	25	tumor	tumor	NOUN
cuesj-385	37	26	(	(	PUNCT
cuesj-385	37	27	r	r	NOUN
cuesj-385	37	28	=	=	SYM
cuesj-385	37	29	−0.l50	−0.l50	NOUN
cuesj-385	37	30	,	,	PUNCT
cuesj-385	37	31	p	p	X
cuesj-385	37	32	>	>	X
cuesj-385	37	33	0.05	0.05	NUM
cuesj-385	37	34	)	)	PUNCT
cuesj-385	37	35	,	,	PUNCT
cuesj-385	38	1	[	[	X
cuesj-385	38	2	figure	figure	NOUN
cuesj-385	38	3	5	5	NUM
cuesj-385	38	4	]	]	PUNCT
cuesj-385	38	5	.	.	PUNCT
cuesj-385	39	1	in	in	ADP
cuesj-385	39	2	addition	addition	NOUN
cuesj-385	39	3	,	,	PUNCT
cuesj-385	39	4	these	these	DET
cuesj-385	39	5	findings	finding	NOUN
cuesj-385	39	6	did	do	AUX
cuesj-385	39	7	not	not	PART
cuesj-385	39	8	show	show	VERB
cuesj-385	39	9	any	any	DET
cuesj-385	39	10	significant	significant	ADJ
cuesj-385	39	11	differences	difference	NOUN
cuesj-385	39	12	in	in	ADP
cuesj-385	39	13	mean	mean	ADJ
cuesj-385	39	14	gray	gray	ADJ
cuesj-385	39	15	scale	scale	NOUN
cuesj-385	39	16	between	between	ADP
cuesj-385	39	17	patients	patient	NOUN
cuesj-385	39	18	with	with	ADP
cuesj-385	39	19	positive	positive	ADJ
cuesj-385	39	20	p53	p53	NOUN
cuesj-385	39	21	expression	expression	NOUN
cuesj-385	39	22	and	and	CCONJ
cuesj-385	39	23	patients	patient	NOUN
cuesj-385	39	24	with	with	ADP
cuesj-385	39	25	negative	negative	ADJ
cuesj-385	39	26	p53	p53	NOUN
cuesj-385	39	27	expression	expression	NOUN
cuesj-385	39	28	p53	p53	NOUN
cuesj-385	39	29	genotype	genotype	NOUN
cuesj-385	39	30	determined	determine	VERB
cuesj-385	39	31	by	by	ADP
cuesj-385	39	32	pcr	pcr	NOUN
cuesj-385	39	33	the	the	DET
cuesj-385	39	34	rate	rate	NOUN
cuesj-385	39	35	of	of	ADP
cuesj-385	39	36	positivity	positivity	NOUN
cuesj-385	39	37	for	for	ADP
cuesj-385	39	38	tp53	tp53	PROPN
cuesj-385	39	39	pro	pro	ADJ
cuesj-385	39	40	/	/	SYM
cuesj-385	39	41	pro	pro	ADJ
cuesj-385	39	42	genotype	genotype	NOUN
cuesj-385	39	43	was	be	AUX
cuesj-385	39	44	more	more	ADV
cuesj-385	39	45	frequent	frequent	ADJ
cuesj-385	39	46	in	in	ADP
cuesj-385	39	47	control	control	NOUN
cuesj-385	39	48	than	than	ADP
cuesj-385	39	49	in	in	ADP
cuesj-385	39	50	patients	patient	NOUN
cuesj-385	39	51	’	'	PUNCT
cuesj-385	39	52	groups	group	NOUN
cuesj-385	39	53	and	and	CCONJ
cuesj-385	39	54	this	this	DET
cuesj-385	39	55	difference	difference	NOUN
cuesj-385	39	56	was	be	AUX
cuesj-385	39	57	statistically	statistically	ADV
cuesj-385	39	58	significant	significant	ADJ
cuesj-385	39	59	(	(	PUNCT
cuesj-385	39	60	p	p	X
cuesj-385	39	61	<	<	X
cuesj-385	39	62	0.00l	0.00l	NOUN
cuesj-385	39	63	)	)	PUNCT
cuesj-385	39	64	,	,	PUNCT
cuesj-385	39	65	as	as	SCONJ
cuesj-385	39	66	shown	show	VERB
cuesj-385	39	67	in	in	ADP
cuesj-385	39	68	table	table	NOUN
cuesj-385	39	69	2	2	NUM
cuesj-385	39	70	.	.	PUNCT
cuesj-385	40	1	the	the	DET
cuesj-385	40	2	risk	risk	NOUN
cuesj-385	40	3	was	be	AUX
cuesj-385	40	4	estimated	estimate	VERB
cuesj-385	40	5	by	by	ADP
cuesj-385	40	6	the	the	DET
cuesj-385	40	7	use	use	NOUN
cuesj-385	40	8	of	of	ADP
cuesj-385	40	9	odds	odd	NOUN
cuesj-385	40	10	ratio	ratio	NOUN
cuesj-385	40	11	statistic	statistic	NOUN
cuesj-385	40	12	which	which	PRON
cuesj-385	40	13	was	be	AUX
cuesj-385	40	14	0.097	0.097	NUM
cuesj-385	40	15	with	with	ADP
cuesj-385	40	16	a	a	DET
cuesj-385	40	17	95	95	NUM
cuesj-385	40	18	%	%	NOUN
cuesj-385	40	19	confidence	confidence	NOUN
cuesj-385	40	20	interval	interval	NOUN
cuesj-385	40	21	of	of	ADP
cuesj-385	40	22	0.034–0.28l	0.034–0.28l	PROPN
cuesj-385	40	23	,	,	PUNCT
cuesj-385	40	24	this	this	PRON
cuesj-385	40	25	was	be	AUX
cuesj-385	40	26	due	due	ADJ
cuesj-385	40	27	to	to	ADP
cuesj-385	40	28	odds	odd	NOUN
cuesj-385	40	29	ratio	ratio	NOUN
cuesj-385	40	30	which	which	PRON
cuesj-385	40	31	is	be	AUX
cuesj-385	40	32	<	<	X
cuesj-385	40	33	l.	l.	X
cuesj-385	40	34	pro	pro	ADJ
cuesj-385	40	35	/	/	SYM
cuesj-385	40	36	pro	pro	ADJ
cuesj-385	40	37	genotype	genotype	NOUN
cuesj-385	40	38	would	would	AUX
cuesj-385	40	39	be	be	AUX
cuesj-385	40	40	considered	consider	VERB
cuesj-385	40	41	protective	protective	ADJ
cuesj-385	40	42	against	against	ADP
cuesj-385	40	43	colorectal	colorectal	ADJ
cuesj-385	40	44	carcinoma	carcinoma	NOUN
cuesj-385	40	45	with	with	ADP
cuesj-385	40	46	a	a	DET
cuesj-385	40	47	preventive	preventive	ADJ
cuesj-385	40	48	fraction	fraction	NOUN
cuesj-385	40	49	of	of	ADP
cuesj-385	40	50	0.767	0.767	NUM
cuesj-385	40	51	,	,	PUNCT
cuesj-385	40	52	as	as	SCONJ
cuesj-385	40	53	shown	show	VERB
cuesj-385	40	54	in	in	ADP
cuesj-385	40	55	figure	figure	NOUN
cuesj-385	40	56	6	6	NUM
cuesj-385	40	57	.	.	PUNCT
cuesj-385	41	1	the	the	DET
cuesj-385	41	2	rate	rate	NOUN
cuesj-385	41	3	of	of	ADP
cuesj-385	41	4	positivity	positivity	NOUN
cuesj-385	41	5	for	for	ADP
cuesj-385	41	6	the	the	DET
cuesj-385	41	7	p53	p53	NOUN
cuesj-385	41	8	arg	arg	NOUN
cuesj-385	41	9	/	/	SYM
cuesj-385	41	10	arg	arg	NOUN
cuesj-385	41	11	genotype	genotype	NOUN
cuesj-385	41	12	was	be	AUX
cuesj-385	41	13	more	more	ADV
cuesj-385	41	14	frequent	frequent	ADJ
cuesj-385	41	15	in	in	ADP
cuesj-385	41	16	the	the	DET
cuesj-385	41	17	patients	patient	NOUN
cuesj-385	41	18	group	group	NOUN
cuesj-385	41	19	than	than	ADP
cuesj-385	41	20	in	in	ADP
cuesj-385	41	21	the	the	DET
cuesj-385	41	22	control	control	NOUN
cuesj-385	41	23	group	group	NOUN
cuesj-385	41	24	and	and	CCONJ
cuesj-385	41	25	this	this	DET
cuesj-385	41	26	difference	difference	NOUN
cuesj-385	41	27	was	be	AUX
cuesj-385	41	28	statistically	statistically	ADV
cuesj-385	41	29	significant	significant	ADJ
cuesj-385	41	30	(	(	PUNCT
cuesj-385	41	31	p	p	X
cuesj-385	41	32	=	=	NOUN
cuesj-385	41	33	0.019	0.019	NUM
cuesj-385	41	34	)	)	PUNCT
cuesj-385	41	35	,	,	PUNCT
cuesj-385	41	36	as	as	SCONJ
cuesj-385	41	37	shown	show	VERB
cuesj-385	41	38	in	in	ADP
cuesj-385	41	39	table	table	NOUN
cuesj-385	41	40	3	3	NUM
cuesj-385	41	41	.	.	X
cuesj-385	41	42	risk	risk	NOUN
cuesj-385	41	43	was	be	AUX
cuesj-385	41	44	estimated	estimate	VERB
cuesj-385	41	45	by	by	ADP
cuesj-385	41	46	the	the	DET
cuesj-385	41	47	use	use	NOUN
cuesj-385	41	48	of	of	ADP
cuesj-385	41	49	adjusted	adjust	VERB
cuesj-385	41	50	odds	odd	NOUN
cuesj-385	41	51	ratio	ratio	NOUN
cuesj-385	41	52	statistic	statistic	NOUN
cuesj-385	41	53	which	which	PRON
cuesj-385	41	54	was	be	AUX
cuesj-385	41	55	14.2	14.2	NUM
cuesj-385	41	56	with	with	ADP
cuesj-385	41	57	a	a	DET
cuesj-385	41	58	95	95	NUM
cuesj-385	41	59	%	%	NOUN
cuesj-385	41	60	confidence	confidence	NOUN
cuesj-385	41	61	interval	interval	NOUN
cuesj-385	41	62	of	of	ADP
cuesj-385	41	63	0.792–245.7	0.792–245.7	NOUN
cuesj-385	41	64	because	because	SCONJ
cuesj-385	41	65	odds	odd	NOUN
cuesj-385	41	66	ratio	ratio	NOUN
cuesj-385	41	67	is	be	AUX
cuesj-385	41	68	>	>	X
cuesj-385	41	69	1	1	NUM
cuesj-385	41	70	.	.	PUNCT
cuesj-385	42	1	among	among	ADP
cuesj-385	42	2	these	these	DET
cuesj-385	42	3	findings	finding	NOUN
cuesj-385	42	4	,	,	PUNCT
cuesj-385	42	5	the	the	DET
cuesj-385	42	6	arg	arg	NOUN
cuesj-385	42	7	/	/	SYM
cuesj-385	42	8	arg	arg	NOUN
cuesj-385	42	9	genotype	genotype	NOUN
cuesj-385	42	10	would	would	AUX
cuesj-385	42	11	be	be	AUX
cuesj-385	42	12	considered	consider	VERB
cuesj-385	42	13	a	a	DET
cuesj-385	42	14	risk	risk	NOUN
cuesj-385	42	15	factor	factor	NOUN
cuesj-385	42	16	for	for	ADP
cuesj-385	42	17	colorectal	colorectal	ADJ
cuesj-385	42	18	carcinoma	carcinoma	NOUN
cuesj-385	42	19	.	.	PUNCT
cuesj-385	43	1	the	the	DET
cuesj-385	43	2	etiologic	etiologic	ADJ
cuesj-385	43	3	fraction	fraction	NOUN
cuesj-385	43	4	was	be	AUX
cuesj-385	43	5	not	not	PART
cuesj-385	43	6	estimated	estimate	VERB
cuesj-385	43	7	because	because	SCONJ
cuesj-385	43	8	one	one	NUM
cuesj-385	43	9	of	of	ADP
cuesj-385	43	10	the	the	DET
cuesj-385	43	11	cells	cell	NOUN
cuesj-385	43	12	contains	contain	VERB
cuesj-385	43	13	zero	zero	NUM
cuesj-385	43	14	counts	count	NOUN
cuesj-385	43	15	,	,	PUNCT
cuesj-385	43	16	as	as	SCONJ
cuesj-385	43	17	shown	show	VERB
cuesj-385	43	18	in	in	ADP
cuesj-385	43	19	figure	figure	NOUN
cuesj-385	43	20	7	7	NUM
cuesj-385	43	21	.	.	PUNCT
cuesj-385	44	1	these	these	DET
cuesj-385	44	2	results	result	NOUN
cuesj-385	44	3	did	do	AUX
cuesj-385	44	4	not	not	PART
cuesj-385	44	5	reveal	reveal	VERB
cuesj-385	44	6	any	any	DET
cuesj-385	44	7	significant	significant	ADJ
cuesj-385	44	8	association	association	NOUN
cuesj-385	44	9	between	between	ADP
cuesj-385	44	10	arg	arg	NOUN
cuesj-385	44	11	/	/	SYM
cuesj-385	44	12	arg	arg	NOUN
cuesj-385	44	13	genotype	genotype	NOUN
cuesj-385	44	14	,	,	PUNCT
cuesj-385	44	15	in	in	ADP
cuesj-385	44	16	patients	patient	NOUN
cuesj-385	44	17	group	group	NOUN
cuesj-385	44	18	,	,	PUNCT
cuesj-385	44	19	and	and	CCONJ
cuesj-385	44	20	table	table	NOUN
cuesj-385	44	21	2	2	NUM
cuesj-385	44	22	:	:	PUNCT
cuesj-385	44	23	age	age	NOUN
cuesj-385	44	24	and	and	CCONJ
cuesj-385	44	25	agnor	agnor	NOUN
cuesj-385	44	26	in	in	ADP
cuesj-385	44	27	colorectal	colorectal	ADJ
cuesj-385	44	28	carcinoma	carcinoma	NOUN
cuesj-385	44	29	patients	patient	NOUN
cuesj-385	44	30	in	in	ADP
cuesj-385	44	31	relation	relation	NOUN
cuesj-385	44	32	to	to	PART
cuesj-385	44	33	pro	pro	ADJ
cuesj-385	44	34	/	/	SYM
cuesj-385	44	35	pro	pro	ADJ
cuesj-385	44	36	genotype	genotype	NOUN
cuesj-385	44	37	pro	pro	ADJ
cuesj-385	44	38	/	/	SYM
cuesj-385	44	39	pro	pro	X
cuesj-385	44	40	n	n	PRON
cuesj-385	44	41	mean	mean	VERB
cuesj-385	44	42	sd	sd	ADP
cuesj-385	44	43	p	p	NOUN
cuesj-385	44	44	-	-	PUNCT
cuesj-385	44	45	value	value	NOUN
cuesj-385	44	46	age	age	NOUN
cuesj-385	44	47	negative	negative	ADJ
cuesj-385	44	48	34	34	NUM
cuesj-385	45	1	49.824	49.824	NUM
cuesj-385	45	2	18.300	18.300	NUM
cuesj-385	45	3	positive	positive	ADJ
cuesj-385	45	4	16	16	NUM
cuesj-385	45	5	54.875	54.875	NUM
cuesj-385	45	6	12.366	12.366	NUM
cuesj-385	45	7	0.323	0.323	NUM
cuesj-385	45	8	total	total	NOUN
cuesj-385	45	9	50	50	NUM
cuesj-385	45	10	51.440	51.440	NUM
cuesj-385	45	11	16.674	16.674	NUM
cuesj-385	45	12	agnor	agnor	NOUN
cuesj-385	45	13	negative	negative	ADJ
cuesj-385	45	14	34	34	NUM
cuesj-385	45	15	6.097	6.097	NUM
cuesj-385	45	16	0.817	0.817	NUM
cuesj-385	45	17	positive	positive	ADJ
cuesj-385	45	18	16	16	NUM
cuesj-385	45	19	6.238	6.238	NUM
cuesj-385	45	20	0.784	0.784	NUM
cuesj-385	45	21	0.569	0.569	NUM
cuesj-385	45	22	total	total	ADJ
cuesj-385	45	23	50	50	NUM
cuesj-385	45	24	6.142	6.142	NUM
cuesj-385	45	25	0.801	0.801	NUM
cuesj-385	45	26	table	table	NOUN
cuesj-385	45	27	3	3	NUM
cuesj-385	45	28	:	:	PUNCT
cuesj-385	45	29	age	age	NOUN
cuesj-385	45	30	and	and	CCONJ
cuesj-385	45	31	agnor	agnor	NOUN
cuesj-385	45	32	in	in	ADP
cuesj-385	45	33	colorectal	colorectal	ADJ
cuesj-385	45	34	carcinoma	carcinoma	NOUN
cuesj-385	45	35	patients	patient	NOUN
cuesj-385	45	36	in	in	ADP
cuesj-385	45	37	relation	relation	NOUN
cuesj-385	45	38	to	to	PART
cuesj-385	45	39	arg	arg	VERB
cuesj-385	45	40	/	/	SYM
cuesj-385	45	41	arg	arg	NOUN
cuesj-385	45	42	genotype	genotype	NOUN
cuesj-385	45	43	arg	arg	PROPN
cuesj-385	45	44	/	/	SYM
cuesj-385	45	45	arg	arg	NOUN
cuesj-385	45	46	n	n	NOUN
cuesj-385	45	47	mean	mean	VERB
cuesj-385	45	48	sd	sd	ADP
cuesj-385	45	49	p	p	NOUN
cuesj-385	45	50	-	-	PUNCT
cuesj-385	45	51	value	value	NOUN
cuesj-385	45	52	age	age	NOUN
cuesj-385	45	53	negative	negative	ADJ
cuesj-385	45	54	42	42	NUM
cuesj-385	45	55	51.405	51.405	NUM
cuesj-385	45	56	16.200	16.200	NUM
cuesj-385	45	57	positive	positive	ADJ
cuesj-385	45	58	8	8	NUM
cuesj-385	45	59	51.625	51.625	NUM
cuesj-385	45	60	20.220	20.220	NUM
cuesj-385	45	61	0.973	0.973	NUM
cuesj-385	45	62	total	total	ADJ
cuesj-385	45	63	50	50	NUM
cuesj-385	45	64	51.440	51.440	NUM
cuesj-385	45	65	16.674	16.674	NUM
cuesj-385	45	66	agnor	agnor	NOUN
cuesj-385	45	67	42	42	NUM
cuesj-385	45	68	6.088	6.088	NUM
cuesj-385	45	69	0.737	0.737	NUM
cuesj-385	45	70	negative	negative	ADJ
cuesj-385	45	71	positive	positive	ADJ
cuesj-385	45	72	8	8	NUM
cuesj-385	45	73	6.425	6.425	NUM
cuesj-385	45	74	1.099	1.099	NUM
cuesj-385	45	75	0.280	0.280	NUM
cuesj-385	45	76	total	total	ADJ
cuesj-385	45	77	50	50	NUM
cuesj-385	45	78	6.142	6.142	NUM
cuesj-385	45	79	0.801	0.801	NUM
cuesj-385	45	80	table	table	NOUN
cuesj-385	45	81	1	1	NUM
cuesj-385	45	82	:	:	PUNCT
cuesj-385	45	83	the	the	DET
cuesj-385	45	84	rate	rate	NOUN
cuesj-385	45	85	of	of	ADP
cuesj-385	45	86	positive	positive	ADJ
cuesj-385	45	87	p53	p53	NOUN
cuesj-385	45	88	ihc	ihc	NOUN
cuesj-385	45	89	expression	expression	NOUN
cuesj-385	45	90	in	in	ADP
cuesj-385	45	91	control	control	NOUN
cuesj-385	45	92	and	and	CCONJ
cuesj-385	45	93	patients	patient	NOUN
cuesj-385	45	94	groups	group	NOUN
cuesj-385	45	95	p53	p53	NOUN
cuesj-385	45	96	control	control	NOUN
cuesj-385	45	97	colonic	colonic	NOUN
cuesj-385	45	98	carcinoma	carcinoma	NOUN
cuesj-385	45	99	no	no	INTJ
cuesj-385	45	100	.	.	PUNCT
cuesj-385	46	1	%	%	INTJ
cuesj-385	47	1	no	no	INTJ
cuesj-385	47	2	.	.	PUNCT
cuesj-385	48	1	%	%	INTJ
cuesj-385	49	1	positive	positive	ADJ
cuesj-385	49	2	0	0	NUM
cuesj-385	49	3	0	0	NUM
cuesj-385	49	4	23	23	NUM
cuesj-385	49	5	46	46	NUM
cuesj-385	49	6	negative	negative	ADJ
cuesj-385	49	7	35	35	NUM
cuesj-385	49	8	l00	l00	NOUN
cuesj-385	49	9	27	27	NUM
cuesj-385	49	10	54	54	NUM
cuesj-385	49	11	total	total	NOUN
cuesj-385	49	12	35	35	NUM
cuesj-385	49	13	l00	l00	NOUN
cuesj-385	49	14	50	50	NUM
cuesj-385	49	15	l00	l00	NOUN
cuesj-385	49	16	p<0.00l	p<0.00l	PROPN
cuesj-385	49	17	,	,	PUNCT
cuesj-385	49	18	corrected	correct	VERB
cuesj-385	49	19	χ2	χ2	NOUN
cuesj-385	49	20	=	=	NOUN
cuesj-385	49	21	l9.803	l9.803	NOUN
cuesj-385	49	22	;	;	PUNCT
cuesj-385	49	23	df	df	PROPN
cuesj-385	49	24	=	=	NOUN
cuesj-385	49	25	i	i	PRON
cuesj-385	49	26	score	score	VERB
cuesj-385	49	27	1	1	NUM
cuesj-385	49	28	2	2	NUM
cuesj-385	49	29	9	9	NUM
cuesj-385	49	30	%	%	NOUN
cuesj-385	49	31	score	score	NOUN
cuesj-385	49	32	2	2	NUM
cuesj-385	49	33	18	18	NUM
cuesj-385	49	34	78	78	NUM
cuesj-385	49	35	%	%	NOUN
cuesj-385	49	36	score3	score3	NOUN
cuesj-385	49	37	3	3	NUM
cuesj-385	49	38	13	13	NUM
cuesj-385	49	39	%	%	NOUN
cuesj-385	49	40	figure	figure	NOUN
cuesj-385	49	41	4	4	NUM
cuesj-385	49	42	:	:	PUNCT
cuesj-385	49	43	the	the	DET
cuesj-385	49	44	proportions	proportion	NOUN
cuesj-385	49	45	of	of	ADP
cuesj-385	49	46	p53	p53	NOUN
cuesj-385	49	47	scores	score	NOUN
cuesj-385	49	48	figure	figure	VERB
cuesj-385	49	49	5	5	NUM
cuesj-385	49	50	:	:	PUNCT
cuesj-385	49	51	the	the	DET
cuesj-385	49	52	spearman	spearman	NOUN
cuesj-385	49	53	correlation	correlation	NOUN
cuesj-385	49	54	between	between	ADP
cuesj-385	49	55	gray	gray	ADJ
cuesj-385	49	56	scale	scale	NOUN
cuesj-385	49	57	intensity	intensity	NOUN
cuesj-385	49	58	and	and	CCONJ
cuesj-385	49	59	stage	stage	NOUN
cuesj-385	49	60	homady	homady	NOUN
cuesj-385	49	61	,	,	PUNCT
cuesj-385	49	62	et	et	PROPN
cuesj-385	49	63	al	al	PROPN
cuesj-385	49	64	.	.	PROPN
cuesj-385	49	65	:	:	PUNCT
cuesj-385	50	1	immunohistochemical	immunohistochemical	ADJ
cuesj-385	50	2	and	and	CCONJ
cuesj-385	50	3	molecular	molecular	ADJ
cuesj-385	50	4	studies	study	NOUN
cuesj-385	50	5	of	of	ADP
cuesj-385	50	6	p53	p53	NOUN
cuesj-385	50	7	and	and	CCONJ
cuesj-385	50	8	kras	kras	PROPN
cuesj-385	50	9	protein	protein	NOUN
cuesj-385	50	10	31	31	NUM
cuesj-385	50	11	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	50	12	cuesj	cuesj	ADJ
cuesj-385	50	13	2021	2021	NUM
cuesj-385	50	14	,	,	PUNCT
cuesj-385	50	15	5	5	NUM
cuesj-385	50	16	(	(	PUNCT
cuesj-385	50	17	1	1	NUM
cuesj-385	50	18	):	):	PUNCT
cuesj-385	50	19	28	28	NUM
cuesj-385	50	20	-	-	SYM
cuesj-385	50	21	33	33	NUM
cuesj-385	50	22	clinicopathological	clinicopathological	ADJ
cuesj-385	50	23	parameters	parameter	NOUN
cuesj-385	50	24	including	include	VERB
cuesj-385	50	25	age	age	NOUN
cuesj-385	50	26	,	,	PUNCT
cuesj-385	50	27	gender	gender	NOUN
cuesj-385	50	28	,	,	PUNCT
cuesj-385	50	29	site	site	NOUN
cuesj-385	50	30	of	of	ADP
cuesj-385	50	31	tumor	tumor	NOUN
cuesj-385	50	32	,	,	PUNCT
cuesj-385	50	33	grade	grade	NOUN
cuesj-385	50	34	,	,	PUNCT
cuesj-385	50	35	stage	stage	NOUN
cuesj-385	50	36	,	,	PUNCT
cuesj-385	50	37	and	and	CCONJ
cuesj-385	50	38	agnor	agnor	PROPN
cuesj-385	50	39	count	count	NOUN
cuesj-385	50	40	.	.	PUNCT
cuesj-385	51	1	the	the	DET
cuesj-385	51	2	rate	rate	NOUN
cuesj-385	51	3	of	of	ADP
cuesj-385	51	4	positivity	positivity	NOUN
cuesj-385	51	5	for	for	ADP
cuesj-385	51	6	p53	p53	NOUN
cuesj-385	51	7	arg	arg	NOUN
cuesj-385	51	8	/	/	SYM
cuesj-385	51	9	pro	pro	ADJ
cuesj-385	51	10	genotype	genotype	NOUN
cuesj-385	51	11	was	be	AUX
cuesj-385	51	12	more	more	ADV
cuesj-385	51	13	frequent	frequent	ADJ
cuesj-385	51	14	in	in	ADP
cuesj-385	51	15	patient	patient	ADJ
cuesj-385	51	16	groups	group	NOUN
cuesj-385	51	17	than	than	ADP
cuesj-385	51	18	in	in	ADP
cuesj-385	51	19	control	control	NOUN
cuesj-385	51	20	group	group	NOUN
cuesj-385	51	21	and	and	CCONJ
cuesj-385	51	22	this	this	DET
cuesj-385	51	23	difference	difference	NOUN
cuesj-385	51	24	was	be	AUX
cuesj-385	51	25	statistically	statistically	ADV
cuesj-385	51	26	significant	significant	ADJ
cuesj-385	51	27	(	(	PUNCT
cuesj-385	51	28	p	p	X
cuesj-385	51	29	<	<	X
cuesj-385	51	30	0.001	0.001	NUM
cuesj-385	51	31	)	)	PUNCT
cuesj-385	51	32	,	,	PUNCT
cuesj-385	51	33	as	as	SCONJ
cuesj-385	51	34	shown	show	VERB
cuesj-385	51	35	in	in	ADP
cuesj-385	51	36	table	table	NOUN
cuesj-385	51	37	4	4	NUM
cuesj-385	51	38	.	.	PUNCT
cuesj-385	51	39	value	value	NOUN
cuesj-385	51	40	was	be	AUX
cuesj-385	51	41	estimated	estimate	VERB
cuesj-385	51	42	by	by	ADP
cuesj-385	51	43	the	the	DET
cuesj-385	51	44	use	use	NOUN
cuesj-385	51	45	of	of	ADP
cuesj-385	51	46	odds	odd	NOUN
cuesj-385	51	47	ratio	ratio	NOUN
cuesj-385	51	48	statistic	statistic	NOUN
cuesj-385	51	49	which	which	PRON
cuesj-385	51	50	was	be	AUX
cuesj-385	51	51	5.236	5.236	NUM
cuesj-385	51	52	with	with	ADP
cuesj-385	51	53	a	a	DET
cuesj-385	51	54	95	95	NUM
cuesj-385	51	55	%	%	NOUN
cuesj-385	51	56	confidence	confidence	NOUN
cuesj-385	51	57	interval	interval	NOUN
cuesj-385	51	58	of	of	ADP
cuesj-385	51	59	1.852	1.852	NUM
cuesj-385	51	60	–	–	PUNCT
cuesj-385	51	61	14.807	14.807	NUM
cuesj-385	51	62	(	(	PUNCT
cuesj-385	51	63	odds	odd	NOUN
cuesj-385	51	64	ratio	ratio	NOUN
cuesj-385	51	65	is	be	AUX
cuesj-385	51	66	>	>	X
cuesj-385	51	67	l	l	NOUN
cuesj-385	51	68	)	)	PUNCT
cuesj-385	51	69	.	.	PUNCT
cuesj-385	52	1	therefore	therefore	ADV
cuesj-385	52	2	,	,	PUNCT
cuesj-385	52	3	we	we	PRON
cuesj-385	52	4	can	can	AUX
cuesj-385	52	5	conclude	conclude	VERB
cuesj-385	52	6	that	that	DET
cuesj-385	52	7	arg	arg	VERB
cuesj-385	52	8	/	/	SYM
cuesj-385	52	9	pro	pro	ADJ
cuesj-385	52	10	genotype	genotype	NOUN
cuesj-385	52	11	would	would	AUX
cuesj-385	52	12	be	be	AUX
cuesj-385	52	13	considered	consider	VERB
cuesj-385	52	14	a	a	DET
cuesj-385	52	15	risk	risk	NOUN
cuesj-385	52	16	factor	factor	NOUN
cuesj-385	52	17	for	for	ADP
cuesj-385	52	18	colorectal	colorectal	ADJ
cuesj-385	52	19	carcinoma	carcinoma	NOUN
cuesj-385	52	20	(	(	PUNCT
cuesj-385	52	21	etiologic	etiologic	ADJ
cuesj-385	52	22	fraction	fraction	NOUN
cuesj-385	52	23	was	be	AUX
cuesj-385	52	24	0.657	0.657	NUM
cuesj-385	52	25	)	)	PUNCT
cuesj-385	52	26	.	.	PUNCT
cuesj-385	53	1	evaluation	evaluation	NOUN
cuesj-385	53	2	of	of	ADP
cuesj-385	53	3	kras	kras	PROPN
cuesj-385	53	4	mutation	mutation	NOUN
cuesj-385	53	5	using	use	VERB
cuesj-385	53	6	rflp	rflp	PROPN
cuesj-385	53	7	-	-	PUNCT
cuesj-385	53	8	pcr	pcr	ADJ
cuesj-385	53	9	colonic	colonic	NOUN
cuesj-385	53	10	tissue	tissue	NOUN
cuesj-385	53	11	obtained	obtain	VERB
cuesj-385	53	12	from	from	ADP
cuesj-385	53	13	all	all	DET
cuesj-385	53	14	patients	patient	NOUN
cuesj-385	53	15	with	with	ADP
cuesj-385	53	16	colorectal	colorectal	ADJ
cuesj-385	53	17	carcinoma	carcinoma	NOUN
cuesj-385	53	18	was	be	AUX
cuesj-385	53	19	proved	prove	VERB
cuesj-385	53	20	to	to	PART
cuesj-385	53	21	be	be	AUX
cuesj-385	53	22	negative	negative	ADJ
cuesj-385	53	23	for	for	ADP
cuesj-385	53	24	kras	kra	NOUN
cuesj-385	53	25	mutation	mutation	NOUN
cuesj-385	53	26	by	by	ADP
cuesj-385	53	27	the	the	DET
cuesj-385	53	28	use	use	NOUN
cuesj-385	53	29	of	of	ADP
cuesj-385	53	30	the	the	DET
cuesj-385	53	31	rflp	rflp	PROPN
cuesj-385	53	32	-	-	PUNCT
cuesj-385	53	33	pcr	pcr	NOUN
cuesj-385	53	34	technique	technique	NOUN
cuesj-385	53	35	.	.	PUNCT
cuesj-385	54	1	discussion	discussion	NOUN
cuesj-385	54	2	role	role	NOUN
cuesj-385	54	3	of	of	ADP
cuesj-385	54	4	immunohistochemical	immunohistochemical	ADJ
cuesj-385	54	5	p53	p53	NOUN
cuesj-385	54	6	expression	expression	NOUN
cuesj-385	54	7	in	in	ADP
cuesj-385	54	8	colorectal	colorectal	ADJ
cuesj-385	54	9	carcinoma	carcinoma	NOUN
cuesj-385	54	10	the	the	DET
cuesj-385	54	11	present	present	ADJ
cuesj-385	54	12	study	study	NOUN
cuesj-385	54	13	showed	show	VERB
cuesj-385	54	14	that	that	SCONJ
cuesj-385	54	15	p53	p53	NOUN
cuesj-385	54	16	immunohistochemical	immunohistochemical	ADJ
cuesj-385	54	17	expression	expression	NOUN
cuesj-385	54	18	was	be	AUX
cuesj-385	54	19	not	not	PART
cuesj-385	54	20	correlated	correlate	VERB
cuesj-385	54	21	with	with	ADP
cuesj-385	54	22	grade	grade	NOUN
cuesj-385	54	23	or	or	CCONJ
cuesj-385	54	24	stage	stage	NOUN
cuesj-385	54	25	of	of	ADP
cuesj-385	54	26	tumor	tumor	NOUN
cuesj-385	54	27	in	in	ADP
cuesj-385	54	28	patients	patient	NOUN
cuesj-385	54	29	with	with	ADP
cuesj-385	54	30	colorectal	colorectal	ADJ
cuesj-385	54	31	carcinoma	carcinoma	NOUN
cuesj-385	54	32	.	.	PUNCT
cuesj-385	55	1	to	to	PART
cuesj-385	55	2	explain	explain	VERB
cuesj-385	55	3	that	that	SCONJ
cuesj-385	55	4	,	,	PUNCT
cuesj-385	55	5	one	one	PRON
cuesj-385	55	6	may	may	AUX
cuesj-385	55	7	suppose	suppose	VERB
cuesj-385	55	8	that	that	SCONJ
cuesj-385	55	9	p53	p53	NOUN
cuesj-385	55	10	mutation	mutation	NOUN
cuesj-385	55	11	is	be	AUX
cuesj-385	55	12	an	an	DET
cuesj-385	55	13	early	early	ADJ
cuesj-385	55	14	event	event	NOUN
cuesj-385	55	15	in	in	ADP
cuesj-385	55	16	colorectal	colorectal	ADJ
cuesj-385	55	17	carcinoma	carcinoma	NOUN
cuesj-385	55	18	and	and	CCONJ
cuesj-385	55	19	hence	hence	ADV
cuesj-385	55	20	can	can	AUX
cuesj-385	55	21	be	be	AUX
cuesj-385	55	22	seen	see	VERB
cuesj-385	55	23	in	in	ADP
cuesj-385	55	24	low	low	ADJ
cuesj-385	55	25	-	-	PUNCT
cuesj-385	55	26	grade	grade	NOUN
cuesj-385	55	27	,	,	PUNCT
cuesj-385	55	28	intermediategrade	intermediategrade	NOUN
cuesj-385	55	29	,	,	PUNCT
cuesj-385	55	30	and	and	CCONJ
cuesj-385	55	31	high	high	ADJ
cuesj-385	55	32	-	-	PUNCT
cuesj-385	55	33	grade	grade	NOUN
cuesj-385	55	34	lesions	lesion	NOUN
cuesj-385	55	35	and	and	CCONJ
cuesj-385	55	36	can	can	AUX
cuesj-385	55	37	be	be	AUX
cuesj-385	55	38	seen	see	VERB
cuesj-385	55	39	in	in	ADP
cuesj-385	55	40	all	all	DET
cuesj-385	55	41	stages	stage	NOUN
cuesj-385	55	42	of	of	ADP
cuesj-385	55	43	disease.[13	disease.[13	NOUN
cuesj-385	55	44	]	]	PUNCT
cuesj-385	55	45	another	another	DET
cuesj-385	55	46	opinion	opinion	NOUN
cuesj-385	55	47	is	be	AUX
cuesj-385	55	48	that	that	SCONJ
cuesj-385	55	49	p35	p35	NOUN
cuesj-385	55	50	occurs	occur	VERB
cuesj-385	55	51	very	very	ADV
cuesj-385	55	52	early	early	ADV
cuesj-385	55	53	in	in	ADP
cuesj-385	55	54	the	the	DET
cuesj-385	55	55	progression	progression	NOUN
cuesj-385	55	56	of	of	ADP
cuesj-385	55	57	the	the	DET
cuesj-385	55	58	tumor	tumor	NOUN
cuesj-385	55	59	during	during	ADP
cuesj-385	55	60	time	time	NOUN
cuesj-385	55	61	of	of	ADP
cuesj-385	55	62	conversion	conversion	NOUN
cuesj-385	55	63	from	from	ADP
cuesj-385	55	64	adenoma	adenoma	ADV
cuesj-385	55	65	to	to	ADP
cuesj-385	55	66	carcinoma	carcinoma	NOUN
cuesj-385	55	67	,	,	PUNCT
cuesj-385	55	68	and	and	CCONJ
cuesj-385	55	69	hence	hence	ADV
cuesj-385	55	70	,	,	PUNCT
cuesj-385	55	71	it	it	PRON
cuesj-385	55	72	will	will	AUX
cuesj-385	55	73	be	be	AUX
cuesj-385	55	74	a	a	DET
cuesj-385	55	75	fixed	fix	VERB
cuesj-385	55	76	mutation	mutation	NOUN
cuesj-385	55	77	pattern	pattern	NOUN
cuesj-385	55	78	in	in	ADP
cuesj-385	55	79	all	all	DET
cuesj-385	55	80	grades	grade	NOUN
cuesj-385	55	81	and	and	CCONJ
cuesj-385	55	82	stages	stage	NOUN
cuesj-385	55	83	and	and	CCONJ
cuesj-385	55	84	eventually	eventually	ADV
cuesj-385	55	85	no	no	DET
cuesj-385	55	86	association	association	NOUN
cuesj-385	55	87	will	will	AUX
cuesj-385	55	88	be	be	AUX
cuesj-385	55	89	obtained	obtain	VERB
cuesj-385	55	90	between	between	ADP
cuesj-385	55	91	p53	p53	NOUN
cuesj-385	55	92	mutation	mutation	NOUN
cuesj-385	55	93	and	and	CCONJ
cuesj-385	55	94	grade	grade	NOUN
cuesj-385	55	95	of	of	ADP
cuesj-385	55	96	tumor	tumor	NOUN
cuesj-385	55	97	and	and	CCONJ
cuesj-385	55	98	between	between	ADP
cuesj-385	55	99	p53	p53	NOUN
cuesj-385	55	100	mutation	mutation	NOUN
cuesj-385	55	101	and	and	CCONJ
cuesj-385	55	102	stage	stage	NOUN
cuesj-385	55	103	of	of	ADP
cuesj-385	55	104	the	the	DET
cuesj-385	55	105	disease.[14	disease.[14	PROPN
cuesj-385	55	106	]	]	PUNCT
cuesj-385	55	107	importantly	importantly	ADV
cuesj-385	55	108	,	,	PUNCT
cuesj-385	55	109	the	the	DET
cuesj-385	55	110	absence	absence	NOUN
cuesj-385	55	111	of	of	ADP
cuesj-385	55	112	p53	p53	NOUN
cuesj-385	55	113	expression	expression	NOUN
cuesj-385	55	114	in	in	ADP
cuesj-385	55	115	benign	benign	ADJ
cuesj-385	55	116	tumors	tumor	NOUN
cuesj-385	55	117	indicated	indicate	VERB
cuesj-385	55	118	that	that	SCONJ
cuesj-385	55	119	p53	p53	NOUN
cuesj-385	55	120	can	can	AUX
cuesj-385	55	121	be	be	AUX
cuesj-385	55	122	considered	consider	VERB
cuesj-385	55	123	as	as	ADP
cuesj-385	55	124	a	a	DET
cuesj-385	55	125	good	good	ADJ
cuesj-385	55	126	marker	marker	NOUN
cuesj-385	55	127	for	for	ADP
cuesj-385	55	128	malignant	malignant	ADJ
cuesj-385	55	129	colorectal	colorectal	ADJ
cuesj-385	55	130	tumors	tumor	NOUN
cuesj-385	55	131	.	.	PUNCT
cuesj-385	56	1	however	however	ADV
cuesj-385	56	2	,	,	PUNCT
cuesj-385	56	3	and	and	CCONJ
cuesj-385	56	4	in	in	ADP
cuesj-385	56	5	harmony	harmony	NOUN
cuesj-385	56	6	with	with	ADP
cuesj-385	56	7	several	several	ADJ
cuesj-385	56	8	studies;[l3,14	studies;[l3,14	NOUN
cuesj-385	56	9	]	]	PUNCT
cuesj-385	56	10	this	this	DET
cuesj-385	56	11	marker	marker	NOUN
cuesj-385	56	12	was	be	AUX
cuesj-385	56	13	not	not	PART
cuesj-385	56	14	useful	useful	ADJ
cuesj-385	56	15	for	for	ADP
cuesj-385	56	16	the	the	DET
cuesj-385	56	17	classification	classification	NOUN
cuesj-385	56	18	of	of	ADP
cuesj-385	56	19	the	the	DET
cuesj-385	56	20	different	different	ADJ
cuesj-385	56	21	histopathological	histopathological	ADJ
cuesj-385	56	22	grades	grade	NOUN
cuesj-385	56	23	and	and	CCONJ
cuesj-385	56	24	hence	hence	ADV
cuesj-385	56	25	prognosis	prognosis	NOUN
cuesj-385	56	26	of	of	ADP
cuesj-385	56	27	the	the	DET
cuesj-385	56	28	disease	disease	NOUN
cuesj-385	56	29	.	.	PUNCT
cuesj-385	57	1	the	the	DET
cuesj-385	57	2	reported	report	VERB
cuesj-385	57	3	pattern	pattern	NOUN
cuesj-385	57	4	of	of	ADP
cuesj-385	57	5	p53	p53	NOUN
cuesj-385	57	6	expression	expression	NOUN
cuesj-385	57	7	in	in	ADP
cuesj-385	57	8	the	the	DET
cuesj-385	57	9	different	different	ADJ
cuesj-385	57	10	stages	stage	NOUN
cuesj-385	57	11	has	have	AUX
cuesj-385	57	12	been	be	AUX
cuesj-385	57	13	interpreted	interpret	VERB
cuesj-385	57	14	into	into	ADP
cuesj-385	57	15	different	different	ADJ
cuesj-385	57	16	and	and	CCONJ
cuesj-385	57	17	sometimes	sometimes	ADV
cuesj-385	57	18	contradicting	contradict	VERB
cuesj-385	57	19	directions	direction	NOUN
cuesj-385	57	20	.	.	PUNCT
cuesj-385	58	1	if	if	SCONJ
cuesj-385	58	2	we	we	PRON
cuesj-385	58	3	consider	consider	VERB
cuesj-385	58	4	that	that	SCONJ
cuesj-385	58	5	only	only	ADV
cuesj-385	58	6	50	50	NUM
cuesj-385	58	7	%	%	NOUN
cuesj-385	58	8	of	of	ADP
cuesj-385	58	9	poorly	poorly	ADV
cuesj-385	58	10	differentiated	differentiate	VERB
cuesj-385	58	11	tumors	tumor	NOUN
cuesj-385	58	12	expressed	express	VERB
cuesj-385	58	13	p53	p53	NOUN
cuesj-385	58	14	,	,	PUNCT
cuesj-385	58	15	p53	p53	NOUN
cuesj-385	58	16	might	might	AUX
cuesj-385	58	17	be	be	AUX
cuesj-385	58	18	correlated	correlate	VERB
cuesj-385	58	19	with	with	ADP
cuesj-385	58	20	poor	poor	ADJ
cuesj-385	58	21	outcome	outcome	NOUN
cuesj-385	58	22	and	and	CCONJ
cuesj-385	58	23	bad	bad	ADJ
cuesj-385	58	24	prognosis	prognosis	NOUN
cuesj-385	58	25	.	.	PUNCT
cuesj-385	59	1	on	on	ADP
cuesj-385	59	2	the	the	DET
cuesj-385	59	3	other	other	ADJ
cuesj-385	59	4	hand	hand	NOUN
cuesj-385	59	5	,	,	PUNCT
cuesj-385	59	6	differences	difference	NOUN
cuesj-385	59	7	between	between	ADP
cuesj-385	59	8	the	the	DET
cuesj-385	59	9	different	different	ADJ
cuesj-385	59	10	histological	histological	ADJ
cuesj-385	59	11	grades	grade	NOUN
cuesj-385	59	12	were	be	AUX
cuesj-385	59	13	not	not	PART
cuesj-385	59	14	significant	significant	ADJ
cuesj-385	59	15	abolishing	abolish	VERB
cuesj-385	59	16	the	the	DET
cuesj-385	59	17	prognostic	prognostic	ADJ
cuesj-385	59	18	value	value	NOUN
cuesj-385	59	19	of	of	ADP
cuesj-385	59	20	this	this	DET
cuesj-385	59	21	marker	marker	NOUN
cuesj-385	59	22	.	.	PUNCT
cuesj-385	60	1	this	this	PRON
cuesj-385	60	2	might	might	AUX
cuesj-385	60	3	not	not	PART
cuesj-385	60	4	be	be	AUX
cuesj-385	60	5	surprising	surprising	ADJ
cuesj-385	60	6	if	if	SCONJ
cuesj-385	60	7	we	we	PRON
cuesj-385	60	8	know	know	VERB
cuesj-385	60	9	that	that	SCONJ
cuesj-385	60	10	several	several	ADJ
cuesj-385	60	11	studies	study	NOUN
cuesj-385	60	12	indicated	indicate	VERB
cuesj-385	60	13	that	that	SCONJ
cuesj-385	60	14	p53	p53	NOUN
cuesj-385	60	15	nuclear	nuclear	NOUN
cuesj-385	60	16	staining	staining	NOUN
cuesj-385	60	17	does	do	AUX
cuesj-385	60	18	not	not	PART
cuesj-385	60	19	always	always	ADV
cuesj-385	60	20	rule	rule	VERB
cuesj-385	60	21	out	out	ADP
cuesj-385	60	22	the	the	DET
cuesj-385	60	23	presence	presence	NOUN
cuesj-385	60	24	of	of	ADP
cuesj-385	60	25	mutated	mutate	VERB
cuesj-385	60	26	malfunctioned	malfunction	VERB
cuesj-385	60	27	p53	p53	NOUN
cuesj-385	60	28	protein.[15	protein.[15	NOUN
cuesj-385	60	29	]	]	PUNCT
cuesj-385	60	30	menezes[14	menezes[14	PROPN
cuesj-385	60	31	]	]	PUNCT
cuesj-385	60	32	studied	study	VERB
cuesj-385	60	33	82	82	NUM
cuesj-385	60	34	patients	patient	NOUN
cuesj-385	60	35	with	with	ADP
cuesj-385	60	36	colorectal	colorectal	ADJ
cuesj-385	60	37	carcinoma	carcinoma	NOUN
cuesj-385	60	38	for	for	ADP
cuesj-385	60	39	the	the	DET
cuesj-385	60	40	immunohistochemical	immunohistochemical	ADJ
cuesj-385	60	41	expression	expression	NOUN
cuesj-385	60	42	of	of	ADP
cuesj-385	60	43	p53	p53	NOUN
cuesj-385	60	44	,	,	PUNCT
cuesj-385	60	45	bcl-2	bcl-2	NOUN
cuesj-385	60	46	,	,	PUNCT
cuesj-385	60	47	and	and	CCONJ
cuesj-385	60	48	ki67	ki67	PROPN
cuesj-385	60	49	and	and	CCONJ
cuesj-385	60	50	concluded	conclude	VERB
cuesj-385	60	51	that	that	SCONJ
cuesj-385	60	52	there	there	PRON
cuesj-385	60	53	was	be	VERB
cuesj-385	60	54	no	no	DET
cuesj-385	60	55	significant	significant	ADJ
cuesj-385	60	56	correlation	correlation	NOUN
cuesj-385	60	57	between	between	ADP
cuesj-385	60	58	the	the	DET
cuesj-385	60	59	expressions	expression	NOUN
cuesj-385	60	60	of	of	ADP
cuesj-385	60	61	these	these	DET
cuesj-385	60	62	markers	marker	NOUN
cuesj-385	60	63	separately	separately	ADV
cuesj-385	60	64	or	or	CCONJ
cuesj-385	60	65	in	in	ADP
cuesj-385	60	66	conjunction	conjunction	NOUN
cuesj-385	60	67	,	,	PUNCT
cuesj-385	60	68	table	table	NOUN
cuesj-385	60	69	4	4	NUM
cuesj-385	60	70	:	:	PUNCT
cuesj-385	60	71	arg	arg	VERB
cuesj-385	60	72	/	/	SYM
cuesj-385	60	73	pro	pro	ADJ
cuesj-385	60	74	genotype	genotype	NOUN
cuesj-385	60	75	in	in	ADP
cuesj-385	60	76	colorectal	colorectal	ADJ
cuesj-385	60	77	carcinoma	carcinoma	NOUN
cuesj-385	60	78	patients	patient	NOUN
cuesj-385	60	79	and	and	CCONJ
cuesj-385	60	80	control	control	NOUN
cuesj-385	60	81	group	group	NOUN
cuesj-385	60	82	among	among	ADP
cuesj-385	60	83	this	this	DET
cuesj-385	60	84	study	study	NOUN
cuesj-385	60	85	there	there	PRON
cuesj-385	60	86	was	be	VERB
cuesj-385	60	87	no	no	DET
cuesj-385	60	88	significant	significant	ADJ
cuesj-385	60	89	association	association	NOUN
cuesj-385	60	90	between	between	ADP
cuesj-385	60	91	arg	arg	NOUN
cuesj-385	60	92	/	/	SYM
cuesj-385	60	93	pro	pro	ADJ
cuesj-385	60	94	genotype	genotype	NOUN
cuesj-385	60	95	,	,	PUNCT
cuesj-385	60	96	in	in	ADP
cuesj-385	60	97	patients	patient	NOUN
cuesj-385	60	98	group	group	NOUN
cuesj-385	60	99	,	,	PUNCT
cuesj-385	60	100	and	and	CCONJ
cuesj-385	60	101	clinicopathological	clinicopathological	ADJ
cuesj-385	60	102	parameters	parameter	NOUN
cuesj-385	60	103	including	include	VERB
cuesj-385	60	104	age	age	NOUN
cuesj-385	60	105	,	,	PUNCT
cuesj-385	60	106	gender	gender	NOUN
cuesj-385	60	107	,	,	PUNCT
cuesj-385	60	108	site	site	NOUN
cuesj-385	60	109	of	of	ADP
cuesj-385	60	110	tumor	tumor	NOUN
cuesj-385	60	111	,	,	PUNCT
cuesj-385	60	112	grade	grade	NOUN
cuesj-385	60	113	,	,	PUNCT
cuesj-385	60	114	stage	stage	NOUN
cuesj-385	60	115	,	,	PUNCT
cuesj-385	60	116	and	and	CCONJ
cuesj-385	60	117	agnor	agnor	PROPN
cuesj-385	60	118	count	count	PROPN
cuesj-385	60	119	arg	arg	PROPN
cuesj-385	60	120	/	/	SYM
cuesj-385	60	121	pro	pro	ADJ
cuesj-385	60	122	colonic	colonic	ADJ
cuesj-385	60	123	carcinoma	carcinoma	NOUN
cuesj-385	60	124	control	control	VERB
cuesj-385	60	125	p	p	NOUN
cuesj-385	60	126	-	-	PUNCT
cuesj-385	60	127	value	value	NOUN
cuesj-385	60	128	95%ci	95%ci	NUM
cuesj-385	60	129	no	no	NOUN
cuesj-385	60	130	.	.	PUNCT
cuesj-385	61	1	%	%	INTJ
cuesj-385	62	1	no	no	INTJ
cuesj-385	62	2	.	.	PUNCT
cuesj-385	63	1	%	%	NOUN
cuesj-385	63	2	odds	odd	NOUN
cuesj-385	63	3	ratio	ratio	NOUN
cuesj-385	63	4	lower	low	ADJ
cuesj-385	63	5	upper	upper	ADJ
cuesj-385	63	6	ef	ef	X
cuesj-385	63	7	positive	positive	ADJ
cuesj-385	63	8	26	26	NUM
cuesj-385	63	9	52.00	52.00	NUM
cuesj-385	63	10	6	6	NUM
cuesj-385	63	11	17.14	17.14	NUM
cuesj-385	63	12	negative	negative	ADJ
cuesj-385	63	13	24	24	NUM
cuesj-385	63	14	48.00	48.00	NUM
cuesj-385	63	15	29	29	NUM
cuesj-385	63	16	82.86	82.86	NUM
cuesj-385	63	17	0.001	0.001	NUM
cuesj-385	63	18	5.236	5.236	NUM
cuesj-385	63	19	1.852	1.852	NUM
cuesj-385	63	20	14.807	14.807	NUM
cuesj-385	63	21	0.657	0.657	NUM
cuesj-385	63	22	total	total	ADJ
cuesj-385	63	23	50	50	NUM
cuesj-385	63	24	100.0	100.0	NUM
cuesj-385	63	25	35	35	NUM
cuesj-385	63	26	100.00	100.00	NUM
cuesj-385	63	27	figure	figure	NOUN
cuesj-385	63	28	6	6	NUM
cuesj-385	63	29	:	:	PUNCT
cuesj-385	63	30	pcr	pcr	ADJ
cuesj-385	63	31	amplification	amplification	NOUN
cuesj-385	63	32	of	of	ADP
cuesj-385	63	33	the	the	DET
cuesj-385	63	34	tp53	tp53	PROPN
cuesj-385	63	35	codon	codon	NOUN
cuesj-385	63	36	72	72	NUM
cuesj-385	63	37	(	(	PUNCT
cuesj-385	63	38	electrophoresis	electrophoresis	NOUN
cuesj-385	63	39	in	in	ADP
cuesj-385	63	40	2	2	NUM
cuesj-385	63	41	%	%	NOUN
cuesj-385	63	42	agarose	agarose	NOUN
cuesj-385	63	43	get	get	VERB
cuesj-385	63	44	)	)	PUNCT
cuesj-385	63	45	in	in	ADP
cuesj-385	63	46	13	13	NUM
cuesj-385	63	47	colorectal	colorectal	ADJ
cuesj-385	63	48	adenocarcinoma	adenocarcinoma	NOUN
cuesj-385	63	49	samples	sample	NOUN
cuesj-385	63	50	and	and	CCONJ
cuesj-385	63	51	control	control	NOUN
cuesj-385	63	52	samples	sample	NOUN
cuesj-385	63	53	.	.	PUNCT
cuesj-385	64	1	lanes	lane	NOUN
cuesj-385	64	2	1	1	NUM
cuesj-385	64	3	and	and	CCONJ
cuesj-385	64	4	10	10	NUM
cuesj-385	64	5	markers	marker	NOUN
cuesj-385	64	6	,	,	PUNCT
cuesj-385	64	7	lanes	lane	NOUN
cuesj-385	64	8	3	3	NUM
cuesj-385	64	9	,	,	PUNCT
cuesj-385	64	10	4	4	NUM
cuesj-385	64	11	,	,	PUNCT
cuesj-385	64	12	5	5	NUM
cuesj-385	64	13	,	,	PUNCT
cuesj-385	64	14	6	6	NUM
cuesj-385	64	15	,	,	PUNCT
cuesj-385	64	16	7	7	NUM
cuesj-385	64	17	,	,	PUNCT
cuesj-385	64	18	12	12	NUM
cuesj-385	64	19	,	,	PUNCT
cuesj-385	64	20	and	and	CCONJ
cuesj-385	64	21	13	13	NUM
cuesj-385	64	22	positive	positive	ADJ
cuesj-385	64	23	for	for	ADP
cuesj-385	64	24	pro	pro	ADJ
cuesj-385	64	25	allele	allele	NOUN
cuesj-385	64	26	(	(	PUNCT
cuesj-385	64	27	177	177	NUM
cuesj-385	64	28	bp	bp	NOUN
cuesj-385	64	29	)	)	PUNCT
cuesj-385	64	30	.	.	PUNCT
cuesj-385	65	1	lanes	lane	NOUN
cuesj-385	65	2	2	2	NUM
cuesj-385	65	3	,	,	PUNCT
cuesj-385	65	4	8	8	NUM
cuesj-385	65	5	,	,	PUNCT
cuesj-385	65	6	9	9	NUM
cuesj-385	65	7	,	,	PUNCT
cuesj-385	65	8	and	and	CCONJ
cuesj-385	65	9	11	11	NUM
cuesj-385	65	10	negative	negative	ADJ
cuesj-385	65	11	for	for	ADP
cuesj-385	65	12	pro	pro	ADJ
cuesj-385	65	13	allele	allele	NOUN
cuesj-385	65	14	.	.	PUNCT
cuesj-385	66	1	lanes	lane	NOUN
cuesj-385	66	2	14	14	NUM
cuesj-385	66	3	and	and	CCONJ
cuesj-385	66	4	15	15	NUM
cuesj-385	66	5	negative	negative	ADJ
cuesj-385	66	6	control	control	NOUN
cuesj-385	66	7	figure	figure	NOUN
cuesj-385	66	8	7	7	NUM
cuesj-385	66	9	:	:	PUNCT
cuesj-385	66	10	pcr	pcr	ADJ
cuesj-385	66	11	amplification	amplification	NOUN
cuesj-385	66	12	of	of	ADP
cuesj-385	66	13	the	the	DET
cuesj-385	66	14	tp53	tp53	PROPN
cuesj-385	66	15	codon	codon	NOUN
cuesj-385	66	16	72	72	NUM
cuesj-385	66	17	(	(	PUNCT
cuesj-385	66	18	electrophoresis	electrophoresis	NOUN
cuesj-385	66	19	in	in	ADP
cuesj-385	66	20	2	2	NUM
cuesj-385	66	21	%	%	NOUN
cuesj-385	66	22	agarose	agarose	NOUN
cuesj-385	66	23	get	get	VERB
cuesj-385	66	24	)	)	PUNCT
cuesj-385	66	25	in	in	ADP
cuesj-385	66	26	13	13	NUM
cuesj-385	66	27	colorecta1	colorecta1	NOUN
cuesj-385	66	28	adenocarcinoma	adenocarcinoma	NOUN
cuesj-385	66	29	samples	sample	NOUN
cuesj-385	66	30	and	and	CCONJ
cuesj-385	66	31	control	control	NOUN
cuesj-385	66	32	samples	sample	NOUN
cuesj-385	66	33	.	.	PUNCT
cuesj-385	67	1	lane	lane	NOUN
cuesj-385	67	2	1	1	NUM
cuesj-385	67	3	and	and	CCONJ
cuesj-385	67	4	10	10	NUM
cuesj-385	67	5	markers	marker	NOUN
cuesj-385	67	6	,	,	PUNCT
cuesj-385	67	7	lanes	lane	NOUN
cuesj-385	67	8	3	3	NUM
cuesj-385	67	9	,	,	PUNCT
cuesj-385	67	10	5	5	NUM
cuesj-385	67	11	,	,	PUNCT
cuesj-385	67	12	6	6	NUM
cuesj-385	67	13	,	,	PUNCT
cuesj-385	67	14	12	12	NUM
cuesj-385	67	15	,	,	PUNCT
cuesj-385	67	16	and	and	CCONJ
cuesj-385	67	17	14	14	NUM
cuesj-385	67	18	positive	positive	ADJ
cuesj-385	67	19	for	for	ADP
cuesj-385	67	20	arg	arg	NOUN
cuesj-385	67	21	allele	allele	NOUN
cuesj-385	67	22	(	(	PUNCT
cuesj-385	67	23	141	141	NUM
cuesj-385	67	24	bp	bp	NOUN
cuesj-385	67	25	)	)	PUNCT
cuesj-385	67	26	.	.	PUNCT
cuesj-385	68	1	lanes	lane	NOUN
cuesj-385	68	2	2	2	NUM
cuesj-385	68	3	,	,	PUNCT
cuesj-385	68	4	4	4	NUM
cuesj-385	68	5	,	,	PUNCT
cuesj-385	68	6	7	7	NUM
cuesj-385	68	7	,	,	PUNCT
cuesj-385	68	8	8	8	NUM
cuesj-385	68	9	,	,	PUNCT
cuesj-385	68	10	and	and	CCONJ
cuesj-385	68	11	9	9	NUM
cuesj-385	68	12	negatives	negative	NOUN
cuesj-385	68	13	for	for	ADP
cuesj-385	68	14	arg	arg	NOUN
cuesj-385	68	15	allele	allele	PROPN
cuesj-385	68	16	.	.	PUNCT
cuesj-385	69	1	lanes	lane	NOUN
cuesj-385	69	2	11	11	NUM
cuesj-385	69	3	,	,	PUNCT
cuesj-385	69	4	13	13	NUM
cuesj-385	69	5	,	,	PUNCT
cuesj-385	69	6	and	and	CCONJ
cuesj-385	69	7	15	15	NUM
cuesj-385	69	8	negative	negative	ADJ
cuesj-385	69	9	control	control	PROPN
cuesj-385	69	10	homady	homady	PROPN
cuesj-385	69	11	,	,	PUNCT
cuesj-385	69	12	et	et	PROPN
cuesj-385	69	13	al	al	PROPN
cuesj-385	69	14	.	.	PROPN
cuesj-385	69	15	:	:	PUNCT
cuesj-385	70	1	immunohistochemical	immunohistochemical	ADJ
cuesj-385	70	2	and	and	CCONJ
cuesj-385	70	3	molecular	molecular	ADJ
cuesj-385	70	4	studies	study	NOUN
cuesj-385	70	5	of	of	ADP
cuesj-385	70	6	p53	p53	NOUN
cuesj-385	70	7	and	and	CCONJ
cuesj-385	70	8	kras	kras	PROPN
cuesj-385	70	9	protein	protein	NOUN
cuesj-385	70	10	32	32	NUM
cuesj-385	70	11	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	70	12	cuesj	cuesj	ADJ
cuesj-385	70	13	2021	2021	NUM
cuesj-385	70	14	,	,	PUNCT
cuesj-385	70	15	5	5	NUM
cuesj-385	70	16	(	(	PUNCT
cuesj-385	70	17	1	1	NUM
cuesj-385	70	18	):	):	PUNCT
cuesj-385	70	19	28	28	NUM
cuesj-385	70	20	-	-	SYM
cuesj-385	70	21	33	33	NUM
cuesj-385	70	22	concerning	concern	VERB
cuesj-385	70	23	the	the	DET
cuesj-385	70	24	grade	grade	NOUN
cuesj-385	70	25	of	of	ADP
cuesj-385	70	26	tumor	tumor	NOUN
cuesj-385	70	27	.	.	PUNCT
cuesj-385	71	1	asaad[16	asaad[16	PROPN
cuesj-385	71	2	]	]	PUNCT
cuesj-385	71	3	conducted	conduct	VERB
cuesj-385	71	4	a	a	DET
cuesj-385	71	5	study	study	NOUN
cuesj-385	71	6	on	on	ADP
cuesj-385	71	7	the	the	DET
cuesj-385	71	8	role	role	NOUN
cuesj-385	71	9	of	of	ADP
cuesj-385	71	10	p53	p53	NOUN
cuesj-385	71	11	and	and	CCONJ
cuesj-385	71	12	cyclin	cyclin	NOUN
cuesj-385	71	13	d1	d1	PROPN
cuesj-385	71	14	in	in	ADP
cuesj-385	71	15	41	41	NUM
cuesj-385	71	16	patients	patient	NOUN
cuesj-385	71	17	with	with	ADP
cuesj-385	71	18	colorectal	colorectal	ADJ
cuesj-385	71	19	carcinoma	carcinoma	NOUN
cuesj-385	71	20	and	and	CCONJ
cuesj-385	71	21	reported	report	VERB
cuesj-385	71	22	that	that	SCONJ
cuesj-385	71	23	p53	p53	NOUN
cuesj-385	71	24	immunohistochemical	immunohistochemical	ADJ
cuesj-385	71	25	expression	expression	NOUN
cuesj-385	71	26	was	be	AUX
cuesj-385	71	27	not	not	PART
cuesj-385	71	28	correlated	correlate	VERB
cuesj-385	71	29	to	to	ADP
cuesj-385	71	30	grade	grade	NOUN
cuesj-385	71	31	or	or	CCONJ
cuesj-385	71	32	stage	stage	NOUN
cuesj-385	71	33	of	of	ADP
cuesj-385	71	34	tumor	tumor	NOUN
cuesj-385	71	35	.	.	PUNCT
cuesj-385	72	1	another	another	DET
cuesj-385	72	2	study	study	NOUN
cuesj-385	72	3	conducted	conduct	VERB
cuesj-385	72	4	by	by	ADP
cuesj-385	72	5	malik[17	malik[17	VERB
cuesj-385	72	6	]	]	X
cuesj-385	72	7	on	on	ADP
cuesj-385	72	8	50	50	NUM
cuesj-385	72	9	patients	patient	NOUN
cuesj-385	72	10	with	with	ADP
cuesj-385	72	11	colorectal	colorectal	ADJ
cuesj-385	72	12	carcinoma	carcinoma	NOUN
cuesj-385	72	13	and	and	CCONJ
cuesj-385	72	14	found	find	VERB
cuesj-385	72	15	no	no	DET
cuesj-385	72	16	association	association	NOUN
cuesj-385	72	17	between	between	ADP
cuesj-385	72	18	grade	grade	NOUN
cuesj-385	72	19	of	of	ADP
cuesj-385	72	20	tumor	tumor	NOUN
cuesj-385	72	21	and	and	CCONJ
cuesj-385	72	22	p53	p53	NOUN
cuesj-385	72	23	mutation	mutation	NOUN
cuesj-385	72	24	.	.	PUNCT
cuesj-385	73	1	it	it	PRON
cuesj-385	73	2	was	be	AUX
cuesj-385	73	3	reported	report	VERB
cuesj-385	73	4	that	that	SCONJ
cuesj-385	73	5	by	by	ADP
cuesj-385	73	6	ghavamnasiri,[18	ghavamnasiri,[18	PROPN
cuesj-385	73	7	]	]	PUNCT
cuesj-385	73	8	there	there	PRON
cuesj-385	73	9	was	be	VERB
cuesj-385	73	10	no	no	DET
cuesj-385	73	11	significant	significant	ADJ
cuesj-385	73	12	association	association	NOUN
cuesj-385	73	13	between	between	ADP
cuesj-385	73	14	p53	p53	NOUN
cuesj-385	73	15	protein	protein	NOUN
cuesj-385	73	16	expression	expression	NOUN
cuesj-385	73	17	and	and	CCONJ
cuesj-385	73	18	some	some	DET
cuesj-385	73	19	common	common	ADJ
cuesj-385	73	20	clinicopathologic	clinicopathologic	ADJ
cuesj-385	73	21	variables	variable	NOUN
cuesj-385	73	22	such	such	ADJ
cuesj-385	73	23	as	as	ADP
cuesj-385	73	24	age	age	NOUN
cuesj-385	73	25	,	,	PUNCT
cuesj-385	73	26	gender	gender	NOUN
cuesj-385	73	27	,	,	PUNCT
cuesj-385	73	28	site	site	NOUN
cuesj-385	73	29	of	of	ADP
cuesj-385	73	30	tumor	tumor	NOUN
cuesj-385	73	31	,	,	PUNCT
cuesj-385	73	32	pathologic	pathologic	ADJ
cuesj-385	73	33	type	type	NOUN
cuesj-385	73	34	,	,	PUNCT
cuesj-385	73	35	and	and	CCONJ
cuesj-385	73	36	stage	stage	NOUN
cuesj-385	73	37	of	of	ADP
cuesj-385	73	38	the	the	DET
cuesj-385	73	39	disease	disease	NOUN
cuesj-385	73	40	.	.	PUNCT
cuesj-385	74	1	the	the	DET
cuesj-385	74	2	lack	lack	NOUN
cuesj-385	74	3	of	of	ADP
cuesj-385	74	4	significance	significance	NOUN
cuesj-385	74	5	reported	report	VERB
cuesj-385	74	6	herein	herein	NOUN
cuesj-385	74	7	might	might	AUX
cuesj-385	74	8	indicate	indicate	VERB
cuesj-385	74	9	that	that	SCONJ
cuesj-385	74	10	the	the	DET
cuesj-385	74	11	defensive	defensive	ADJ
cuesj-385	74	12	role	role	NOUN
cuesj-385	74	13	of	of	ADP
cuesj-385	74	14	p53	p53	NOUN
cuesj-385	74	15	expression	expression	NOUN
cuesj-385	74	16	is	be	AUX
cuesj-385	74	17	accompanied	accompany	VERB
cuesj-385	74	18	by	by	ADP
cuesj-385	74	19	other	other	ADJ
cuesj-385	74	20	pathways	pathway	NOUN
cuesj-385	74	21	that	that	PRON
cuesj-385	74	22	define	define	VERB
cuesj-385	74	23	the	the	DET
cuesj-385	74	24	prognosis	prognosis	NOUN
cuesj-385	74	25	and	and	CCONJ
cuesj-385	74	26	grade	grade	NOUN
cuesj-385	74	27	of	of	ADP
cuesj-385	74	28	the	the	DET
cuesj-385	74	29	tumor	tumor	NOUN
cuesj-385	74	30	.	.	PUNCT
cuesj-385	75	1	kras	kra	NOUN
cuesj-385	75	2	mutations	mutation	NOUN
cuesj-385	75	3	,	,	PUNCT
cuesj-385	75	4	for	for	ADP
cuesj-385	75	5	example	example	NOUN
cuesj-385	75	6	,	,	PUNCT
cuesj-385	75	7	were	be	AUX
cuesj-385	75	8	one	one	NUM
cuesj-385	75	9	of	of	ADP
cuesj-385	75	10	the	the	DET
cuesj-385	75	11	targets	target	NOUN
cuesj-385	75	12	which	which	PRON
cuesj-385	75	13	support	support	VERB
cuesj-385	75	14	that	that	DET
cuesj-385	75	15	direction.[19	direction.[19	VERB
cuesj-385	75	16	]	]	PUNCT
cuesj-385	75	17	on	on	ADP
cuesj-385	75	18	the	the	DET
cuesj-385	75	19	contrary	contrary	NOUN
cuesj-385	75	20	,	,	PUNCT
cuesj-385	75	21	several	several	ADJ
cuesj-385	75	22	works	work	NOUN
cuesj-385	75	23	of	of	ADP
cuesj-385	75	24	literature	literature	NOUN
cuesj-385	75	25	had	have	AUX
cuesj-385	75	26	reported	report	VERB
cuesj-385	75	27	significant	significant	ADJ
cuesj-385	75	28	associations	association	NOUN
cuesj-385	75	29	between	between	ADP
cuesj-385	75	30	p53	p53	NOUN
cuesj-385	75	31	expression	expression	NOUN
cuesj-385	75	32	and	and	CCONJ
cuesj-385	75	33	grade	grade	NOUN
cuesj-385	75	34	and	and	CCONJ
cuesj-385	75	35	stage	stage	NOUN
cuesj-385	75	36	of	of	ADP
cuesj-385	75	37	tumor	tumor	NOUN
cuesj-385	75	38	:	:	PUNCT
cuesj-385	76	1	[	[	X
cuesj-385	76	2	20,21	20,21	NUM
cuesj-385	76	3	]	]	PUNCT
cuesj-385	76	4	from	from	ADP
cuesj-385	76	5	the	the	DET
cuesj-385	76	6	above	above	ADJ
cuesj-385	76	7	discussion	discussion	NOUN
cuesj-385	76	8	,	,	PUNCT
cuesj-385	76	9	one	one	PRON
cuesj-385	76	10	can	can	AUX
cuesj-385	76	11	conclude	conclude	VERB
cuesj-385	76	12	that	that	SCONJ
cuesj-385	76	13	the	the	DET
cuesj-385	76	14	role	role	NOUN
cuesj-385	76	15	of	of	ADP
cuesj-385	76	16	p53	p53	NOUN
cuesj-385	76	17	as	as	ADP
cuesj-385	76	18	a	a	DET
cuesj-385	76	19	prognostic	prognostic	ADJ
cuesj-385	76	20	factor	factor	NOUN
cuesj-385	76	21	in	in	ADP
cuesj-385	76	22	colorectal	colorectal	ADJ
cuesj-385	76	23	carcinoma	carcinoma	NOUN
cuesj-385	76	24	is	be	AUX
cuesj-385	76	25	still	still	ADV
cuesj-385	76	26	controversial	controversial	ADJ
cuesj-385	76	27	and	and	CCONJ
cuesj-385	76	28	need	need	VERB
cuesj-385	76	29	thorough	thorough	ADJ
cuesj-385	76	30	investigation	investigation	NOUN
cuesj-385	76	31	of	of	ADP
cuesj-385	76	32	the	the	DET
cuesj-385	76	33	contrary	contrary	NOUN
cuesj-385	76	34	to	to	ADP
cuesj-385	76	35	the	the	DET
cuesj-385	76	36	proven	proven	ADJ
cuesj-385	76	37	fact	fact	NOUN
cuesj-385	76	38	of	of	ADP
cuesj-385	76	39	the	the	DET
cuesj-385	76	40	prognostic	prognostic	ADJ
cuesj-385	76	41	value	value	NOUN
cuesj-385	76	42	for	for	ADP
cuesj-385	76	43	p53	p53	NOUN
cuesj-385	76	44	expression	expression	NOUN
cuesj-385	76	45	in	in	ADP
cuesj-385	76	46	several	several	ADJ
cuesj-385	76	47	other	other	ADJ
cuesj-385	76	48	solid	solid	ADJ
cuesj-385	76	49	tumors	tumor	NOUN
cuesj-385	76	50	.	.	PUNCT
cuesj-385	77	1	role	role	NOUN
cuesj-385	77	2	of	of	ADP
cuesj-385	77	3	agnor	agnor	NOUN
cuesj-385	77	4	in	in	ADP
cuesj-385	77	5	colorectal	colorectal	ADJ
cuesj-385	77	6	carcinoma	carcinoma	NOUN
cuesj-385	77	7	the	the	DET
cuesj-385	77	8	present	present	ADJ
cuesj-385	77	9	study	study	NOUN
cuesj-385	77	10	showed	show	VERB
cuesj-385	77	11	that	that	SCONJ
cuesj-385	77	12	agnor	agnor	NOUN
cuesj-385	77	13	score	score	NOUN
cuesj-385	77	14	was	be	AUX
cuesj-385	77	15	significantly	significantly	ADV
cuesj-385	77	16	higher	high	ADJ
cuesj-385	77	17	the	the	DET
cuesj-385	77	18	patient	patient	ADJ
cuesj-385	77	19	group	group	NOUN
cuesj-385	77	20	in	in	ADP
cuesj-385	77	21	comparison	comparison	NOUN
cuesj-385	77	22	with	with	ADP
cuesj-385	77	23	the	the	DET
cuesj-385	77	24	control	control	NOUN
cuesj-385	77	25	one	one	NUM
cuesj-385	77	26	,	,	PUNCT
cuesj-385	77	27	and	and	CCONJ
cuesj-385	77	28	also	also	ADV
cuesj-385	77	29	,	,	PUNCT
cuesj-385	77	30	it	it	PRON
cuesj-385	77	31	was	be	AUX
cuesj-385	77	32	significantly	significantly	ADV
cuesj-385	77	33	correlated	correlate	VERB
cuesj-385	77	34	with	with	ADP
cuesj-385	77	35	the	the	DET
cuesj-385	77	36	grade	grade	NOUN
cuesj-385	77	37	of	of	ADP
cuesj-385	77	38	tumor	tumor	NOUN
cuesj-385	77	39	,	,	PUNCT
cuesj-385	77	40	being	be	AUX
cuesj-385	77	41	higher	high	ADJ
cuesj-385	77	42	with	with	ADP
cuesj-385	77	43	less	less	ADV
cuesj-385	77	44	differentiated	differentiated	ADJ
cuesj-385	77	45	tumors	tumor	NOUN
cuesj-385	77	46	.	.	PUNCT
cuesj-385	78	1	these	these	DET
cuesj-385	78	2	findings	finding	NOUN
cuesj-385	78	3	can	can	AUX
cuesj-385	78	4	be	be	AUX
cuesj-385	78	5	attributed	attribute	VERB
cuesj-385	78	6	to	to	ADP
cuesj-385	78	7	the	the	DET
cuesj-385	78	8	fact	fact	NOUN
cuesj-385	78	9	that	that	SCONJ
cuesj-385	78	10	malignant	malignant	ADJ
cuesj-385	78	11	tumor	tumor	NOUN
cuesj-385	78	12	cells	cell	NOUN
cuesj-385	78	13	are	be	AUX
cuesj-385	78	14	often	often	ADV
cuesj-385	78	15	characterized	characterize	VERB
cuesj-385	78	16	by	by	ADP
cuesj-385	78	17	aberrant	aberrant	ADJ
cuesj-385	78	18	chromatin	chromatin	NOUN
cuesj-385	78	19	patterns	pattern	NOUN
cuesj-385	78	20	such	such	ADJ
cuesj-385	78	21	as	as	ADP
cuesj-385	78	22	polyploidy	polyploidy	ADJ
cuesj-385	78	23	and	and	CCONJ
cuesj-385	78	24	aneuploidy	aneuploidy	VERB
cuesj-385	78	25	,	,	PUNCT
cuesj-385	78	26	and	and	CCONJ
cuesj-385	78	27	this	this	DET
cuesj-385	78	28	abnormal	abnormal	ADJ
cuesj-385	78	29	chromatin	chromatin	NOUN
cuesj-385	78	30	pattern	pattern	NOUN
cuesj-385	78	31	will	will	AUX
cuesj-385	78	32	be	be	AUX
cuesj-385	78	33	reflected	reflect	VERB
cuesj-385	78	34	in	in	ADP
cuesj-385	78	35	the	the	DET
cuesj-385	78	36	form	form	NOUN
cuesj-385	78	37	of	of	ADP
cuesj-385	78	38	high	high	ADJ
cuesj-385	78	39	score	score	NOUN
cuesj-385	78	40	nuclear	nuclear	ADJ
cuesj-385	78	41	organizing	organizing	NOUN
cuesj-385	78	42	regions	region	NOUN
cuesj-385	78	43	.	.	PUNCT
cuesj-385	79	1	arginine	arginine	NOUN
cuesj-385	79	2	and	and	CCONJ
cuesj-385	79	3	proline	proline	NOUN
cuesj-385	79	4	genotype	genotype	NOUN
cuesj-385	79	5	polymorphism	polymorphism	NOUN
cuesj-385	79	6	in	in	ADP
cuesj-385	79	7	colorectal	colorectal	ADJ
cuesj-385	79	8	carcinoma	carcinoma	NOUN
cuesj-385	79	9	the	the	DET
cuesj-385	79	10	present	present	ADJ
cuesj-385	79	11	study	study	NOUN
cuesj-385	79	12	showed	show	VERB
cuesj-385	79	13	that	that	SCONJ
cuesj-385	79	14	pro	pro	ADJ
cuesj-385	79	15	/	/	SYM
cuesj-385	79	16	pro	pro	ADJ
cuesj-385	79	17	genotype	genotype	NOUN
cuesj-385	79	18	was	be	AUX
cuesj-385	79	19	protective	protective	ADJ
cuesj-385	79	20	against	against	ADP
cuesj-385	79	21	colorectal	colorectal	ADJ
cuesj-385	79	22	carcinoma	carcinoma	NOUN
cuesj-385	79	23	while	while	SCONJ
cuesj-385	79	24	arg	arg	NOUN
cuesj-385	79	25	/	/	SYM
cuesj-385	79	26	arg	arg	NOUN
cuesj-385	79	27	and	and	CCONJ
cuesj-385	79	28	arg	arg	NOUN
cuesj-385	79	29	/	/	SYM
cuesj-385	79	30	pro	pro	ADJ
cuesj-385	79	31	genotypes	genotype	NOUN
cuesj-385	79	32	were	be	AUX
cuesj-385	79	33	risk	risk	NOUN
cuesj-385	79	34	factors	factor	NOUN
cuesj-385	79	35	for	for	ADP
cuesj-385	79	36	colorectal	colorectal	ADJ
cuesj-385	79	37	carcinoma	carcinoma	NOUN
cuesj-385	79	38	,	,	PUNCT
cuesj-385	79	39	on	on	ADP
cuesj-385	79	40	the	the	DET
cuesj-385	79	41	other	other	ADJ
cuesj-385	79	42	hands	hand	NOUN
cuesj-385	79	43	,	,	PUNCT
cuesj-385	79	44	the	the	DET
cuesj-385	79	45	present	present	ADJ
cuesj-385	79	46	study	study	NOUN
cuesj-385	79	47	failed	fail	VERB
cuesj-385	79	48	to	to	PART
cuesj-385	79	49	establish	establish	VERB
cuesj-385	79	50	any	any	DET
cuesj-385	79	51	significant	significant	ADJ
cuesj-385	79	52	correlation	correlation	NOUN
cuesj-385	79	53	between	between	ADP
cuesj-385	79	54	above	above	ADV
cuesj-385	79	55	-	-	PUNCT
cuesj-385	79	56	mentioned	mention	VERB
cuesj-385	79	57	genotypes	genotype	NOUN
cuesj-385	79	58	and	and	CCONJ
cuesj-385	79	59	various	various	ADJ
cuesj-385	79	60	clinicopathological	clinicopathological	ADJ
cuesj-385	79	61	characteristics	characteristic	NOUN
cuesj-385	79	62	of	of	ADP
cuesj-385	79	63	patients	patient	NOUN
cuesj-385	79	64	enrolled	enrol	VERB
cuesj-385	79	65	in	in	ADP
cuesj-385	79	66	the	the	DET
cuesj-385	79	67	study	study	NOUN
cuesj-385	79	68	.	.	PUNCT
cuesj-385	80	1	this	this	PRON
cuesj-385	80	2	may	may	AUX
cuesj-385	80	3	be	be	AUX
cuesj-385	80	4	attributed	attribute	VERB
cuesj-385	80	5	to	to	ADP
cuesj-385	80	6	the	the	DET
cuesj-385	80	7	following	follow	VERB
cuesj-385	80	8	suggestion	suggestion	NOUN
cuesj-385	80	9	:	:	PUNCT
cuesj-385	80	10	arg	arg	NOUN
cuesj-385	80	11	/	/	SYM
cuesj-385	80	12	arg	arg	NOUN
cuesj-385	80	13	genotype	genotype	NOUN
cuesj-385	80	14	may	may	AUX
cuesj-385	80	15	be	be	AUX
cuesj-385	80	16	transcribed	transcribe	VERB
cuesj-385	80	17	into	into	ADP
cuesj-385	80	18	less	less	ADV
cuesj-385	80	19	functioning	functioning	ADJ
cuesj-385	80	20	or	or	CCONJ
cuesj-385	80	21	malfunctioning	malfunction	VERB
cuesj-385	80	22	p53	p53	NOUN
cuesj-385	80	23	protein	protein	NOUN
cuesj-385	80	24	and	and	CCONJ
cuesj-385	80	25	as	as	SCONJ
cuesj-385	80	26	it	it	PRON
cuesj-385	80	27	is	be	AUX
cuesj-385	80	28	well	well	ADV
cuesj-385	80	29	known	know	VERB
cuesj-385	80	30	that	that	SCONJ
cuesj-385	80	31	p53	p53	NOUN
cuesj-385	80	32	is	be	AUX
cuesj-385	80	33	the	the	DET
cuesj-385	80	34	guardian	guardian	NOUN
cuesj-385	80	35	of	of	ADP
cuesj-385	80	36	the	the	DET
cuesj-385	80	37	genome	genome	NOUN
cuesj-385	80	38	,	,	PUNCT
cuesj-385	80	39	the	the	DET
cuesj-385	80	40	cell	cell	NOUN
cuesj-385	80	41	will	will	AUX
cuesj-385	80	42	be	be	AUX
cuesj-385	80	43	rendered	render	VERB
cuesj-385	80	44	liable	liable	ADJ
cuesj-385	80	45	for	for	ADP
cuesj-385	80	46	targeting	target	VERB
cuesj-385	80	47	by	by	ADP
cuesj-385	80	48	many	many	ADJ
cuesj-385	80	49	mutagenic	mutagenic	ADJ
cuesj-385	80	50	agents	agent	NOUN
cuesj-385	80	51	with	with	ADP
cuesj-385	80	52	the	the	DET
cuesj-385	80	53	ultimate	ultimate	ADJ
cuesj-385	80	54	acquisition	acquisition	NOUN
cuesj-385	80	55	of	of	ADP
cuesj-385	80	56	the	the	DET
cuesj-385	80	57	neoplastic	neoplastic	ADJ
cuesj-385	80	58	phenotype	phenotype	NOUN
cuesj-385	80	59	.	.	PUNCT
cuesj-385	81	1	onrat[22	onrat[22	ADJ
cuesj-385	81	2	]	]	PUNCT
cuesj-385	81	3	conducted	conduct	VERB
cuesj-385	81	4	a	a	DET
cuesj-385	81	5	study	study	NOUN
cuesj-385	81	6	on	on	ADP
cuesj-385	81	7	35	35	NUM
cuesj-385	81	8	patients	patient	NOUN
cuesj-385	81	9	with	with	ADP
cuesj-385	81	10	colorectal	colorectal	ADJ
cuesj-385	81	11	carcinoma	carcinoma	NOUN
cuesj-385	81	12	and	and	CCONJ
cuesj-385	81	13	reported	report	VERB
cuesj-385	81	14	that	that	SCONJ
cuesj-385	81	15	individuals	individual	NOUN
cuesj-385	81	16	homozygous	homozygous	ADJ
cuesj-385	81	17	for	for	ADP
cuesj-385	81	18	the	the	DET
cuesj-385	81	19	arg	arg	NOUN
cuesj-385	81	20	allele	allele	NOUN
cuesj-385	81	21	have	have	VERB
cuesj-385	81	22	a	a	DET
cuesj-385	81	23	higher	high	ADJ
cuesj-385	81	24	frequency	frequency	NOUN
cuesj-385	81	25	than	than	ADP
cuesj-385	81	26	other	other	ADJ
cuesj-385	81	27	alleles	allele	NOUN
cuesj-385	81	28	and	and	CCONJ
cuesj-385	81	29	that	that	SCONJ
cuesj-385	81	30	colon	colon	NOUN
cuesj-385	81	31	cancer	cancer	NOUN
cuesj-385	81	32	may	may	AUX
cuesj-385	81	33	be	be	AUX
cuesj-385	81	34	related	relate	VERB
cuesj-385	81	35	to	to	PART
cuesj-385	81	36	arg	arg	VERB
cuesj-385	81	37	allele	allele	NOUN
cuesj-385	81	38	frequency	frequency	NOUN
cuesj-385	81	39	.	.	PUNCT
cuesj-385	82	1	dastjerdi[23	dastjerdi[23	PROPN
cuesj-385	82	2	]	]	PUNCT
cuesj-385	82	3	also	also	ADV
cuesj-385	82	4	studied	study	VERB
cuesj-385	82	5	tp53	tp53	PROPN
cuesj-385	82	6	gene	gene	NOUN
cuesj-385	82	7	polymorphism	polymorphism	NOUN
cuesj-385	82	8	in	in	ADP
cuesj-385	82	9	iran	iran	PROPN
cuesj-385	82	10	and	and	CCONJ
cuesj-385	82	11	stated	state	VERB
cuesj-385	82	12	that	that	SCONJ
cuesj-385	82	13	a	a	DET
cuesj-385	82	14	significant	significant	ADJ
cuesj-385	82	15	difference	difference	NOUN
cuesj-385	82	16	between	between	ADP
cuesj-385	82	17	cases	case	NOUN
cuesj-385	82	18	and	and	CCONJ
cuesj-385	82	19	controls	control	NOUN
cuesj-385	82	20	was	be	AUX
cuesj-385	82	21	found	find	VERB
cuesj-385	82	22	for	for	ADP
cuesj-385	82	23	the	the	DET
cuesj-385	82	24	arginine	arginine	NOUN
cuesj-385	82	25	/	/	SYM
cuesj-385	82	26	arginine	arginine	NOUN
cuesj-385	82	27	genotype	genotype	NOUN
cuesj-385	82	28	compared	compare	VERB
cuesj-385	82	29	with	with	ADP
cuesj-385	82	30	(	(	PUNCT
cuesj-385	82	31	grouped	group	VERB
cuesj-385	82	32	)	)	PUNCT
cuesj-385	82	33	arginine	arginine	NOUN
cuesj-385	82	34	/	/	SYM
cuesj-385	82	35	proline	proline	NOUN
cuesj-385	82	36	and	and	CCONJ
cuesj-385	82	37	proline	proline	NOUN
cuesj-385	82	38	/	/	SYM
cuesj-385	82	39	proline	proline	NOUN
cuesj-385	82	40	genotypes	genotype	NOUN
cuesj-385	82	41	(	(	PUNCT
cuesj-385	82	42	odds	odd	NOUN
cuesj-385	82	43	ratio	ratio	NOUN
cuesj-385	82	44	=	=	SYM
cuesj-385	82	45	1.451	1.451	NUM
cuesj-385	83	1	[	[	X
cuesj-385	83	2	1.002–2.103	1.002–2.103	NUM
cuesj-385	83	3	]	]	PUNCT
cuesj-385	83	4	,	,	PUNCT
cuesj-385	83	5	p	p	X
cuesj-385	83	6	=	=	NOUN
cuesj-385	83	7	0.048	0.048	NUM
cuesj-385	83	8	)	)	PUNCT
cuesj-385	83	9	and	and	CCONJ
cuesj-385	83	10	that	that	DET
cuesj-385	83	11	arginine	arginine	NOUN
cuesj-385	83	12	/	/	SYM
cuesj-385	83	13	arginine	arginine	NOUN
cuesj-385	83	14	genotype	genotype	NOUN
cuesj-385	83	15	may	may	AUX
cuesj-385	83	16	be	be	AUX
cuesj-385	83	17	correlated	correlate	VERB
cuesj-385	83	18	with	with	ADP
cuesj-385	83	19	overexpression	overexpression	NOUN
cuesj-385	83	20	of	of	ADP
cuesj-385	83	21	p53	p53	NOUN
cuesj-385	83	22	and	and	CCONJ
cuesj-385	83	23	increased	increase	VERB
cuesj-385	83	24	risk	risk	NOUN
cuesj-385	83	25	for	for	ADP
cuesj-385	83	26	crc	crc	NOUN
cuesj-385	83	27	.	.	PUNCT
cuesj-385	84	1	these	these	DET
cuesj-385	84	2	findings	finding	NOUN
cuesj-385	84	3	support	support	VERB
cuesj-385	84	4	the	the	DET
cuesj-385	84	5	findings	finding	NOUN
cuesj-385	84	6	of	of	ADP
cuesj-385	84	7	the	the	DET
cuesj-385	84	8	current	current	ADJ
cuesj-385	84	9	study	study	NOUN
cuesj-385	84	10	.	.	PUNCT
cuesj-385	85	1	in	in	ADP
cuesj-385	85	2	the	the	DET
cuesj-385	85	3	present	present	ADJ
cuesj-385	85	4	study	study	NOUN
cuesj-385	85	5	,	,	PUNCT
cuesj-385	85	6	none	none	NOUN
cuesj-385	85	7	of	of	ADP
cuesj-385	85	8	the	the	DET
cuesj-385	85	9	tissue	tissue	NOUN
cuesj-385	85	10	samples	sample	NOUN
cuesj-385	85	11	taken	take	VERB
cuesj-385	85	12	from	from	ADP
cuesj-385	85	13	the	the	DET
cuesj-385	85	14	paraffin	paraffin	NOUN
cuesj-385	85	15	block	block	NOUN
cuesj-385	85	16	of	of	ADP
cuesj-385	85	17	patients	patient	NOUN
cuesj-385	85	18	with	with	ADP
cuesj-385	85	19	colorectal	colorectal	ADJ
cuesj-385	85	20	carcinoma	carcinoma	NOUN
cuesj-385	85	21	was	be	AUX
cuesj-385	85	22	positive	positive	ADJ
cuesj-385	85	23	for	for	ADP
cuesj-385	85	24	kras	kras	PROPN
cuesj-385	85	25	mutation	mutation	NOUN
cuesj-385	85	26	.	.	PUNCT
cuesj-385	86	1	smith[24	smith[24	PROPN
cuesj-385	86	2	-	-	PUNCT
cuesj-385	86	3	26	26	NUM
cuesj-385	86	4	]	]	PUNCT
cuesj-385	86	5	stated	state	VERB
cuesj-385	86	6	the	the	DET
cuesj-385	86	7	kras	kras	PROPN
cuesj-385	86	8	mutations	mutation	NOUN
cuesj-385	86	9	were	be	AUX
cuesj-385	86	10	significantly	significantly	ADV
cuesj-385	86	11	more	more	ADV
cuesj-385	86	12	common	common	ADJ
cuesj-385	86	13	in	in	ADP
cuesj-385	86	14	rectal	rectal	NOUN
cuesj-385	86	15	than	than	ADP
cuesj-385	86	16	in	in	ADP
cuesj-385	86	17	colon	colon	NOUN
cuesj-385	86	18	tumors	tumor	NOUN
cuesj-385	86	19	,	,	PUNCT
cuesj-385	86	20	indicating	indicate	VERB
cuesj-385	86	21	differences	difference	NOUN
cuesj-385	86	22	in	in	ADP
cuesj-385	86	23	the	the	DET
cuesj-385	86	24	pathways	pathway	NOUN
cuesj-385	86	25	of	of	ADP
cuesj-385	86	26	carcinogenesis	carcinogenesis	NOUN
cuesj-385	86	27	in	in	ADP
cuesj-385	86	28	these	these	DET
cuesj-385	86	29	tissues	tissue	NOUN
cuesj-385	86	30	.	.	PUNCT
cuesj-385	87	1	p53	p53	NOUN
cuesj-385	87	2	and	and	CCONJ
cuesj-385	87	3	kras	kras	PROPN
cuesj-385	87	4	mutations	mutation	NOUN
cuesj-385	87	5	were	be	AUX
cuesj-385	87	6	rarely	rarely	ADV
cuesj-385	87	7	found	find	VERB
cuesj-385	87	8	together	together	ADV
cuesj-385	87	9	in	in	ADP
cuesj-385	87	10	the	the	DET
cuesj-385	87	11	same	same	ADJ
cuesj-385	87	12	tumor	tumor	NOUN
cuesj-385	87	13	,	,	PUNCT
cuesj-385	87	14	suggesting	suggest	VERB
cuesj-385	87	15	different	different	ADJ
cuesj-385	87	16	genetic	genetic	ADJ
cuesj-385	87	17	pathways	pathway	NOUN
cuesj-385	87	18	leading	lead	VERB
cuesj-385	87	19	to	to	ADP
cuesj-385	87	20	tumor	tumor	NOUN
cuesj-385	87	21	formation	formation	NOUN
cuesj-385	87	22	,	,	PUNCT
cuesj-385	87	23	a	a	DET
cuesj-385	87	24	finding	finding	NOUN
cuesj-385	87	25	which	which	PRON
cuesj-385	87	26	strongly	strongly	ADV
cuesj-385	87	27	supported	support	VERB
cuesj-385	87	28	the	the	DET
cuesj-385	87	29	finding	finding	NOUN
cuesj-385	87	30	of	of	ADP
cuesj-385	87	31	the	the	DET
cuesj-385	87	32	present	present	ADJ
cuesj-385	87	33	study	study	NOUN
cuesj-385	87	34	.	.	PUNCT
cuesj-385	88	1	it	it	PRON
cuesj-385	88	2	was	be	AUX
cuesj-385	88	3	reported	report	VERB
cuesj-385	88	4	that	that	SCONJ
cuesj-385	88	5	the	the	DET
cuesj-385	88	6	kras	kras	PROPN
cuesj-385	88	7	and	and	CCONJ
cuesj-385	88	8	p53	p53	NOUN
cuesj-385	88	9	mutations	mutation	NOUN
cuesj-385	88	10	rarely	rarely	ADV
cuesj-385	88	11	coexist	coexist	VERB
cuesj-385	88	12	in	in	ADP
cuesj-385	88	13	the	the	DET
cuesj-385	88	14	same	same	ADJ
cuesj-385	88	15	tumor,[27	tumor,[27	NOUN
cuesj-385	88	16	]	]	PUNCT
cuesj-385	88	17	indicating	indicate	VERB
cuesj-385	88	18	that	that	SCONJ
cuesj-385	88	19	these	these	DET
cuesj-385	88	20	alterations	alteration	NOUN
cuesj-385	88	21	do	do	AUX
cuesj-385	88	22	not	not	PART
cuesj-385	88	23	represent	represent	VERB
cuesj-385	88	24	a	a	DET
cuesj-385	88	25	synergistic	synergistic	ADJ
cuesj-385	88	26	evolutionary	evolutionary	ADJ
cuesj-385	88	27	pathway	pathway	NOUN
cuesj-385	88	28	,	,	PUNCT
cuesj-385	88	29	again	again	ADV
cuesj-385	88	30	these	these	DET
cuesj-385	88	31	findings	finding	NOUN
cuesj-385	88	32	are	be	AUX
cuesj-385	88	33	similar	similar	ADJ
cuesj-385	88	34	to	to	ADP
cuesj-385	88	35	the	the	DET
cuesj-385	88	36	findings	finding	NOUN
cuesj-385	88	37	of	of	ADP
cuesj-385	88	38	the	the	DET
cuesj-385	88	39	present	present	ADJ
cuesj-385	88	40	study	study	NOUN
cuesj-385	88	41	.	.	PUNCT
cuesj-385	89	1	conclusions	conclusion	NOUN
cuesj-385	89	2	from	from	ADP
cuesj-385	89	3	the	the	DET
cuesj-385	89	4	achieved	achieve	VERB
cuesj-385	89	5	results	result	NOUN
cuesj-385	89	6	of	of	ADP
cuesj-385	89	7	this	this	DET
cuesj-385	89	8	study	study	NOUN
cuesj-385	89	9	,	,	PUNCT
cuesj-385	89	10	we	we	PRON
cuesj-385	89	11	can	can	AUX
cuesj-385	89	12	conclude	conclude	VERB
cuesj-385	89	13	the	the	DET
cuesj-385	89	14	following	following	NOUN
cuesj-385	89	15	:	:	PUNCT
cuesj-385	89	16	p53	p53	NOUN
cuesj-385	89	17	is	be	AUX
cuesj-385	89	18	an	an	DET
cuesj-385	89	19	independent	independent	ADJ
cuesj-385	89	20	prognostic	prognostic	ADJ
cuesj-385	89	21	marker	marker	NOUN
cuesj-385	89	22	and	and	CCONJ
cuesj-385	89	23	be	be	AUX
cuesj-385	89	24	regarded	regard	VERB
cuesj-385	89	25	as	as	ADP
cuesj-385	89	26	an	an	DET
cuesj-385	89	27	early	early	ADJ
cuesj-385	89	28	event	event	NOUN
cuesj-385	89	29	in	in	ADP
cuesj-385	89	30	the	the	DET
cuesj-385	89	31	pathogenesis	pathogenesis	NOUN
cuesj-385	89	32	of	of	ADP
cuesj-385	89	33	crc	crc	PROPN
cuesj-385	89	34	.	.	PUNCT
cuesj-385	90	1	the	the	DET
cuesj-385	90	2	p53	p53	NOUN
cuesj-385	90	3	and	and	CCONJ
cuesj-385	90	4	kras	kras	PROPN
cuesj-385	90	5	mutations	mutation	NOUN
cuesj-385	90	6	are	be	AUX
cuesj-385	90	7	not	not	PART
cuesj-385	90	8	found	find	VERB
cuesj-385	90	9	together	together	ADV
cuesj-385	90	10	in	in	ADP
cuesj-385	90	11	the	the	DET
cuesj-385	90	12	same	same	ADJ
cuesj-385	90	13	tumor	tumor	NOUN
cuesj-385	90	14	and	and	CCONJ
cuesj-385	90	15	neither	neither	CCONJ
cuesj-385	90	16	kras	kras	PROPN
cuesj-385	90	17	gene	gene	NOUN
cuesj-385	90	18	mutations	mutation	NOUN
cuesj-385	90	19	nor	nor	CCONJ
cuesj-385	90	20	its	its	PRON
cuesj-385	90	21	protein	protein	NOUN
cuesj-385	90	22	overexpression	overexpression	NOUN
cuesj-385	90	23	were	be	AUX
cuesj-385	90	24	detected	detect	VERB
cuesj-385	90	25	in	in	ADP
cuesj-385	90	26	colorectal	colorectal	ADJ
cuesj-385	90	27	carcinoma	carcinoma	NOUN
cuesj-385	90	28	.	.	PUNCT
cuesj-385	91	1	such	such	ADJ
cuesj-385	91	2	findings	finding	NOUN
cuesj-385	91	3	necessitate	necessitate	ADJ
cuesj-385	91	4	the	the	DET
cuesj-385	91	5	need	need	NOUN
cuesj-385	91	6	for	for	ADP
cuesj-385	91	7	conducting	conduct	VERB
cuesj-385	91	8	a	a	DET
cuesj-385	91	9	specific	specific	ADJ
cuesj-385	91	10	study	study	NOUN
cuesj-385	91	11	focusing	focus	VERB
cuesj-385	91	12	on	on	ADP
cuesj-385	91	13	kras	kra	NOUN
cuesj-385	91	14	genes	gene	NOUN
cuesj-385	91	15	expression	expression	NOUN
cuesj-385	91	16	and	and	CCONJ
cuesj-385	91	17	protein	protein	NOUN
cuesj-385	91	18	overexpression	overexpression	NOUN
cuesj-385	91	19	in	in	ADP
cuesj-385	91	20	colorectal	colorectal	ADJ
cuesj-385	91	21	carcinoma	carcinoma	NOUN
cuesj-385	91	22	.	.	PUNCT
cuesj-385	92	1	references	reference	NOUN
cuesj-385	92	2	1	1	NUM
cuesj-385	92	3	.	.	PUNCT
cuesj-385	92	4	e.	e.	PROPN
cuesj-385	92	5	r.	r.	PROPN
cuesj-385	92	6	fearon	fearon	PROPN
cuesj-385	92	7	and	and	CCONJ
cuesj-385	92	8	b.	b.	PROPN
cuesj-385	92	9	vogelstein	vogelstein	PROPN
cuesj-385	92	10	.	.	PUNCT
cuesj-385	93	1	a	a	DET
cuesj-385	93	2	genetic	genetic	ADJ
cuesj-385	93	3	model	model	NOUN
cuesj-385	93	4	for	for	ADP
cuesj-385	93	5	colorectal	colorectal	ADJ
cuesj-385	93	6	tumorigenesis	tumorigenesis	NOUN
cuesj-385	93	7	.	.	PUNCT
cuesj-385	94	1	cell	cell	NOUN
cuesj-385	94	2	vol	vol	NOUN
cuesj-385	94	3	.	.	PROPN
cuesj-385	95	1	61	61	NUM
cuesj-385	95	2	,	,	PUNCT
cuesj-385	95	3	no	no	INTJ
cuesj-385	95	4	.	.	NOUN
cuesj-385	95	5	5	5	NUM
cuesj-385	95	6	,	,	PUNCT
cuesj-385	95	7	pp	pp	ADJ
cuesj-385	95	8	.	.	PUNCT
cuesj-385	96	1	759	759	NUM
cuesj-385	96	2	-	-	NUM
cuesj-385	96	3	767	767	NUM
cuesj-385	96	4	,	,	PUNCT
cuesj-385	96	5	1990	1990	NUM
cuesj-385	96	6	.	.	PUNCT
cuesj-385	97	1	2	2	NUM
cuesj-385	97	2	.	.	PUNCT
cuesj-385	97	3	a.	a.	NOUN
cuesj-385	97	4	russo	russo	PROPN
cuesj-385	97	5	,	,	PUNCT
cuesj-385	97	6	s.	s.	PROPN
cuesj-385	97	7	rizzo	rizzo	PROPN
cuesj-385	97	8	,	,	PUNCT
cuesj-385	97	9	g.	g.	PROPN
cuesj-385	97	10	bronte	bronte	PROPN
cuesj-385	97	11	,	,	PUNCT
cuesj-385	97	12	n.	n.	NOUN
cuesj-385	97	13	silvestris	silvestris	PROPN
cuesj-385	97	14	,	,	PUNCT
cuesj-385	97	15	g.	g.	PROPN
cuesj-385	97	16	colucci	colucci	PROPN
cuesj-385	97	17	,	,	PUNCT
cuesj-385	97	18	n.	n.	PROPN
cuesj-385	97	19	gebbia	gebbia	PROPN
cuesj-385	97	20	,	,	PUNCT
cuesj-385	97	21	v.	v.	PROPN
cuesj-385	97	22	bazan	bazan	PROPN
cuesj-385	97	23	and	and	CCONJ
cuesj-385	97	24	f.	f.	PROPN
cuesj-385	97	25	fulfaro	fulfaro	PROPN
cuesj-385	97	26	.	.	PUNCT
cuesj-385	98	1	the	the	DET
cuesj-385	98	2	long	long	ADJ
cuesj-385	98	3	and	and	CCONJ
cuesj-385	98	4	winding	wind	VERB
cuesj-385	98	5	road	road	NOUN
cuesj-385	98	6	to	to	ADP
cuesj-385	98	7	useful	useful	ADJ
cuesj-385	98	8	predictive	predictive	ADJ
cuesj-385	98	9	factors	factor	NOUN
cuesj-385	98	10	for	for	ADP
cuesj-385	98	11	anti	anti	ADJ
cuesj-385	98	12	-	-	ADJ
cuesj-385	98	13	egfr	egfr	ADJ
cuesj-385	98	14	therapy	therapy	NOUN
cuesj-385	98	15	in	in	ADP
cuesj-385	98	16	metastatic	metastatic	ADJ
cuesj-385	98	17	colorectal	colorectal	ADJ
cuesj-385	98	18	carcinoma	carcinoma	NOUN
cuesj-385	98	19	:	:	PUNCT
cuesj-385	98	20	the	the	DET
cuesj-385	98	21	kras	kras	PROPN
cuesj-385	98	22	/	/	SYM
cuesj-385	98	23	braf	braf	NOUN
cuesj-385	98	24	pathway	pathway	NOUN
cuesj-385	98	25	.	.	PUNCT
cuesj-385	99	1	oncology	oncology	NOUN
cuesj-385	99	2	,	,	PUNCT
cuesj-385	99	3	vol	vol	NOUN
cuesj-385	99	4	.	.	PROPN
cuesj-385	99	5	77	77	NUM
cuesj-385	99	6	,	,	PUNCT
cuesj-385	99	7	no	no	INTJ
cuesj-385	99	8	.	.	PUNCT
cuesj-385	100	1	suppl	suppl	PROPN
cuesj-385	100	2	1	1	NUM
cuesj-385	100	3	,	,	PUNCT
cuesj-385	100	4	pp	pp	ADJ
cuesj-385	100	5	.	.	PUNCT
cuesj-385	101	1	57	57	NUM
cuesj-385	101	2	-	-	SYM
cuesj-385	101	3	68	68	NUM
cuesj-385	101	4	,	,	PUNCT
cuesj-385	101	5	2009	2009	NUM
cuesj-385	101	6	.	.	PUNCT
cuesj-385	102	1	3	3	X
cuesj-385	102	2	.	.	PUNCT
cuesj-385	102	3	f.	f.	PROPN
cuesj-385	102	4	coppedè	coppedè	PROPN
cuesj-385	102	5	,	,	PUNCT
cuesj-385	102	6	a.	a.	PROPN
cuesj-385	102	7	lopomo	lopomo	PROPN
cuesj-385	102	8	,	,	PUNCT
cuesj-385	102	9	r.	r.	PROPN
cuesj-385	102	10	spisni	spisni	PROPN
cuesj-385	102	11	and	and	CCONJ
cuesj-385	102	12	l.	l.	PROPN
cuesj-385	102	13	migliore	migliore	PROPN
cuesj-385	102	14	.	.	PUNCT
cuesj-385	103	1	genetic	genetic	ADJ
cuesj-385	103	2	and	and	CCONJ
cuesj-385	103	3	epigenetic	epigenetic	ADJ
cuesj-385	103	4	biomarkers	biomarker	NOUN
cuesj-385	103	5	for	for	ADP
cuesj-385	103	6	diagnosis	diagnosis	NOUN
cuesj-385	103	7	,	,	PUNCT
cuesj-385	103	8	prognosis	prognosis	NOUN
cuesj-385	103	9	and	and	CCONJ
cuesj-385	103	10	treatment	treatment	NOUN
cuesj-385	103	11	of	of	ADP
cuesj-385	103	12	colorectal	colorectal	ADJ
cuesj-385	103	13	cancer	cancer	NOUN
cuesj-385	103	14	.	.	PUNCT
cuesj-385	104	1	world	world	PROPN
cuesj-385	104	2	journal	journal	PROPN
cuesj-385	104	3	of	of	ADP
cuesj-385	104	4	gastroenterology	gastroenterology	NOUN
cuesj-385	104	5	,	,	PUNCT
cuesj-385	104	6	vol	vol	NOUN
cuesj-385	104	7	.	.	PROPN
cuesj-385	104	8	20	20	NUM
cuesj-385	104	9	,	,	PUNCT
cuesj-385	104	10	no	no	INTJ
cuesj-385	104	11	.	.	NOUN
cuesj-385	104	12	4	4	NUM
cuesj-385	104	13	,	,	PUNCT
cuesj-385	104	14	p.	p.	NOUN
cuesj-385	104	15	943	943	NUM
cuesj-385	104	16	,	,	PUNCT
cuesj-385	104	17	2014	2014	NUM
cuesj-385	104	18	.	.	PUNCT
cuesj-385	105	1	4	4	X
cuesj-385	105	2	.	.	X
cuesj-385	105	3	b.	b.	PROPN
cuesj-385	105	4	leggett	leggett	PROPN
cuesj-385	105	5	and	and	CCONJ
cuesj-385	105	6	v.	v.	ADP
cuesj-385	105	7	whitehall	whitehall	NOUN
cuesj-385	105	8	.	.	PUNCT
cuesj-385	106	1	role	role	NOUN
cuesj-385	106	2	of	of	ADP
cuesj-385	106	3	the	the	DET
cuesj-385	106	4	serrated	serrate	VERB
cuesj-385	106	5	pathway	pathway	NOUN
cuesj-385	106	6	in	in	ADP
cuesj-385	106	7	colorectal	colorectal	ADJ
cuesj-385	106	8	cancer	cancer	NOUN
cuesj-385	106	9	pathogenesis	pathogenesis	NOUN
cuesj-385	106	10	.	.	PUNCT
cuesj-385	107	1	gastroenterology	gastroenterology	NOUN
cuesj-385	107	2	,	,	PUNCT
cuesj-385	107	3	vol	vol	NOUN
cuesj-385	107	4	.	.	PROPN
cuesj-385	107	5	138	138	NUM
cuesj-385	107	6	,	,	PUNCT
cuesj-385	107	7	no	no	INTJ
cuesj-385	107	8	.	.	NOUN
cuesj-385	107	9	6	6	NUM
cuesj-385	107	10	,	,	PUNCT
cuesj-385	107	11	pp	pp	ADJ
cuesj-385	107	12	.	.	PUNCT
cuesj-385	108	1	2088	2088	NUM
cuesj-385	108	2	-	-	SYM
cuesj-385	108	3	2100	2100	NUM
cuesj-385	108	4	,	,	PUNCT
cuesj-385	108	5	2010	2010	NUM
cuesj-385	108	6	.	.	PUNCT
cuesj-385	109	1	5	5	NUM
cuesj-385	109	2	.	.	X
cuesj-385	109	3	w.	w.	PROPN
cuesj-385	109	4	jin	jin	PROPN
cuesj-385	109	5	,	,	PUNCT
cuesj-385	109	6	m.	m.	NOUN
cuesj-385	109	7	q.	q.	PROPN
cuesj-385	109	8	gao	gao	PROPN
cuesj-385	109	9	,	,	PUNCT
cuesj-385	109	10	z.	z.	PROPN
cuesj-385	109	11	w.	w.	PROPN
cuesj-385	109	12	lin	lin	PROPN
cuesj-385	109	13	and	and	CCONJ
cuesj-385	109	14	d.	d.	PROPN
cuesj-385	109	15	x.	x.	PROPN
cuesj-385	109	16	yang	yang	PROPN
cuesj-385	109	17	.	.	PUNCT
cuesj-385	110	1	multiple	multiple	ADJ
cuesj-385	110	2	biomarkers	biomarker	NOUN
cuesj-385	110	3	of	of	ADP
cuesj-385	110	4	colorectal	colorectal	ADJ
cuesj-385	110	5	tumor	tumor	NOUN
cuesj-385	110	6	in	in	ADP
cuesj-385	110	7	a	a	DET
cuesj-385	110	8	differentia1	differentia1	NOUN
cuesj-385	110	9	diagnosis	diagnosis	NOUN
cuesj-385	110	10	model	model	NOUN
cuesj-385	110	11	:	:	PUNCT
cuesj-385	110	12	a	a	DET
cuesj-385	110	13	quantitative	quantitative	ADJ
cuesj-385	110	14	study	study	NOUN
cuesj-385	110	15	.	.	PUNCT
cuesj-385	111	1	world	world	PROPN
cuesj-385	111	2	journal	journal	PROPN
cuesj-385	111	3	of	of	ADP
cuesj-385	111	4	gastroenterology	gastroenterology	NOUN
cuesj-385	111	5	,	,	PUNCT
cuesj-385	111	6	vol	vol	NOUN
cuesj-385	111	7	.	.	PROPN
cuesj-385	111	8	10	10	NUM
cuesj-385	111	9	,	,	PUNCT
cuesj-385	111	10	no	no	INTJ
cuesj-385	111	11	.	.	NOUN
cuesj-385	111	12	3	3	NUM
cuesj-385	111	13	,	,	PUNCT
cuesj-385	111	14	pp	pp	ADJ
cuesj-385	111	15	.	.	PUNCT
cuesj-385	111	16	439442	439442	NUM
cuesj-385	111	17	,	,	PUNCT
cuesj-385	111	18	2004	2004	NUM
cuesj-385	111	19	.	.	PUNCT
cuesj-385	112	1	6	6	NUM
cuesj-385	112	2	.	.	PUNCT
cuesj-385	112	3	s.	s.	PROPN
cuesj-385	112	4	d.	d.	PROPN
cuesj-385	112	5	markowitz	markowitz	PROPN
cuesj-385	112	6	and	and	CCONJ
cuesj-385	112	7	m.	m.	PROPN
cuesj-385	112	8	m.	m.	PROPN
cuesj-385	112	9	bertagnolli	bertagnolli	PROPN
cuesj-385	112	10	.	.	PUNCT
cuesj-385	113	1	molecular	molecular	ADJ
cuesj-385	113	2	basis	basis	NOUN
cuesj-385	113	3	of	of	ADP
cuesj-385	113	4	colorectal	colorectal	ADJ
cuesj-385	113	5	cancer	cancer	NOUN
cuesj-385	113	6	.	.	PUNCT
cuesj-385	114	1	new	new	PROPN
cuesj-385	114	2	england	england	PROPN
cuesj-385	114	3	journal	journal	PROPN
cuesj-385	114	4	of	of	ADP
cuesj-385	114	5	medicine	medicine	NOUN
cuesj-385	114	6	,	,	PUNCT
cuesj-385	114	7	vol	vol	NOUN
cuesj-385	114	8	.	.	PROPN
cuesj-385	114	9	361	361	NUM
cuesj-385	114	10	,	,	PUNCT
cuesj-385	114	11	no	no	INTJ
cuesj-385	114	12	.	.	NOUN
cuesj-385	114	13	25	25	NUM
cuesj-385	114	14	,	,	PUNCT
cuesj-385	114	15	pp	pp	ADJ
cuesj-385	114	16	.	.	PUNCT
cuesj-385	115	1	2449	2449	NUM
cuesj-385	115	2	-	-	SYM
cuesj-385	115	3	2460	2460	NUM
cuesj-385	115	4	,	,	PUNCT
cuesj-385	115	5	2009	2009	NUM
cuesj-385	115	6	.	.	PUNCT
cuesj-385	116	1	7	7	X
cuesj-385	116	2	.	.	X
cuesj-385	116	3	b.	b.	PROPN
cuesj-385	116	4	iacopetta	iacopetta	PROPN
cuesj-385	116	5	.	.	PUNCT
cuesj-385	117	1	tp53	tp53	PROPN
cuesj-385	117	2	mutation	mutation	NOUN
cuesj-385	117	3	in	in	ADP
cuesj-385	117	4	colorectal	colorectal	ADJ
cuesj-385	117	5	cancer	cancer	NOUN
cuesj-385	117	6	.	.	PUNCT
cuesj-385	118	1	human	human	ADJ
cuesj-385	118	2	mutation	mutation	NOUN
cuesj-385	118	3	,	,	PUNCT
cuesj-385	118	4	vol	vol	NOUN
cuesj-385	118	5	.	.	PROPN
cuesj-385	118	6	21	21	NUM
cuesj-385	118	7	,	,	PUNCT
cuesj-385	118	8	no	no	INTJ
cuesj-385	118	9	.	.	NOUN
cuesj-385	118	10	3	3	NUM
cuesj-385	118	11	,	,	PUNCT
cuesj-385	118	12	pp	pp	ADJ
cuesj-385	118	13	.	.	PUNCT
cuesj-385	119	1	271	271	NUM
cuesj-385	119	2	-	-	SYM
cuesj-385	119	3	276	276	NUM
cuesj-385	119	4	,	,	PUNCT
cuesj-385	119	5	2003	2003	NUM
cuesj-385	119	6	.	.	PUNCT
cuesj-385	120	1	8	8	NUM
cuesj-385	120	2	.	.	PUNCT
cuesj-385	121	1	y.	y.	PROPN
cuesj-385	121	2	imamura	imamura	PROPN
cuesj-385	121	3	,	,	PUNCT
cuesj-385	121	4	t.	t.	NOUN
cuesj-385	121	5	morikawa	morikawa	PROPN
cuesj-385	121	6	,	,	PUNCT
cuesj-385	121	7	x.	x.	PROPN
cuesj-385	121	8	liao	liao	PROPN
cuesj-385	121	9	,	,	PUNCT
cuesj-385	121	10	p.	p.	PROPN
cuesj-385	121	11	lochhead	lochhead	PROPN
cuesj-385	121	12	,	,	PUNCT
cuesj-385	121	13	a.	a.	PROPN
cuesj-385	121	14	kuchiba	kuchiba	PROPN
cuesj-385	121	15	,	,	PUNCT
cuesj-385	121	16	m.	m.	NOUN
cuesj-385	121	17	yamauchi	yamauchi	PROPN
cuesj-385	121	18	,	,	PUNCT
cuesj-385	121	19	z.	z.	PROPN
cuesj-385	121	20	r.	r.	PROPN
cuesj-385	121	21	qian	qian	PROPN
cuesj-385	121	22	,	,	PUNCT
cuesj-385	121	23	r.	r.	PROPN
cuesj-385	121	24	nishihara	nishihara	PROPN
cuesj-385	121	25	,	,	PUNCT
cuesj-385	121	26	j.	j.	PROPN
cuesj-385	121	27	a.	a.	PROPN
cuesj-385	121	28	meyerhardt	meyerhardt	PROPN
cuesj-385	121	29	,	,	PUNCT
cuesj-385	121	30	k.	k.	PROPN
cuesj-385	121	31	m.	m.	PROPN
cuesj-385	121	32	haigis	haigis	PROPN
cuesj-385	121	33	,	,	PUNCT
cuesj-385	121	34	c.	c.	PROPN
cuesj-385	121	35	s.	s.	PROPN
cuesj-385	121	36	fuchs	fuchs	PROPN
cuesj-385	121	37	and	and	CCONJ
cuesj-385	121	38	s.	s.	PROPN
cuesj-385	121	39	ogino	ogino	PROPN
cuesj-385	121	40	.	.	PUNCT
cuesj-385	122	1	specific	specific	ADJ
cuesj-385	122	2	mutations	mutation	NOUN
cuesj-385	122	3	in	in	ADP
cuesj-385	122	4	kras	kras	PROPN
cuesj-385	122	5	codons	codon	NOUN
cuesj-385	122	6	12	12	NUM
cuesj-385	122	7	and	and	CCONJ
cuesj-385	122	8	13	13	NUM
cuesj-385	122	9	,	,	PUNCT
cuesj-385	122	10	and	and	CCONJ
cuesj-385	122	11	patient	patient	ADJ
cuesj-385	122	12	prognosis	prognosis	NOUN
cuesj-385	122	13	in	in	ADP
cuesj-385	122	14	1075	1075	NUM
cuesj-385	122	15	braf	braf	NOUN
cuesj-385	122	16	wild	wild	ADJ
cuesj-385	122	17	-	-	PUNCT
cuesj-385	122	18	type	type	NOUN
cuesj-385	122	19	colorectal	colorectal	ADJ
cuesj-385	122	20	cancers	cancer	NOUN
cuesj-385	122	21	.	.	PUNCT
cuesj-385	123	1	clinical	clinical	ADJ
cuesj-385	123	2	cancer	cancer	NOUN
cuesj-385	123	3	research	research	NOUN
cuesj-385	123	4	,	,	PUNCT
cuesj-385	123	5	vol	vol	NOUN
cuesj-385	123	6	.	.	PROPN
cuesj-385	123	7	18	18	NUM
cuesj-385	123	8	,	,	PUNCT
cuesj-385	123	9	no	no	INTJ
cuesj-385	123	10	.	.	NOUN
cuesj-385	123	11	17	17	NUM
cuesj-385	123	12	,	,	PUNCT
cuesj-385	123	13	pp	pp	ADJ
cuesj-385	123	14	.	.	PUNCT
cuesj-385	123	15	4753	4753	NUM
cuesj-385	123	16	-	-	SYM
cuesj-385	123	17	4763	4763	NUM
cuesj-385	123	18	,	,	PUNCT
cuesj-385	123	19	2012	2012	NUM
cuesj-385	123	20	.	.	PUNCT
cuesj-385	124	1	9	9	X
cuesj-385	124	2	.	.	X
cuesj-385	124	3	m.	m.	PROPN
cuesj-385	124	4	b.	b.	PROPN
cuesj-385	124	5	al	al	PROPN
cuesj-385	124	6	-	-	PUNCT
cuesj-385	124	7	jubori	jubori	PROPN
cuesj-385	124	8	.	.	PUNCT
cuesj-385	125	1	immunohisto	immunohisto	NOUN
cuesj-385	125	2	chemical	chemical	PROPN
cuesj-385	125	3	and	and	CCONJ
cuesj-385	125	4	molecular	molecular	ADJ
cuesj-385	125	5	study	study	NOUN
cuesj-385	125	6	of	of	ADP
cuesj-385	125	7	colorectal	colorectal	ADJ
cuesj-385	125	8	cancer	cancer	NOUN
cuesj-385	125	9	patients	patient	NOUN
cuesj-385	125	10	.	.	PUNCT
cuesj-385	126	1	ph.d	ph.d	PROPN
cuesj-385	126	2	.	.	PUNCT
cuesj-385	127	1	thesis	thesis	NOUN
cuesj-385	127	2	,	,	PUNCT
cuesj-385	127	3	college	college	NOUN
cuesj-385	127	4	of	of	ADP
cuesj-385	127	5	science	science	PROPN
cuesj-385	127	6	,	,	PUNCT
cuesj-385	127	7	kufa	kufa	PROPN
cuesj-385	127	8	university	university	PROPN
cuesj-385	127	9	,	,	PUNCT
cuesj-385	127	10	iraq	iraq	PROPN
cuesj-385	127	11	,	,	PUNCT
cuesj-385	127	12	2015	2015	NUM
cuesj-385	127	13	.	.	PUNCT
cuesj-385	128	1	10	10	NUM
cuesj-385	128	2	.	.	PUNCT
cuesj-385	129	1	p.	p.	PROPN
cuesj-385	129	2	uribe	uribe	PROPN
cuesj-385	129	3	,	,	PUNCT
cuesj-385	129	4	l.	l.	PROPN
cuesj-385	129	5	andrade	andrade	PROPN
cuesj-385	129	6	and	and	CCONJ
cuesj-385	129	7	s.	s.	PROPN
cuesj-385	129	8	gonzalez	gonzalez	PROPN
cuesj-385	129	9	.	.	PUNCT
cuesj-385	130	1	lack	lack	NOUN
cuesj-385	130	2	of	of	ADP
cuesj-385	130	3	association	association	NOUN
cuesj-385	130	4	between	between	ADP
cuesj-385	130	5	braf	braf	NOUN
cuesj-385	130	6	mutation	mutation	NOUN
cuesj-385	130	7	and	and	CCONJ
cuesj-385	130	8	mapk	mapk	NOUN
cuesj-385	130	9	erk	erk	NOUN
cuesj-385	130	10	activation	activation	NOUN
cuesj-385	130	11	in	in	ADP
cuesj-385	130	12	melanocytic	melanocytic	ADJ
cuesj-385	130	13	nevi	nevi	NOUN
cuesj-385	130	14	.	.	PUNCT
cuesj-385	131	1	homady	homady	PROPN
cuesj-385	131	2	,	,	PUNCT
cuesj-385	131	3	et	et	PROPN
cuesj-385	131	4	al	al	PROPN
cuesj-385	131	5	.	.	PROPN
cuesj-385	131	6	:	:	PUNCT
cuesj-385	132	1	immunohistochemical	immunohistochemical	ADJ
cuesj-385	132	2	and	and	CCONJ
cuesj-385	132	3	molecular	molecular	ADJ
cuesj-385	132	4	studies	study	NOUN
cuesj-385	132	5	of	of	ADP
cuesj-385	132	6	p53	p53	NOUN
cuesj-385	132	7	and	and	CCONJ
cuesj-385	132	8	kras	kras	PROPN
cuesj-385	132	9	protein	protein	NOUN
cuesj-385	132	10	33	33	NUM
cuesj-385	132	11	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-385	132	12	cuesj	cuesj	ADJ
cuesj-385	132	13	2021	2021	NUM
cuesj-385	132	14	,	,	PUNCT
cuesj-385	132	15	5	5	NUM
cuesj-385	132	16	(	(	PUNCT
cuesj-385	132	17	1	1	NUM
cuesj-385	132	18	):	):	PUNCT
cuesj-385	132	19	28	28	NUM
cuesj-385	132	20	-	-	SYM
cuesj-385	132	21	33	33	NUM
cuesj-385	132	22	journal	journal	NOUN
cuesj-385	132	23	of	of	ADP
cuesj-385	132	24	investigative	investigative	ADJ
cuesj-385	132	25	dermatology	dermatology	NOUN
cuesj-385	132	26	,	,	PUNCT
cuesj-385	132	27	vol	vol	NOUN
cuesj-385	132	28	.	.	PROPN
cuesj-385	132	29	126	126	NUM
cuesj-385	132	30	,	,	PUNCT
cuesj-385	132	31	no	no	INTJ
cuesj-385	132	32	.	.	NOUN
cuesj-385	132	33	1	1	NUM
cuesj-385	132	34	,	,	PUNCT
cuesj-385	132	35	pp	pp	ADJ
cuesj-385	132	36	.	.	PUNCT
cuesj-385	133	1	161	161	NUM
cuesj-385	133	2	-	-	SYM
cuesj-385	133	3	166	166	NUM
cuesj-385	133	4	,	,	PUNCT
cuesj-385	133	5	2006	2006	NUM
cuesj-385	133	6	.	.	PUNCT
cuesj-385	134	1	11	11	NUM
cuesj-385	134	2	.	.	X
cuesj-385	134	3	l.	l.	PROPN
cuesj-385	134	4	m.	m.	PROPN
cuesj-385	134	5	mcglynn	mcglynn	PROPN
cuesj-385	134	6	,	,	PUNCT
cuesj-385	134	7	t.	t.	PROPN
cuesj-385	134	8	kirkegaard	kirkegaard	NOUN
cuesj-385	134	9	,	,	PUNCT
cuesj-385	134	10	j.	j.	PROPN
cuesj-385	134	11	edwards	edwards	PROPN
cuesj-385	134	12	,	,	PUNCT
cuesj-385	134	13	s.	s.	PROPN
cuesj-385	134	14	tovey	tovey	PROPN
cuesj-385	134	15	,	,	PUNCT
cuesj-385	134	16	d.	d.	PROPN
cuesj-385	134	17	cameron	cameron	PROPN
cuesj-385	134	18	,	,	PUNCT
cuesj-385	134	19	c.	c.	PROPN
cuesj-385	134	20	twelves	twelves	PROPN
cuesj-385	134	21	,	,	PUNCT
cuesj-385	134	22	j.	j.	PROPN
cuesj-385	134	23	m.	m.	PROPN
cuesj-385	134	24	s.	s.	PROPN
cuesj-385	134	25	bartlett	bartlett	PROPN
cuesj-385	134	26	and	and	CCONJ
cuesj-385	134	27	t.	t.	PROPN
cuesj-385	134	28	g.	g.	PROPN
cuesj-385	134	29	cooke	cooke	PROPN
cuesj-385	134	30	.	.	PUNCT
cuesj-385	135	1	ras	ras	NOUN
cuesj-385	135	2	/	/	SYM
cuesj-385	135	3	raf-1	raf-1	NOUN
cuesj-385	135	4	/	/	SYM
cuesj-385	135	5	mapk	mapk	NOUN
cuesj-385	135	6	pathway	pathway	NOUN
cuesj-385	135	7	mediates	mediate	VERB
cuesj-385	135	8	response	response	NOUN
cuesj-385	135	9	to	to	ADP
cuesj-385	135	10	tamoxifen	tamoxifen	NOUN
cuesj-385	135	11	but	but	CCONJ
cuesj-385	135	12	not	not	PART
cuesj-385	135	13	chemotherapy	chemotherapy	NOUN
cuesj-385	135	14	in	in	ADP
cuesj-385	135	15	breast	breast	NOUN
cuesj-385	135	16	cancer	cancer	NOUN
cuesj-385	135	17	patients	patient	NOUN
cuesj-385	135	18	.	.	PUNCT
cuesj-385	136	1	clinical	clinical	ADJ
cuesj-385	136	2	cancer	cancer	NOUN
cuesj-385	136	3	research	research	NOUN
cuesj-385	136	4	,	,	PUNCT
cuesj-385	136	5	vol	vol	NOUN
cuesj-385	136	6	.	.	PROPN
cuesj-385	136	7	15	15	NUM
cuesj-385	136	8	,	,	PUNCT
cuesj-385	136	9	no	no	INTJ
cuesj-385	136	10	.	.	NOUN
cuesj-385	136	11	4	4	NUM
cuesj-385	136	12	,	,	PUNCT
cuesj-385	136	13	1487	1487	NUM
cuesj-385	136	14	-	-	SYM
cuesj-385	136	15	1495	1495	NUM
cuesj-385	136	16	,	,	PUNCT
cuesj-385	136	17	pp	pp	ADJ
cuesj-385	136	18	.	.	PUNCT
cuesj-385	136	19	2009	2009	NUM
cuesj-385	136	20	.	.	PUNCT
cuesj-385	137	1	12	12	NUM
cuesj-385	137	2	.	.	PUNCT
cuesj-385	138	1	e.	e.	PROPN
cuesj-385	138	2	ioachim	ioachim	PROPN
cuesj-385	138	3	,	,	PUNCT
cuesj-385	138	4	m.	m.	PROPN
cuesj-385	138	5	c.	c.	PROPN
cuesj-385	138	6	michael	michael	PROPN
cuesj-385	138	7	,	,	PUNCT
cuesj-385	138	8	m.	m.	NOUN
cuesj-385	138	9	salmas	salmas	PROPN
cuesj-385	138	10	,	,	PUNCT
cuesj-385	138	11	k.	k.	PROPN
cuesj-385	138	12	damala	damala	PROPN
cuesj-385	138	13	,	,	PUNCT
cuesj-385	138	14	e.	e.	PROPN
cuesj-385	138	15	tsanou	tsanou	PROPN
cuesj-385	138	16	,	,	PUNCT
cuesj-385	138	17	m.	m.	NOUN
cuesj-385	138	18	m.	m.	PROPN
cuesj-385	138	19	michael	michael	PROPN
cuesj-385	138	20	,	,	PUNCT
cuesj-385	138	21	v.	v.	ADP
cuesj-385	138	22	malamou	malamou	NOUN
cuesj-385	138	23	-	-	PUNCT
cuesj-385	138	24	mitsi	mitsi	PROPN
cuesj-385	138	25	and	and	CCONJ
cuesj-385	138	26	n.	n.	PROPN
cuesj-385	138	27	e.	e.	PROPN
cuesj-385	138	28	stavropoulos	stavropoulos	PROPN
cuesj-385	138	29	.	.	PUNCT
cuesj-385	139	1	thrombospondin-1	thrombospondin-1	NUM
cuesj-385	139	2	expression	expression	NOUN
cuesj-385	139	3	in	in	ADP
cuesj-385	139	4	urothelial	urothelial	ADJ
cuesj-385	139	5	carcinoma	carcinoma	NOUN
cuesj-385	139	6	:	:	PUNCT
cuesj-385	139	7	prognostic	prognostic	ADJ
cuesj-385	139	8	significance	significance	NOUN
cuesj-385	139	9	and	and	CCONJ
cuesj-385	139	10	association	association	NOUN
cuesj-385	139	11	with	with	ADP
cuesj-385	139	12	p53	p53	NOUN
cuesj-385	139	13	alterations	alteration	NOUN
cuesj-385	139	14	,	,	PUNCT
cuesj-385	139	15	tumour	tumour	NOUN
cuesj-385	139	16	angiogenesis	angiogenesis	NOUN
cuesj-385	139	17	and	and	CCONJ
cuesj-385	139	18	extracellular	extracellular	ADJ
cuesj-385	139	19	matrix	matrix	NOUN
cuesj-385	139	20	components	component	NOUN
cuesj-385	139	21	.	.	PUNCT
cuesj-385	140	1	bmc	bmc	ADJ
cuesj-385	140	2	cancer	cancer	NOUN
cuesj-385	140	3	,	,	PUNCT
cuesj-385	140	4	vol	vol	NOUN
cuesj-385	140	5	.	.	PROPN
cuesj-385	140	6	6	6	NUM
cuesj-385	140	7	,	,	PUNCT
cuesj-385	140	8	no	no	INTJ
cuesj-385	140	9	.	.	NOUN
cuesj-385	140	10	1	1	NUM
cuesj-385	140	11	,	,	PUNCT
cuesj-385	140	12	pp	pp	ADJ
cuesj-385	140	13	.	.	PUNCT
cuesj-385	141	1	1	1	NUM
cuesj-385	141	2	-	-	SYM
cuesj-385	141	3	8	8	NUM
cuesj-385	141	4	,	,	PUNCT
cuesj-385	141	5	2006	2006	NUM
cuesj-385	141	6	.	.	PUNCT
cuesj-385	142	1	13	13	NUM
cuesj-385	142	2	.	.	PUNCT
cuesj-385	143	1	p.	p.	NOUN
cuesj-385	143	2	f.	f.	PROPN
cuesj-385	143	3	rambau	rambau	PROPN
cuesj-385	143	4	,	,	PUNCT
cuesj-385	143	5	m.	m.	NOUN
cuesj-385	143	6	odida	odida	PROPN
cuesj-385	143	7	and	and	CCONJ
cuesj-385	143	8	h.	h.	PROPN
cuesj-385	143	9	wabinga	wabinga	PROPN
cuesj-385	143	10	.	.	PUNCT
cuesj-385	144	1	p53	p53	NOUN
cuesj-385	144	2	expression	expression	NOUN
cuesj-385	144	3	in	in	ADP
cuesj-385	144	4	colorectal	colorectal	ADJ
cuesj-385	144	5	carcinoma	carcinoma	NOUN
cuesj-385	144	6	in	in	ADP
cuesj-385	144	7	relation	relation	NOUN
cuesj-385	144	8	to	to	ADP
cuesj-385	144	9	histopathological	histopathological	ADJ
cuesj-385	144	10	features	feature	NOUN
cuesj-385	144	11	in	in	ADP
cuesj-385	144	12	ugandan	ugandan	ADJ
cuesj-385	144	13	patients	patient	NOUN
cuesj-385	144	14	.	.	PUNCT
cuesj-385	145	1	african	african	ADJ
cuesj-385	145	2	health	health	NOUN
cuesj-385	145	3	sciences	sciences	PROPN
cuesj-385	145	4	,	,	PUNCT
cuesj-385	145	5	vol	vol	NOUN
cuesj-385	145	6	.	.	PROPN
cuesj-385	145	7	8	8	NUM
cuesj-385	145	8	,	,	PUNCT
cuesj-385	145	9	no	no	INTJ
cuesj-385	145	10	.	.	NOUN
cuesj-385	145	11	4	4	NUM
cuesj-385	145	12	,	,	PUNCT
cuesj-385	145	13	pp	pp	ADJ
cuesj-385	145	14	.	.	PUNCT
cuesj-385	145	15	234238	234238	NUM
cuesj-385	145	16	,	,	PUNCT
cuesj-385	145	17	pp	pp	ADJ
cuesj-385	145	18	.	.	PUNCT
cuesj-385	145	19	2008	2008	NUM
cuesj-385	145	20	.	.	PUNCT
cuesj-385	146	1	14	14	NUM
cuesj-385	146	2	.	.	PUNCT
cuesj-385	147	1	h.	h.	PROPN
cuesj-385	147	2	l.	l.	PROPN
cuesj-385	147	3	de	de	PROPN
cuesj-385	147	4	menezes	menezes	PROPN
cuesj-385	147	5	,	,	PUNCT
cuesj-385	147	6	m.	m.	NOUN
cuesj-385	147	7	j.	j.	PROPN
cuesj-385	147	8	jucá	jucá	PROPN
cuesj-385	147	9	,	,	PUNCT
cuesj-385	147	10	e.	e.	PROPN
cuesj-385	147	11	g.	g.	PROPN
cuesj-385	147	12	a.	a.	PROPN
cuesj-385	147	13	de	de	PROPN
cuesj-385	147	14	gomes	gomes	PROPN
cuesj-385	147	15	,	,	PUNCT
cuesj-385	147	16	b.	b.	PROPN
cuesj-385	147	17	l.	l.	PROPN
cuesj-385	147	18	nunes	nunes	PROPN
cuesj-385	147	19	,	,	PUNCT
cuesj-385	147	20	h.	h.	PROPN
cuesj-385	147	21	o.	o.	PROPN
cuesj-385	147	22	costa	costa	PROPN
cuesj-385	147	23	and	and	CCONJ
cuesj-385	147	24	d.	d.	PROPN
cuesj-385	147	25	matos	matos	PROPN
cuesj-385	147	26	.	.	PUNCT
cuesj-385	148	1	analysis	analysis	NOUN
cuesj-385	148	2	of	of	ADP
cuesj-385	148	3	the	the	DET
cuesj-385	148	4	immunohistochemical	immunohistochemical	ADJ
cuesj-385	148	5	expressions	expression	NOUN
cuesj-385	148	6	of	of	ADP
cuesj-385	148	7	p53	p53	NOUN
cuesj-385	148	8	,	,	PUNCT
cuesj-385	148	9	bcl-2	bcl-2	PUNCT
cuesj-385	148	10	and	and	CCONJ
cuesj-385	148	11	ki-67	ki-67	ADJ
cuesj-385	148	12	in	in	ADP
cuesj-385	148	13	colorectal	colorectal	ADJ
cuesj-385	148	14	adenocarcinoma	adenocarcinoma	NOUN
cuesj-385	148	15	and	and	CCONJ
cuesj-385	148	16	their	their	PRON
cuesj-385	148	17	correlations	correlation	NOUN
cuesj-385	148	18	with	with	ADP
cuesj-385	148	19	the	the	DET
cuesj-385	148	20	prognostic	prognostic	ADJ
cuesj-385	148	21	factors	factor	NOUN
cuesj-385	148	22	.	.	PUNCT
cuesj-385	149	1	arquivos	arquivos	PROPN
cuesj-385	149	2	de	de	PROPN
cuesj-385	149	3	gastroenterologia	gastroenterologia	PROPN
cuesj-385	149	4	,	,	PUNCT
cuesj-385	149	5	vol	vol	NOUN
cuesj-385	149	6	.	.	PROPN
cuesj-385	150	1	47	47	NUM
cuesj-385	150	2	,	,	PUNCT
cuesj-385	150	3	no	no	INTJ
cuesj-385	150	4	.	.	NOUN
cuesj-385	150	5	2	2	NUM
cuesj-385	150	6	,	,	PUNCT
cuesj-385	150	7	pp	pp	ADJ
cuesj-385	150	8	.	.	PUNCT
cuesj-385	151	1	141	141	NUM
cuesj-385	151	2	-	-	SYM
cuesj-385	151	3	147	147	NUM
cuesj-385	151	4	,	,	PUNCT
cuesj-385	151	5	2010	2010	NUM
cuesj-385	151	6	.	.	PUNCT
cuesj-385	152	1	15	15	NUM
cuesj-385	152	2	.	.	PUNCT
cuesj-385	152	3	s.	s.	PROPN
cuesj-385	152	4	strano	strano	PROPN
cuesj-385	152	5	,	,	PUNCT
cuesj-385	152	6	s.	s.	PROPN
cuesj-385	152	7	dell’orso	dell’orso	PROPN
cuesj-385	152	8	,	,	PUNCT
cuesj-385	152	9	s.	s.	PROPN
cuesj-385	152	10	di	di	PROPN
cuesj-385	152	11	agostino	agostino	PROPN
cuesj-385	152	12	,	,	PUNCT
cuesj-385	152	13	g.	g.	PROPN
cuesj-385	152	14	fontemaggi	fontemaggi	PROPN
cuesj-385	152	15	,	,	PUNCT
cuesj-385	152	16	a.	a.	PROPN
cuesj-385	152	17	sacchi	sacchi	PROPN
cuesj-385	152	18	and	and	CCONJ
cuesj-385	152	19	g.	g.	PROPN
cuesj-385	152	20	blandino	blandino	PROPN
cuesj-385	152	21	.	.	PUNCT
cuesj-385	153	1	mutant	mutant	ADJ
cuesj-385	153	2	p53	p53	PROPN
cuesj-385	153	3	:	:	PUNCT
cuesj-385	153	4	an	an	DET
cuesj-385	153	5	oncogenic	oncogenic	ADJ
cuesj-385	153	6	transcription	transcription	NOUN
cuesj-385	153	7	factor	factor	NOUN
cuesj-385	153	8	.	.	PUNCT
cuesj-385	154	1	oncogene	oncogene	NOUN
cuesj-385	154	2	,	,	PUNCT
cuesj-385	154	3	vol	vol	NOUN
cuesj-385	154	4	.	.	PROPN
cuesj-385	154	5	26	26	NUM
cuesj-385	154	6	,	,	PUNCT
cuesj-385	154	7	no	no	INTJ
cuesj-385	154	8	.	.	NOUN
cuesj-385	154	9	15	15	NUM
cuesj-385	154	10	,	,	PUNCT
cuesj-385	154	11	pp	pp	ADJ
cuesj-385	154	12	.	.	PUNCT
cuesj-385	155	1	2212	2212	NUM
cuesj-385	155	2	-	-	SYM
cuesj-385	155	3	2219	2219	NUM
cuesj-385	155	4	,	,	PUNCT
cuesj-385	155	5	2007	2007	NUM
cuesj-385	155	6	.	.	PUNCT
cuesj-385	156	1	16	16	NUM
cuesj-385	156	2	.	.	PUNCT
cuesj-385	157	1	n.	n.	PROPN
cuesj-385	157	2	y.	y.	PROPN
cuesj-385	157	3	asaad	asaad	PROPN
cuesj-385	157	4	,	,	PUNCT
cuesj-385	157	5	m.	m.	NOUN
cuesj-385	157	6	a.	a.	NOUN
cuesj-385	157	7	kandil	kandil	PROPN
cuesj-385	157	8	and	and	CCONJ
cuesj-385	157	9	n.	n.	PROPN
cuesj-385	157	10	m.	m.	NOUN
cuesj-385	157	11	mokhtar	mokhtar	PROPN
cuesj-385	157	12	.	.	PUNCT
cuesj-385	158	1	prognostic	prognostic	ADJ
cuesj-385	158	2	value	value	NOUN
cuesj-385	158	3	of	of	ADP
cuesj-385	158	4	cyclin	cyclin	NOUN
cuesj-385	158	5	d1	d1	PROPN
cuesj-385	158	6	and	and	CCONJ
cuesj-385	158	7	p53	p53	NOUN
cuesj-385	158	8	protein	protein	NOUN
cuesj-385	158	9	in	in	ADP
cuesj-385	158	10	colorectal	colorectal	ADJ
cuesj-385	158	11	carcinoma	carcinoma	NOUN
cuesj-385	158	12	.	.	PUNCT
cuesj-385	159	1	therapy	therapy	NOUN
cuesj-385	159	2	,	,	PUNCT
cuesj-385	159	3	vol	vol	NOUN
cuesj-385	159	4	.	.	PROPN
cuesj-385	159	5	42	42	NUM
cuesj-385	159	6	,	,	PUNCT
cuesj-385	159	7	p.	p.	NOUN
cuesj-385	159	8	48	48	NUM
cuesj-385	159	9	,	,	PUNCT
cuesj-385	159	10	2000	2000	NUM
cuesj-385	159	11	.	.	PUNCT
cuesj-385	160	1	17	17	NUM
cuesj-385	160	2	.	.	PUNCT
cuesj-385	160	3	a.	a.	PROPN
cuesj-385	160	4	malik	malik	PROPN
cuesj-385	160	5	,	,	PUNCT
cuesj-385	160	6	r.	r.	PROPN
cuesj-385	160	7	n.	n.	PROPN
cuesj-385	160	8	mishra	mishra	PROPN
cuesj-385	160	9	,	,	PUNCT
cuesj-385	160	10	b.	b.	PROPN
cuesj-385	160	11	fanthome	fanthome	PROPN
cuesj-385	160	12	,	,	PUNCT
cuesj-385	160	13	r.	r.	PROPN
cuesj-385	160	14	rao	rao	PROPN
cuesj-385	160	15	and	and	CCONJ
cuesj-385	160	16	s.	s.	PROPN
cuesj-385	160	17	r.	r.	PROPN
cuesj-385	160	18	patrikar	patrikar	PROPN
cuesj-385	160	19	.	.	PUNCT
cuesj-385	161	1	role	role	NOUN
cuesj-385	161	2	of	of	ADP
cuesj-385	161	3	cd34	cd34	PROPN
cuesj-385	161	4	,	,	PUNCT
cuesj-385	161	5	vascular	vascular	ADJ
cuesj-385	161	6	endothelial	endothelial	ADJ
cuesj-385	161	7	growth	growth	NOUN
cuesj-385	161	8	factor	factor	NOUN
cuesj-385	161	9	,	,	PUNCT
cuesj-385	161	10	and	and	CCONJ
cuesj-385	161	11	p53	p53	NOUN
cuesj-385	161	12	in	in	ADP
cuesj-385	161	13	neoangiogenesis	neoangiogenesis	NOUN
cuesj-385	161	14	as	as	SCONJ
cuesj-385	161	15	correlated	correlate	VERB
cuesj-385	161	16	with	with	ADP
cuesj-385	161	17	stage	stage	NOUN
cuesj-385	161	18	of	of	ADP
cuesj-385	161	19	disease	disease	NOUN
cuesj-385	161	20	in	in	ADP
cuesj-385	161	21	colorectal	colorectal	ADJ
cuesj-385	161	22	carcinoma	carcinoma	NOUN
cuesj-385	161	23	.	.	PUNCT
cuesj-385	162	1	medical	medical	ADJ
cuesj-385	162	2	journal	journal	PROPN
cuesj-385	162	3	armed	armed	PROPN
cuesj-385	162	4	forces	forces	PROPN
cuesj-385	162	5	india	india	PROPN
cuesj-385	162	6	,	,	PUNCT
cuesj-385	162	7	vol	vol	NOUN
cuesj-385	162	8	.	.	PROPN
cuesj-385	162	9	67	67	NUM
cuesj-385	162	10	,	,	PUNCT
cuesj-385	162	11	no	no	INTJ
cuesj-385	162	12	.	.	NOUN
cuesj-385	162	13	4	4	NUM
cuesj-385	162	14	,	,	PUNCT
cuesj-385	162	15	pp	pp	ADJ
cuesj-385	162	16	.	.	PUNCT
cuesj-385	162	17	320	320	NUM
cuesj-385	162	18	-	-	SYM
cuesj-385	162	19	325	325	NUM
cuesj-385	162	20	,	,	PUNCT
cuesj-385	162	21	2011	2011	NUM
cuesj-385	162	22	.	.	PUNCT
cuesj-385	163	1	18	18	NUM
cuesj-385	163	2	.	.	PUNCT
cuesj-385	164	1	n.	n.	PROPN
cuesj-385	164	2	mr	mr	PROPN
cuesj-385	164	3	.	.	PROPN
cuesj-385	164	4	ghavam	ghavam	PROPN
cuesj-385	164	5	,	,	PUNCT
cuesj-385	164	6	t.	t.	PROPN
cuesj-385	164	7	m.	m.	PROPN
cuesj-385	164	8	seylanian	seylanian	PROPN
cuesj-385	164	9	,	,	PUNCT
cuesj-385	164	10	e.	e.	PROPN
cuesj-385	164	11	rezaei	rezaei	PROPN
cuesj-385	164	12	,	,	PUNCT
cuesj-385	164	13	k.	k.	PROPN
cuesj-385	164	14	ghafarzadegan	ghafarzadegan	PROPN
cuesj-385	164	15	and	and	CCONJ
cuesj-385	164	16	h.	h.	PROPN
cuesj-385	164	17	malekifard	malekifard	PROPN
cuesj-385	164	18	.	.	PUNCT
cuesj-385	165	1	expression	expression	NOUN
cuesj-385	165	2	of	of	ADP
cuesj-385	165	3	p53	p53	NOUN
cuesj-385	165	4	in	in	ADP
cuesj-385	165	5	colorectal	colorectal	ADJ
cuesj-385	165	6	carcinoma	carcinoma	NOUN
cuesj-385	165	7	:	:	PUNCT
cuesj-385	165	8	correlation	correlation	NOUN
cuesj-385	165	9	with	with	ADP
cuesj-385	165	10	clinicopathologic	clinicopathologic	ADJ
cuesj-385	165	11	features	feature	NOUN
cuesj-385	165	12	.	.	PUNCT
cuesj-385	166	1	vol	vol	NOUN
cuesj-385	166	2	.	.	PROPN
cuesj-385	167	1	10	10	NUM
cuesj-385	167	2	,	,	PUNCT
cuesj-385	167	3	no	no	INTJ
cuesj-385	167	4	.	.	NOUN
cuesj-385	167	5	1	1	NUM
cuesj-385	167	6	,	,	PUNCT
cuesj-385	167	7	pp	pp	ADJ
cuesj-385	167	8	.	.	PUNCT
cuesj-385	168	1	38	38	NUM
cuesj-385	168	2	-	-	SYM
cuesj-385	168	3	42	42	NUM
cuesj-385	168	4	,	,	PUNCT
cuesj-385	168	5	2007	2007	NUM
cuesj-385	168	6	.	.	PUNCT
cuesj-385	169	1	19	19	NUM
cuesj-385	169	2	.	.	PUNCT
cuesj-385	169	3	a.	a.	PROPN
cuesj-385	169	4	conlin	conlin	PROPN
cuesj-385	169	5	,	,	PUNCT
cuesj-385	169	6	g.	g.	PROPN
cuesj-385	169	7	smith	smith	PROPN
cuesj-385	169	8	,	,	PUNCT
cuesj-385	169	9	f.	f.	PROPN
cuesj-385	169	10	a.	a.	PROPN
cuesj-385	169	11	carey	carey	PROPN
cuesj-385	169	12	,	,	PUNCT
cuesj-385	169	13	c.	c.	PROPN
cuesj-385	169	14	r.	r.	PROPN
cuesj-385	169	15	wolf	wolf	PROPN
cuesj-385	169	16	and	and	CCONJ
cuesj-385	169	17	r.	r.	PROPN
cuesj-385	169	18	j.	j.	PROPN
cuesj-385	169	19	c.	c.	PROPN
cuesj-385	169	20	steele	steele	PROPN
cuesj-385	169	21	.	.	PUNCT
cuesj-385	170	1	the	the	DET
cuesj-385	170	2	prognostic	prognostic	ADJ
cuesj-385	170	3	significance	significance	NOUN
cuesj-385	170	4	of	of	ADP
cuesj-385	170	5	k	k	PROPN
cuesj-385	170	6	-	-	PUNCT
cuesj-385	170	7	ras	ras	PROPN
cuesj-385	170	8	,	,	PUNCT
cuesj-385	170	9	p53	p53	NOUN
cuesj-385	170	10	,	,	PUNCT
cuesj-385	170	11	and	and	CCONJ
cuesj-385	170	12	apc	apc	PROPN
cuesj-385	170	13	mutations	mutation	NOUN
cuesj-385	170	14	in	in	ADP
cuesj-385	170	15	colorectal	colorectal	ADJ
cuesj-385	170	16	carcinoma	carcinoma	NOUN
cuesj-385	170	17	.	.	PUNCT
cuesj-385	171	1	gut	gut	VERB
cuesj-385	171	2	,	,	PUNCT
cuesj-385	171	3	vol	vol	NOUN
cuesj-385	171	4	.	.	PROPN
cuesj-385	172	1	54	54	NUM
cuesj-385	172	2	,	,	PUNCT
cuesj-385	172	3	no	no	INTJ
cuesj-385	172	4	.	.	NOUN
cuesj-385	172	5	9	9	NUM
cuesj-385	172	6	,	,	PUNCT
cuesj-385	172	7	pp	pp	ADJ
cuesj-385	172	8	.	.	PUNCT
cuesj-385	173	1	1283	1283	NUM
cuesj-385	173	2	-	-	SYM
cuesj-385	173	3	1286	1286	NUM
cuesj-385	173	4	,	,	PUNCT
cuesj-385	173	5	2005	2005	NUM
cuesj-385	173	6	.	.	PUNCT
cuesj-385	174	1	20	20	NUM
cuesj-385	174	2	.	.	PUNCT
cuesj-385	175	1	c.	c.	PROPN
cuesj-385	175	2	v.	v.	PROPN
cuesj-385	175	3	georgescu	georgescu	PROPN
cuesj-385	175	4	,	,	PUNCT
cuesj-385	175	5	a.	a.	NOUN
cuesj-385	175	6	saftoiu	saftoiu	PROPN
cuesj-385	175	7	,	,	PUNCT
cuesj-385	175	8	c.	c.	PROPN
cuesj-385	175	9	c.	c.	PROPN
cuesj-385	175	10	georgescu	georgescu	PROPN
cuesj-385	175	11	,	,	PUNCT
cuesj-385	175	12	r.	r.	PROPN
cuesj-385	175	13	ciurea	ciurea	PROPN
cuesj-385	175	14	and	and	CCONJ
cuesj-385	175	15	t.	t.	PROPN
cuesj-385	175	16	ciurea	ciurea	PROPN
cuesj-385	175	17	.	.	PUNCT
cuesj-385	176	1	correlations	correlation	NOUN
cuesj-385	176	2	of	of	ADP
cuesj-385	176	3	proliferation	proliferation	NOUN
cuesj-385	176	4	markers	marker	NOUN
cuesj-385	176	5	,	,	PUNCT
cuesj-385	176	6	p53	p53	NOUN
cuesj-385	176	7	expression	expression	NOUN
cuesj-385	176	8	and	and	CCONJ
cuesj-385	176	9	histological	histological	ADJ
cuesj-385	176	10	findings	finding	NOUN
cuesj-385	176	11	in	in	ADP
cuesj-385	176	12	colorectal	colorectal	ADJ
cuesj-385	176	13	carcinoma	carcinoma	NOUN
cuesj-385	176	14	.	.	PUNCT
cuesj-385	177	1	journal	journal	NOUN
cuesj-385	177	2	of	of	ADP
cuesj-385	177	3	gastrointestinal	gastrointestinal	ADJ
cuesj-385	177	4	and	and	CCONJ
cuesj-385	177	5	liver	liver	NOUN
cuesj-385	177	6	diseases	disease	NOUN
cuesj-385	177	7	,	,	PUNCT
cuesj-385	177	8	vol	vol	NOUN
cuesj-385	177	9	.	.	PROPN
cuesj-385	177	10	16	16	NUM
cuesj-385	177	11	,	,	PUNCT
cuesj-385	177	12	no	no	INTJ
cuesj-385	177	13	.	.	NOUN
cuesj-385	177	14	2	2	NUM
cuesj-385	177	15	,	,	PUNCT
cuesj-385	177	16	p.	p.	NOUN
cuesj-385	177	17	133	133	NUM
cuesj-385	177	18	,	,	PUNCT
cuesj-385	177	19	2007	2007	NUM
cuesj-385	177	20	.	.	PUNCT
cuesj-385	178	1	21	21	NUM
cuesj-385	178	2	.	.	PUNCT
cuesj-385	178	3	a.	a.	PROPN
cuesj-385	178	4	hegazy	hegazy	PROPN
cuesj-385	178	5	,	,	PUNCT
cuesj-385	178	6	s.	s.	PROPN
cuesj-385	178	7	a.	a.	PROPN
cuesj-385	178	8	daoud	daoud	PROPN
cuesj-385	178	9	,	,	PUNCT
cuesj-385	178	10	w.	w.	PROPN
cuesj-385	178	11	s.	s.	PROPN
cuesj-385	178	12	ibrahim	ibrahim	PROPN
cuesj-385	178	13	,	,	PUNCT
cuesj-385	178	14	k.	k.	PROPN
cuesj-385	178	15	el	el	PROPN
cuesj-385	178	16	-	-	PROPN
cuesj-385	178	17	atrebi	atrebi	PROPN
cuesj-385	178	18	,	,	PUNCT
cuesj-385	178	19	m.	m.	NOUN
cuesj-385	178	20	saker	saker	PROPN
cuesj-385	178	21	and	and	CCONJ
cuesj-385	178	22	n.	n.	PROPN
cuesj-385	178	23	abdel	abdel	PROPN
cuesj-385	178	24	-	-	PUNCT
cuesj-385	178	25	wahab	wahab	PROPN
cuesj-385	178	26	.	.	PUNCT
cuesj-385	179	1	role	role	NOUN
cuesj-385	179	2	of	of	ADP
cuesj-385	179	3	ki-67	ki-67	PRON
cuesj-385	179	4	,	,	PUNCT
cuesj-385	179	5	p53	p53	NOUN
cuesj-385	179	6	and	and	CCONJ
cuesj-385	179	7	bcl-2	bcl-2	NOUN
cuesj-385	179	8	in	in	ADP
cuesj-385	179	9	advanced	advanced	ADJ
cuesj-385	179	10	colorectal	colorectal	ADJ
cuesj-385	179	11	carcinoma	carcinoma	NOUN
cuesj-385	179	12	(	(	PUNCT
cuesj-385	179	13	histopathological	histopathological	ADJ
cuesj-385	179	14	and	and	CCONJ
cuesj-385	179	15	immunohistochemical	immunohistochemical	ADJ
cuesj-385	179	16	study	study	NOUN
cuesj-385	179	17	)	)	PUNCT
cuesj-385	179	18	.	.	PUNCT
cuesj-385	180	1	academic	academic	ADJ
cuesj-385	180	2	journal	journal	NOUN
cuesj-385	180	3	of	of	ADP
cuesj-385	180	4	cancer	cancer	NOUN
cuesj-385	180	5	research	research	NOUN
cuesj-385	180	6	,	,	PUNCT
cuesj-385	180	7	vol	vol	NOUN
cuesj-385	180	8	.	.	PROPN
cuesj-385	180	9	7	7	NUM
cuesj-385	180	10	,	,	PUNCT
cuesj-385	180	11	no	no	INTJ
cuesj-385	180	12	.	.	NOUN
cuesj-385	180	13	3	3	NUM
cuesj-385	180	14	,	,	PUNCT
cuesj-385	180	15	pp	pp	ADJ
cuesj-385	180	16	.	.	PUNCT
cuesj-385	181	1	168	168	NUM
cuesj-385	181	2	-	-	SYM
cuesj-385	181	3	172	172	NUM
cuesj-385	181	4	.	.	PUNCT
cuesj-385	181	5	2014	2014	NUM
cuesj-385	181	6	.	.	PUNCT
cuesj-385	182	1	22	22	NUM
cuesj-385	182	2	.	.	PUNCT
cuesj-385	183	1	s.	s.	PROPN
cuesj-385	183	2	t.	t.	PROPN
cuesj-385	183	3	onrat	onrat	PROPN
cuesj-385	183	4	,	,	PUNCT
cuesj-385	183	5	e.	e.	PROPN
cuesj-385	183	6	ellidokuz	ellidokuz	PROPN
cuesj-385	183	7	,	,	PUNCT
cuesj-385	183	8	a.	a.	NOUN
cuesj-385	183	9	küpelioğlu	küpelioğlu	PROPN
cuesj-385	183	10	and	and	CCONJ
cuesj-385	183	11	e.	e.	PROPN
cuesj-385	183	12	durhan	durhan	PROPN
cuesj-385	183	13	.	.	PUNCT
cuesj-385	184	1	frequency	frequency	NOUN
cuesj-385	184	2	of	of	ADP
cuesj-385	184	3	tp53	tp53	PROPN
cuesj-385	184	4	codon72	codon72	NOUN
cuesj-385	184	5	polymorphism	polymorphism	NOUN
cuesj-385	184	6	in	in	ADP
cuesj-385	184	7	cases	case	NOUN
cuesj-385	184	8	with	with	ADP
cuesj-385	184	9	colon	colon	NOUN
cuesj-385	184	10	cancer	cancer	NOUN
cuesj-385	184	11	.	.	PUNCT
cuesj-385	185	1	turkish	turkish	ADJ
cuesj-385	185	2	journal	journal	NOUN
cuesj-385	185	3	of	of	ADP
cuesj-385	185	4	cancer	cancer	NOUN
cuesj-385	185	5	,	,	PUNCT
cuesj-385	185	6	vol	vol	NOUN
cuesj-385	185	7	.	.	PROPN
cuesj-385	185	8	39	39	NUM
cuesj-385	185	9	,	,	PUNCT
cuesj-385	185	10	no	no	INTJ
cuesj-385	185	11	.	.	NOUN
cuesj-385	185	12	1	1	NUM
cuesj-385	185	13	,	,	PUNCT
cuesj-385	185	14	p.	p.	NOUN
cuesj-385	185	15	72	72	NUM
cuesj-385	185	16	,	,	PUNCT
cuesj-385	185	17	2009	2009	NUM
cuesj-385	185	18	.	.	PUNCT
cuesj-385	186	1	23	23	NUM
cuesj-385	186	2	.	.	PUNCT
cuesj-385	186	3	m.	m.	NOUN
cuesj-385	186	4	n.	n.	PROPN
cuesj-385	186	5	dastjerdi	dastjerdi	PROPN
cuesj-385	186	6	.	.	PUNCT
cuesj-385	187	1	tp53	tp53	PROPN
cuesj-385	187	2	codon	codon	NOUN
cuesj-385	187	3	72	72	NUM
cuesj-385	187	4	polymorphism	polymorphism	NOUN
cuesj-385	187	5	and	and	CCONJ
cuesj-385	187	6	p53	p53	NOUN
cuesj-385	187	7	protein	protein	NOUN
cuesj-385	187	8	expression	expression	NOUN
cuesj-385	187	9	in	in	ADP
cuesj-385	187	10	colorectal	colorectal	ADJ
cuesj-385	187	11	cancer	cancer	NOUN
cuesj-385	187	12	specimens	specimen	NOUN
cuesj-385	187	13	in	in	ADP
cuesj-385	187	14	isfahan	isfahan	PROPN
cuesj-385	187	15	.	.	PUNCT
cuesj-385	188	1	acta	acta	PROPN
cuesj-385	188	2	medica	medica	PROPN
cuesj-385	188	3	iranica	iranica	PROPN
cuesj-385	188	4	,	,	PUNCT
cuesj-385	188	5	vol	vol	NOUN
cuesj-385	188	6	.	.	PROPN
cuesj-385	188	7	49	49	NUM
cuesj-385	188	8	,	,	PUNCT
cuesj-385	188	9	no	no	INTJ
cuesj-385	188	10	.	.	NOUN
cuesj-385	188	11	2	2	NUM
cuesj-385	188	12	,	,	PUNCT
cuesj-385	188	13	pp	pp	ADJ
cuesj-385	188	14	.	.	PUNCT
cuesj-385	189	1	71	71	NUM
cuesj-385	189	2	-	-	SYM
cuesj-385	189	3	77	77	NUM
cuesj-385	189	4	,	,	PUNCT
cuesj-385	189	5	2011	2011	NUM
cuesj-385	189	6	.	.	PUNCT
cuesj-385	190	1	24	24	NUM
cuesj-385	190	2	.	.	PUNCT
cuesj-385	190	3	g.	g.	PROPN
cuesj-385	190	4	smith	smith	PROPN
cuesj-385	190	5	,	,	PUNCT
cuesj-385	190	6	f.	f.	PROPN
cuesj-385	190	7	a.	a.	PROPN
cuesj-385	190	8	carey	carey	PROPN
cuesj-385	190	9	,	,	PUNCT
cuesj-385	190	10	j.	j.	PROPN
cuesj-385	190	11	beattie	beattie	PROPN
cuesj-385	190	12	,	,	PUNCT
cuesj-385	190	13	m.	m.	NOUN
cuesj-385	190	14	j.	j.	PROPN
cuesj-385	190	15	v.	v.	PROPN
cuesj-385	190	16	wilkie	wilkie	PROPN
cuesj-385	190	17	,	,	PUNCT
cuesj-385	190	18	t.	t.	PROPN
cuesj-385	190	19	j.	j.	PROPN
cuesj-385	190	20	lightfoot	lightfoot	PROPN
cuesj-385	190	21	,	,	PUNCT
cuesj-385	190	22	j.	j.	PROPN
cuesj-385	190	23	coxhead	coxhead	PROPN
cuesj-385	190	24	,	,	PUNCT
cuesj-385	190	25	r.	r.	PROPN
cuesj-385	190	26	c.	c.	PROPN
cuesj-385	190	27	garner	garner	PROPN
cuesj-385	190	28	,	,	PUNCT
cuesj-385	190	29	r.	r.	PROPN
cuesj-385	190	30	j.	j.	PROPN
cuesj-385	190	31	c.	c.	PROPN
cuesj-385	190	32	steele	steele	PROPN
cuesj-385	190	33	and	and	CCONJ
cuesj-385	190	34	c.	c.	PROPN
cuesj-385	190	35	r.	r.	PROPN
cuesj-385	190	36	wolf	wolf	PROPN
cuesj-385	190	37	.	.	PUNCT
cuesj-385	191	1	mutations	mutation	NOUN
cuesj-385	191	2	in	in	ADP
cuesj-385	191	3	apc	apc	PROPN
cuesj-385	191	4	,	,	PUNCT
cuesj-385	191	5	kirsten	kirsten	NOUN
cuesj-385	191	6	-	-	PUNCT
cuesj-385	191	7	ras	ras	NOUN
cuesj-385	191	8	,	,	PUNCT
cuesj-385	191	9	and	and	CCONJ
cuesj-385	191	10	p53	p53	NOUN
cuesj-385	191	11	-	-	PUNCT
cuesj-385	191	12	alternative	alternative	NOUN
cuesj-385	191	13	genetic	genetic	ADJ
cuesj-385	191	14	pathways	pathway	NOUN
cuesj-385	191	15	to	to	ADP
cuesj-385	191	16	colorectal	colorectal	ADJ
cuesj-385	191	17	cancer	cancer	NOUN
cuesj-385	191	18	.	.	PUNCT
cuesj-385	192	1	proceedings	proceeding	NOUN
cuesj-385	192	2	of	of	ADP
cuesj-385	192	3	the	the	DET
cuesj-385	192	4	national	national	PROPN
cuesj-385	192	5	academy	academy	PROPN
cuesj-385	192	6	of	of	ADP
cuesj-385	192	7	sciences	sciences	PROPN
cuesj-385	192	8	,	,	PUNCT
cuesj-385	192	9	vol	vol	NOUN
cuesj-385	192	10	.	.	PROPN
cuesj-385	192	11	99	99	NUM
cuesj-385	192	12	,	,	PUNCT
cuesj-385	192	13	no	no	INTJ
cuesj-385	192	14	.	.	NOUN
cuesj-385	192	15	14	14	NUM
cuesj-385	192	16	,	,	PUNCT
cuesj-385	192	17	pp	pp	ADJ
cuesj-385	192	18	.	.	PUNCT
cuesj-385	192	19	9433	9433	NUM
cuesj-385	192	20	-	-	SYM
cuesj-385	192	21	9438	9438	NUM
cuesj-385	192	22	,	,	PUNCT
cuesj-385	192	23	2002	2002	NUM
cuesj-385	192	24	.	.	PUNCT
cuesj-385	193	1	25	25	NUM
cuesj-385	193	2	.	.	PUNCT
cuesj-385	194	1	s.	s.	PROPN
cuesj-385	194	2	m.	m.	PROPN
cuesj-385	194	3	salama	salama	PROPN
cuesj-385	194	4	,	,	PUNCT
cuesj-385	194	5	i.	i.	PROPN
cuesj-385	194	6	a.	a.	PROPN
cuesj-385	194	7	a.	a.	PROPN
cuesj-385	194	8	ibrahim	ibrahim	PROPN
cuesj-385	194	9	,	,	PUNCT
cuesj-385	194	10	n.	n.	PROPN
cuesj-385	194	11	shahzad	shahzad	PROPN
cuesj-385	194	12	,	,	PUNCT
cuesj-385	194	13	s.	s.	PROPN
cuesj-385	194	14	al	al	PROPN
cuesj-385	194	15	-	-	PUNCT
cuesj-385	194	16	ghamdi	ghamdi	PROPN
cuesj-385	194	17	,	,	PUNCT
cuesj-385	194	18	n.	n.	PROPN
cuesj-385	194	19	ayoub	ayoub	PROPN
cuesj-385	194	20	,	,	PUNCT
cuesj-385	194	21	a.	a.	PROPN
cuesj-385	194	22	s.	s.	PROPN
cuesj-385	194	23	alrashdi	alrashdi	PROPN
cuesj-385	194	24	,	,	PUNCT
cuesj-385	194	25	m.	m.	NOUN
cuesj-385	194	26	a.	a.	PROPN
cuesj-385	194	27	abdulla	abdulla	PROPN
cuesj-385	194	28	,	,	PUNCT
cuesj-385	194	29	n.	n.	PROPN
cuesj-385	194	30	salehen	salehen	PROPN
cuesj-385	194	31	and	and	CCONJ
cuesj-385	194	32	m.	m.	PROPN
cuesj-385	194	33	bilgen	bilgen	PROPN
cuesj-385	194	34	.	.	PUNCT
cuesj-385	195	1	hepatoprotectivity	hepatoprotectivity	NOUN
cuesj-385	195	2	of	of	ADP
cuesj-385	195	3	panduratin	panduratin	NOUN
cuesj-385	195	4	a	a	PRON
cuesj-385	195	5	against	against	ADP
cuesj-385	195	6	liver	liver	NOUN
cuesj-385	195	7	damage	damage	NOUN
cuesj-385	195	8	:	:	PUNCT
cuesj-385	195	9	in	in	ADP
cuesj-385	195	10	vivo	vivo	ADJ
cuesj-385	195	11	demonstration	demonstration	NOUN
cuesj-385	195	12	with	with	ADP
cuesj-385	195	13	a	a	DET
cuesj-385	195	14	rat	rat	NOUN
cuesj-385	195	15	model	model	NOUN
cuesj-385	195	16	of	of	ADP
cuesj-385	195	17	cirrhosis	cirrhosis	NOUN
cuesj-385	195	18	induced	induce	VERB
cuesj-385	195	19	by	by	ADP
cuesj-385	195	20	thioacetamide	thioacetamide	NOUN
cuesj-385	195	21	.	.	PUNCT
cuesj-385	196	1	apmis	apmis	PROPN
cuesj-385	196	2	,	,	PUNCT
cuesj-385	196	3	vol	vol	NOUN
cuesj-385	196	4	.	.	PROPN
cuesj-385	196	5	126	126	NUM
cuesj-385	196	6	,	,	PUNCT
cuesj-385	196	7	no	no	INTJ
cuesj-385	196	8	.	.	NOUN
cuesj-385	196	9	9	9	NUM
cuesj-385	196	10	,	,	PUNCT
cuesj-385	196	11	pp	pp	ADJ
cuesj-385	196	12	.	.	PUNCT
cuesj-385	197	1	710	710	NUM
cuesj-385	197	2	-	-	SYM
cuesj-385	197	3	721	721	NUM
cuesj-385	197	4	,	,	PUNCT
cuesj-385	197	5	2018	2018	NUM
cuesj-385	197	6	.	.	PUNCT
cuesj-385	198	1	26	26	NUM
cuesj-385	198	2	.	.	PUNCT
cuesj-385	198	3	e.	e.	PROPN
cuesj-385	198	4	bagheri	bagheri	PROPN
cuesj-385	198	5	,	,	PUNCT
cuesj-385	198	6	k.	k.	PROPN
cuesj-385	198	7	saremi	saremi	PROPN
cuesj-385	198	8	,	,	PUNCT
cuesj-385	198	9	f.	f.	PROPN
cuesj-385	198	10	hajiaghaalipour	hajiaghaalipour	PROPN
cuesj-385	198	11	,	,	PUNCT
cuesj-385	198	12	f.	f.	PROPN
cuesj-385	198	13	l.	l.	PROPN
cuesj-385	198	14	faraj	faraj	PROPN
cuesj-385	198	15	,	,	PUNCT
cuesj-385	198	16	h.	h.	PROPN
cuesj-385	198	17	m.	m.	PROPN
cuesj-385	198	18	ali	ali	PROPN
cuesj-385	198	19	,	,	PUNCT
cuesj-385	198	20	m.	m.	PROPN
cuesj-385	198	21	a.	a.	PROPN
cuesj-385	198	22	abdulla	abdulla	PROPN
cuesj-385	198	23	,	,	PUNCT
cuesj-385	198	24	s.	s.	PROPN
cuesj-385	198	25	l.	l.	PROPN
cuesj-385	198	26	khaing	khaing	PROPN
cuesj-385	198	27	and	and	CCONJ
cuesj-385	198	28	n.	n.	PROPN
cuesj-385	198	29	salehen	salehen	PROPN
cuesj-385	198	30	.	.	PUNCT
cuesj-385	199	1	synthesis	synthesis	NOUN
cuesj-385	199	2	of	of	ADP
cuesj-385	199	3	novel	novel	ADJ
cuesj-385	199	4	derivatives	derivative	NOUN
cuesj-385	199	5	of	of	ADP
cuesj-385	199	6	quinazoline	quinazoline	ADJ
cuesj-385	199	7	schiff	schiff	NOUN
cuesj-385	199	8	base	base	NOUN
cuesj-385	199	9	compound	compound	NOUN
cuesj-385	199	10	promotes	promote	VERB
cuesj-385	199	11	epithelial	epithelial	ADJ
cuesj-385	199	12	wound	wound	NOUN
cuesj-385	199	13	healing	healing	NOUN
cuesj-385	199	14	.	.	PUNCT
cuesj-385	200	1	current	current	ADJ
cuesj-385	200	2	pharmaceutical	pharmaceutical	ADJ
cuesj-385	200	3	design	design	NOUN
cuesj-385	200	4	,	,	PUNCT
cuesj-385	200	5	vol	vol	NOUN
cuesj-385	200	6	.	.	PROPN
cuesj-385	200	7	24	24	NUM
cuesj-385	200	8	,	,	PUNCT
cuesj-385	200	9	no	no	INTJ
cuesj-385	200	10	.	.	NOUN
cuesj-385	200	11	13	13	NUM
cuesj-385	200	12	,	,	PUNCT
cuesj-385	200	13	pp	pp	ADJ
cuesj-385	200	14	.	.	PUNCT
cuesj-385	201	1	1395	1395	NUM
cuesj-385	201	2	-	-	SYM
cuesj-385	201	3	1404	1404	NUM
cuesj-385	201	4	,	,	PUNCT
cuesj-385	201	5	2018	2018	NUM
cuesj-385	201	6	.	.	PUNCT
cuesj-385	202	1	27	27	NUM
cuesj-385	202	2	.	.	PUNCT
cuesj-385	202	3	d.	d.	PROPN
cuesj-385	202	4	calistri	calistri	PROPN
cuesj-385	202	5	,	,	PUNCT
cuesj-385	202	6	c.	c.	PROPN
cuesj-385	202	7	rengucci	rengucci	PROPN
cuesj-385	202	8	,	,	PUNCT
cuesj-385	202	9	i.	i.	PROPN
cuesj-385	202	10	seymour	seymour	PROPN
cuesj-385	202	11	,	,	PUNCT
cuesj-385	202	12	a.	a.	NOUN
cuesj-385	202	13	lattuneddu	lattuneddu	PROPN
cuesj-385	202	14	,	,	PUNCT
cuesj-385	202	15	a.	a.	NOUN
cuesj-385	202	16	m.	m.	NOUN
cuesj-385	202	17	polifemo	polifemo	NOUN
cuesj-385	202	18	,	,	PUNCT
cuesj-385	202	19	f.	f.	PROPN
cuesj-385	202	20	monti	monti	PROPN
cuesj-385	202	21	,	,	PUNCT
cuesj-385	202	22	l.	l.	PROPN
cuesj-385	202	23	saragoni	saragoni	PROPN
cuesj-385	202	24	and	and	CCONJ
cuesj-385	202	25	d.	d.	PROPN
cuesj-385	202	26	amadori	amadori	PROPN
cuesj-385	202	27	.	.	PUNCT
cuesj-385	203	1	mutation	mutation	NOUN
cuesj-385	203	2	analysis	analysis	NOUN
cuesj-385	203	3	of	of	ADP
cuesj-385	203	4	p53	p53	NOUN
cuesj-385	203	5	,	,	PUNCT
cuesj-385	203	6	k‐ras	k‐ras	PROPN
cuesj-385	203	7	,	,	PUNCT
cuesj-385	203	8	and	and	CCONJ
cuesj-385	203	9	braf	braf	NOUN
cuesj-385	203	10	genes	gene	NOUN
cuesj-385	203	11	in	in	ADP
cuesj-385	203	12	colorectal	colorectal	ADJ
cuesj-385	203	13	cancer	cancer	NOUN
cuesj-385	203	14	progression	progression	NOUN
cuesj-385	203	15	.	.	PUNCT
cuesj-385	204	1	journal	journal	NOUN
cuesj-385	204	2	of	of	ADP
cuesj-385	204	3	cellular	cellular	ADJ
cuesj-385	204	4	physiology	physiology	NOUN
cuesj-385	204	5	,	,	PUNCT
cuesj-385	204	6	vol	vol	NOUN
cuesj-385	204	7	.	.	PROPN
cuesj-385	204	8	204	204	NUM
cuesj-385	204	9	,	,	PUNCT
cuesj-385	204	10	no	no	INTJ
cuesj-385	204	11	.	.	NOUN
cuesj-385	204	12	2	2	NUM
cuesj-385	204	13	,	,	PUNCT
cuesj-385	204	14	pp	pp	ADJ
cuesj-385	204	15	.	.	PUNCT
cuesj-385	205	1	484	484	NUM
cuesj-385	205	2	-	-	SYM
cuesj-385	205	3	488	488	NUM
cuesj-385	205	4	,	,	PUNCT
cuesj-385	205	5	2005	2005	NUM
cuesj-385	205	6	.	.	PUNCT